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Glossary 
ABNORMAL STEMLINC 
ACTUARIAL SURVIVAL 
ADR 
(C)DDP 
CTX 
presence of aneuploid cells 
presentation of survival patterns in which the patients who 
are lost to follow-up are depleted in a mathematical calcula­
tion under continued follow-up = life table method 
Adriamycin 
Cis-platin = cis-dichlorodiammine-platinum-II (C, D or 
Ρ in therapy code) 
Cyclophosamide (C in therapy code) 
CYTOREDUCTivE SURGERY attempt to come to a smallest possible tumour growth; 'com­
plete' when no tumour larger than 2cm in diameter was left 
behind 
DEBULKING 
FCM 
HMM 
IITCS 
HTC 3 
INITIAL TREATMENT 
RESPONSE 
see: cytoreductive surgery 
Flow cytometry 
Hexamethylmelamine (H) 
Human Tumour Cloning System = double layer soft agar 
tissue culture cf. Salmon & Hamburger = stem cell assay 
= HTC 3 
Human Tumour Clonogenic Cell Culture System (see 
HTCS) 
Λ) surgery: first operation for ovarian cancer 
B) chemo-/radiotherapy: first therapy given after the first 
operation = first line treatment 
COMPLETE REMISSION: no residual tumour found in random 
biopsies, peritoneal washings or smears of the diafragm, 
para-colic gutters and cul-de-sac. 
PARTIAL REMISSION: a partial remission can be 'microscopic', 
i.e. when only microscopic tumour deposits are found in ran­
dom biopsies and/or cytologic specimens, or 'macroscopic' 
when macroscopic suspect lesions are seen which constitute 
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less than 50% of the residual tumour after debulking. 
STABLE DISEASE is defined as a tumour-reduction of less than 
50% but more than 25% of the tumourload left behind at 
second-look operation. 
PROGRESSION: less than 25% decrease of tumour 
SALVAGE TREATMENT treatment of minimal residual tumour after primary therapy 
TOP Temporal Growth Pattern = growth curve 
TREATMENT PLAN intentional treatment scheme, which mostly comprises more 
than one treatment modality 
14 
PARTI 
15 
16 
1. Introduction 
1.1 OBJECTIVES OF THIS STUDY 
LI I. Overview of treatment 
The field of diagnosis and therapy of all cancers has been advancing as well as 
expanding in the last two decades Since ovarian carcinoma ranks first among the 
causes of death from female genital tract malignancies, it is likely that these develop-
ments have an impact on the prognosis for patients with this disease In the introduc-
tion to this study an overview is given of the literature regarding especially the new 
ideas that have emerged in the diagnostic field 
The first part of this study is devoted to the treatment of ovarian cancer in our 
institute prior to the introduction of new concepts in the management of this disease 
(chapter 2) It was our intention to give a fair view of the state of ovarian cancer 
treatment m order to be able to assess improvements to be made by new treatment 
strategies that were introduced at the time of this evaluation 
As soon as new very active cytostatic agents were introduced, these agents in combi-
nation did not only prove to be successful, but to be highly toxic as well One of the 
most effective chemotherapy schemes was modified by us in an attempt to reduce 
toxicity, without loosing efficacy (chapter 3) 
112 Introduction of predictive tests for the treatment planning and assessment of prog-
nosis 
Evaluation of therapy results from this new regimen as well as from other studies 
in the literature indicated that by improving surgical and chemotherapeutical regi-
mens, on an empirical basis only, substantial improvement of prognosis cannot be 
achieved We therefore addressed the need for a more basic biologically oriented ap-
proach as a potential alternative, or better addition, to trial and error studies 
The use of the in vitro Human Tumour Cloning System (HTCS) introduced by 
Hamburger and Salmon (1977) reportedly improved treatment results on the basis 
of individualizing chemotherapy selection In our opinion, however, the assay could 
also provide means for tumour biological studies since tumour cells were selectively 
cloned in this system (chapter 4) Investigating properties of in vitro tumour cell growth 
became a prerequisite for clinical use, regarding the criticism directed towards the 
HTCS We, therefore, first sought to investigate some of the properties and potentials 
of tumour cell growth in this assay (chapter 5) 
Better insight into the nature of the tumour cells and colonics that are studied in 
this assay should allow us to define potential clinical applicability of the HTCS, 
especially in ovarian cancer treatment 
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In summary 
The purpose of the first part of this study is to assess both in a literature study 
as well as in personal observations, whether new developments in surgical, chemothera-
peutical and radiotherapeutical treatment of ovanan cancer really improves prognosis 
The purpose of the second part of this study is to define the role of the HTCS 
in selection and evaluation of therapy in ovanan cancer 
1 2 EPIDEMIOLOGY AND fcTioLOGY 
It may seem that ovarian cancer is one of the best documented and one of the mostly 
studied malignant tumours in general and in gynaecological oncology in particular 
However, in one of the most important Dutch gynaecological teaching books of about 
30 years ago - the 'Leerboek der vrouwenziekten' (editor van Bouwdijk Bastiaanse) 
- not one chapter, not even a single paragraph was devoted to malignant ovarian 
tumours (Plate 1956). Among the myriads of histopathological diagnoses of ovarian 
tumours (many of which are unknown m today's pathological nomenclature) malig­
nancies were too rare to be discussed seperately from their benign counterparts. 
In the last decade national survey programs on every continent have given a fair 
view of the incidence of ovarian cancer Regional differences in the incidence of ovarian 
cancer, as well as racial differences exist In Western countries 5 to 17 cases of ovarian 
cancer are diagnosed per 100,000 women per annum (fig 1 1 ) 
The highest incidence is reported in Israel Because the incidence generally increases 
with age, it is striking that there is a decrease after 50 years of age in Japan, where 
the incidence of ovarian cancer is very low (less than 4 per 100,000 population), as 
in all eastern and South-American countries (Doll et al 1972) The assumption that 
these regional differences arc, apart from cultural causes ('reproductive behaviour'), 
at least partly due to a racial factor is supported by the fact that US black women 
have approximately half the risk of developing ovarian malignancy when compared 
with US white women (Cramer & Cutler 1974, Doll et al 1979) 
Unfortunately, despite optimism (Young 1979 'Ovarian carcinoma an optimistic 
epilogue') raised by many reports on new methods of detection and of new treatment 
schemes, ovarian cancer still frustrates gynaecological, surgical, medical and radio-
therapeutical oncologists who combine their efforts in the management of this disease 
(Young 1984. 'Ovarian cancer treatment progress or paralysis') Notably, the inci­
dence rate for ovarian cancer in western countries has increasedin the past two decades, 
in contrast to the decrease in incidence of other gynaecological malignancies such as 
cancer of the uterine cervix and endometrium (American Cancer Society 1981, Hoo-
gendoorn 1976, Berhe et al 1983) In the Netherlands 1 32% of the female babies 
born will develop ovanan cancer at some time in their life, ι e 1 out of every 75 female 
babies (H oogendoorn 1982)' 
Thus, ovarian cancer is still 4th (Disaia 1974) or, according to others, 3rd (Schmidt-
Matthiesen & Bastert 1982) among the leading causes of cancer death in women In 
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Fig 1 1 Estimated new cases of ovarían cancer per 100,000 population (Adapted from Waterhouse el 
al 1982) 
the Netherlands 904 women died of ovarian cancer in 1983, making it the fourth major 
cause of cancer death in women after breast cancer (2897 deaths), colon cancer (1553 
deaths) and gastric cancer (946 deaths) (Van Ginneken & van der Vhst 1985) The 
clinical incidence of ovarian cancer was 17 1 per 100,000 women in 1982-1983, thus 
ranking third after breast cancer (94 5 per 100,000) and colon cancer (26 4 per 
100,000)(CBS 1985) 
For patients referred with ovarian cancer (all histological types) to the Sint Radboud 
Hospital of the Catholic University of Nijmegen* the peak in age distribution is be-
* Data presented in this introduction for patients from the Radboud Hospital are denved from a retrospec 
live study, dealt with in detail in chapter 2 3 
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big 1 2 Age dislribution among patients treated for ovarian cancer (all histological types) in the Radboud 
hospital, from 1967 through 1984 
Percentage of total number ol patients per decade 
tween 50 and 60 years (see fig 1.2), which is also reported in larger series (Day & 
Smith 1975, Cambell 1975) Ovarian cancer is extremely rare in childhood. 
In general 1-1 b"0 of all tumours in children are localized in the ovaries (Acosta 
et al 1972, Lucraft 1979, La Vecchia et al 1983) The majority of these tumours is 
benign Of the 63 patients with an ovarian tumour admitted to the Children's Hospital 
of Los Angeles in the period 1961 to 1981, only 13 had a malignancy of which 1 was 
of epithelial origin, all others were germ cell tumours (Ehren et al 1984) In a large 
British series compiled between 1962 and 1978, 172 cases of malignant ovarian tu­
mours were registered in patients under the age of 15 (La Vecchia et al 1983) Eighty-
four percent of these tumours was of germ cell origin. In contrast to the prognosis 
for epithelial ovarian malignancies in adults, the rare epithelial tumours in children 
have a better prognosis than the far more frequent germ cell tumours (La Vecchia 
et al 1983) 
Familial aggregations are reported in a few case histories of families with several 
ovarian cancer patients (see for a review Lurain & Piver 1979) Although data are 
certainly not conclusive (Day & Smith 1975, Chudinaet al. 1983), patterns of familial 
occurence suggest autosomal dominant inheritance in many instances (Lurain & Piver 
1979) It is reported that in familial ovarian cancer there is an earlier onset of disease 
and worse prognosis than in solitary cases (Franceschi et al 1982, Chudina et al. 1983, 
Lurain & Piver 1979). 
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A history of cancer patients in the family is reported to be positive in the same 
percentage as in the normal population, namely 32 (Kolstad & Beecham 1974) to 
45 0 0 (Pearse & Behrman 1954) In 22 patients from our institute in whom the familial 
history was known, 12 patients were reported to have other members in the family 
with cancer, 4 of whom had also malignant ovarian tumours. Of course this high 
number of patients with a positive history of ovarian cancer in the family may be 
biased by the attention raised by such a history On the other hand, regarding the 
growing number of reports on familial aggregation (Piver 1984), it may be that, to 
date, the role of inheritance in ovarian cancer is underestimated 
Cytogenetic data have been obtained in families with ovarian neoplasms, but no 
consistent chromosome aberration could be observed (Chudina et al 1983) Deletion 
of the long arm of chromosome 6, however, has been associated with ovarian cancer 
(Trent & Salmon 1979) Others deny specific structural changes (Whang-Peng et al. 
1984) The finding of biomarkcr locus may be helpful in establishing the role of genet­
ics On basis of their findings of a decreased alpha-L-fucosidase and in vitro hypcr-
ploidy-both genetically determined-Lynch et al (1985) call for intensive biomarker 
research in suspect families in order to identify patients at risk 
Recently от ogenes have been found to play an important role in oncogenesis. Cellu­
lar homologs of viral genes, specifically Harvey and Kirsten murine sarcoma viruses 
ras
h
 and rask (see for overview. Hamlyn & Sikora, 1983) Transforming activity in 
human solid tumours of such homologs was first observed in human bladder and 
lung carcinoma cell lines (Der et al. 1982) Ras gene activation has been detected in 
only about 20 percent of neoplasms Recently rask gene activation was observed in 
a human ovarian carcinoma (Feig et al 1983) Not only the transforming activity 
of these genes, but also the role of oncogene products in the genesis and maintenance 
of malignant tumours are studied now in this rapidly moving field (Buick & Pollak 
1984) In the near future the use of monoclonal antibodies that can detect minimal 
amounts of oncogene products may lead to the finding of more genes responsible 
for oncogenesis and may furthermore play a role in tumour monitoring 
One of the most striking factors that seems to play a role in the development of 
ovarian cancer is the number of ovulations a high parity (Smith & Day 1975, Joly 
et al 1974, McGowan et al 1979), especially pregnancy at an early age (La Vecchia 
et al 1984a, McGowan et al. 1979) and adequate reproductive capacity or sustained 
use of oral contraceptives seem to protect against ovarian cancer (see for overview. 
Kenemans & Hafez 1984) In our series of 63 patients 49% had never been pregnant 
(24% was not married) and 16% had had at least one abortion Further, in 35 multipar-
ae with ovarian cancer the mean age at first delivery was 25.8 years 
In a case control study Risch et al (1983) compared a large scries of ovarian cancer 
patients ( N = 281) with controls (N= 750) They could only partly confirm the theory 
of'incessant' or 'extravagant' ovulation (Fathalla 1971, Casagrande et al 1979) as 
a possible explanation for the development of ovarian tumours. The rationale for this 
theory is that carcinogenesis is triggered by mechanic violation of the ovarian surface 
by 'incessant' rupturing follicules, as well as by hormonal induction through the con-
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slant contact of this surface with a high estrogen level in the follicular fluid Mechanical 
violation and subsequent repair causes mesothehal or epithelial inclusion cysts in 
which malignant cells might be created Risch et al indeed found histories of childbear-
ing, miscarriage, lactation and the use of oral contraceptives to be associated with 
a decreased risk of ovarian cancer However, they failed to find an association between 
either total dose or total time of exposure to noncontraceptive estrogens or with the 
history of usage of thyroid medication, suggesting that a reduced pituitary gonadotro-
phin secretion (Stadel 1975) cannot be an explanation for reduced risk In a similar 
case control study by the Centers for Disease Control Cancer and Steroid Hormone 
Study (1983) 179 ovanan cancer patients were compared with 1872 controls In this 
study a statistically significant decrease in the risk of developing ovarian cancer could 
be demonstrated with an increasing duration of oral contraception, supporting Sta-
del's theory Results of retrospective studies showed that ovanan carcinoma was asso­
ciated with a relatively high 'ovulatory age', ι e the period between menarche and 
menopauze minus the 'protected time' from pregnancy and hormonal contraception 
(Hildreth et al, 1981, Langer et al 1984) 
Increasing duration of oral contraceptive use appeared to significantly decrease the 
risk of developing ovarian cancer (x2, = 4 85, p = 0 03) in a case control study by La 
Vecchia (1984b) However, protection from the use of oral contraceptives was confined 
to women who had used the pill after first birth This difference between users before 
and after first pregnancy cannot only be explained by the role of the pregnancy in 
reducing the risk because the confidential intervals of the estimates for both groups 
overlap 
In summary, a correlation between a reduced frequency of ovulation and decreased 
risk of subsequent development of ovarian cancer could be demonstrated, but the 
underlying mechanism is still unclear On basis of an overview of the literature Smith 
& Oi (1984) concluded that a group to be regarded at high risk should comprise women 
45 and older who are nulhparous, or whose first pregnancy occured after age 30, who 
experienced menopauze after age 55, or who had 40 years or more of Ovulatory age'. 
The role of the age at menarche in the development of ovarian cancer is unclear 
McGowan (1979) found a relation with late menarche in women with ovanan carcino­
ma of low malignant potential The mean age at menarche in 51 of the patients we 
studied was 15 8 years This is late when we consider that the mean age at menarche 
of normal Dutch school children is 13 4 years, as assessed by van Venrooy-IJsselmui-
den (1975) between 1970 and 1972. This higher age might, however also be due to 
the fact that in the course of the past decades menarchal age is decreasing (Goldfarb 
1968) On the other hand, West (1966) and Kolstad & Beecham (1974) could not find 
any difference with the normal population, whereas Wijnder et al (1969) detected 
even a lower age at menarche for ovarian cancer patients 
Diethylstübestrol (DES) has recently been put in oncological foothght as to its role 
in carcinogenesis Because of the above suggested association of estrogens and the 
induction of cancer, especially of the ovary, attention was also raised in relation to 
DES A retrospective study on 1531 mothers exposed to DES during pregnancy 
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showed a relative risk for cancer of the ovary of 2.83, which increase was, however, 
not significant (Hadjmichacl et al. 1984). As DES is notorious for the induction of 
clear cell carcinoma of the vagina in young women exposed to DES in utero (Herbst 
& Scully 1970), DES exposure and the development of ovarian malignancies might 
also be related. It is reported that DES exposure in utero influences ovarian develop-
ment and function, oogenesis in particular (Eskes & Scheres 1984; Nomura & Kanzaki 
1977; Walker 1984). DES is reported to be capable of inducing (an) abnormal (amount 
of) cell replication(s) (Rao & Engelberg 1967; Chrisman 1974) so that teratogenic or 
carcinogenic effects on the meiotic replicating oocytes in the fetal ovaries is likely. 
In animal studies it has been shown that female offspring of mice treated with DES 
during pregnancy can develop ovarian tumours, structurally similar to human cyst-
adenocarcinomas (Walker 1984). This is particularly interesting, as cystadenocarcino-
mas have never been reported in the type of mice used in this study. 
Women born to mothers who used DES during pregnancy are, however, still under 
the age of high prevalence of ovarian cancer. Epidemiological evidence for increased 
risk of ovarian cancer in women exposed to DES in utero can, therefore, not be ex-
pected within the next 10 to 20 years. A first indication that such a study might provide 
some interesting and revealing data is given by Lazarus (1984), who reported the first 
case of a 12 year old girl with a malignant teratoma of the ovary, possibly related 
to DES exposure in utero. 
A relationship between smoking habits and ovarian cancer has never been proven. 
Theoretically, it is feasible that smoking alters the hormonal status of women, possibly 
through a lower relative weight, responsible for a lower endogeneous estrogen produc-
tion. Although a positive relationship between smoking and mortality from cancer 
of the ovary is reported in studies that did not control for other risk factors (Doll 
et al. 1980, Hammond 1966), Smith and co-workers (1982) could not, however, estab-
lish such a relationship in a cohort study in which they adjusted for other risk factors. 
Analogous to the finding of pleural mesothelioma in subjects exposed to asbestos, 
another hydrous magnesium silicate, talc, has been considered as a possible cause 
of ovarian cancer (Graham & Graham 1967; Henderson et al. 1971; Longo & Young 
1979). Talc particles can enter the pelvic cavity via the genital tract and become embed-
ded in the ovaries (Henderson et al. 1971): the 'pelvic contamination' theory. Cramer 
et al. (1982) observed in a case control study with 45 talc users and 66 non-users, 
that the maximum likelihood estimate of relative risk associated with any perineal 
use of talc was 1.6 (P = 0.03) after simultaneous adjustment for religion, marital status, 
educational level, ponderal index, age at menarche, exact parity, oral contraceptive 
or menopausal hormone use, and smoking. Menstrual characteristics, that might be 
associated with perineal use of talc were virtually identical in cases and controls. 
Whether talc itself, or the asbestos contained in generic 'talc' is the cause of this higher 
chance which talc users have of acquiring ovarian cancer is not clear. 
Both chemical and mechanical factors might play a role in talc induced carcinogene-
sis. There are experimental data (Stanton et al. 1981), suggesting that the shape of 
the particle is essential and that particles with long thin fibers are most carcinogenic. 
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Talc or asbestos particles may be embedded in the ovarian surface by 'uptake' in a 
ruptured follicle and subsequently be incorporated in an inclusion cyst. On the other 
hand it may also be possible that the contact of a talc or asbestos particle with the 
ovarian surface itself induces entrapment of the surface epithelium and act in the same 
way as 'incessant ovulation', the theory proposed by Falhalla (1971). 
If talc plays an important role it might be expected that talc particles were recovered 
at microscopical examination of tumour specimens. Although these can be seen in 
specimens of both normal and abnormal ovaries (Henderson et al. 1971), this phenom-
enon is never consistently reported in papers dealing with the role of talc in carcinogen-
esis. Also in our experience, the presence of talc particles, that arc not clearly due 
to contamination caused by powdered gloves during operation, in tumour specimens 
is a very rare finding. 
The association between the A BO system and ovarian cancer, reported by von Helm-
hold (1961) has been confirmed in large epidemiological studies by Osborne and de 
George (1963) and Björkholm (1984). In these two latter studies, with 200 patients 
vs. 1828 controls and 1930 patients vs. 24120 controls respectively, more patients with 
blood group A were observed than were expected group A. In the series by Björkholm 
(1984) there also appeared to be a disparity between the frequencies of blood group 
A and blood group О (incidence ratio group A/group О = 1.19), especially in women 
with epithelial ovarian tumours (incidence ratio group A/group О = 1.26) In a retro­
spective study Langer et al. (1984) found blood group A in 51.5% of 126 ovarian 
cancer patients, versus 44.1% in 10,000 inhabitants of Vienna. Similar observations 
have been reported in patients with other (malignant) tumours, such as trophoblastic 
neoplasms (Kenemans et al. 1984). A reduction of immunological capacity could be 
an explanation for the elevated risk for developing malignant disease, but conclusive 
arguments are not yet available. 
Dietary factors probably do not play an essential role in the development of ovarian 
cancer. In a case control study, a lower vitamin A and a lower protein intake were 
Table 1.1 Risk factors potenlially associated with ovarian cancer 
- age over 40 years 
- family history of (gynaecological) malignancy 
- lowpanly 
- difficulty in conceiving 
- high age at first pregnancy 
- serious premenstrual symptoms 
- late menarche 
- menstrual disorders 
- coffee drinking 
- talc/asbestos exposure 
- bloodgroupA 
- rubella in penpubcral period 
- irradiation 
> 'high ovulatory age' 
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associated with ovarian cancer, but such relationships are not specific for ovarian 
tumours (Byers 1984) 
A rather peculiar relationship between ovarian cancer and coffee drinking was 
found by Tnchopoulos ( 1981 ) and by La Vecchia ( 1984c) in two south European case 
control studies In the latter study of 247 ovarian cancer patients and 495 age matched 
controls recruited from other patients, elevated coffee consumption was observed in 
patients This increase was not related to duration of use of coffee Also Hartge et 
al (1981) reported similar results for coffee drinking in the United States (relative 
risk = 1 3). Evidence for a real causal relationship is, however, still lacking Both 
experimental data and data from other case control studies, not biased by the use 
of hospital control groups will have to be obtained 
Ionizing irradiation of active ovaries also increases the risk of developing ovarian 
cancer Kleinerman el al (1982) found in a cohort study a small excess relative risk 
(1 6, ρ < 0 05) in women irradiated for cervical carcinoma. Also women who are 
castrated by radiation have a higher risk (Huber 1960) Carcinogenic effects of irradia­
tion appear always after a long post-exposure interval (sec also van Daal 1985). 
Finally, a relationship with viral infection, especially with rubella in the penpuberal 
period has been reported, notably in patients with a late onset of the menarche 
(McGowan et al 1979; Cramer et al. 1983) Early immunization for rubella for all 
children under 12 might, therefore, prevent rubella encephalitis (although non-congen­
ital rubella encephalitis is very rare (Lebon & Lyon 1974)) as well as the induction 
of ovarian cancer Possibly other viral infections, such as measles and mumps in the 
penpuberal period may also play a role in increasing risk, but this could not yet be 
supported by epidemiological data 
In conclusion: 
Although a list of risk factors can be drawn up as in table 1 1, it seems premature 
to give an index of priority as has been done by Smith & Oi (1984) Current estimates 
are done on only a limited number of observations No good study is available in 
which corrections for other risk factors have been applied in the estimation of one 
particular risk factor 
In general, table 1 1 gives the risk factors in an approximate order of importance. 
However, problems in conceiving and menstrual disorders are probably not indepen­
dent factors Therefore it is hard to tell what the contribution is of, for example, parity 
in comparison to family history 
Both patient factors and environmental factors have been assessed epidemiologi-
cally Especially in the latter group often little more than circumstantial evidence for 
association with ovarian cancer is available. 
For future studies it seems advisable to score for all proposed risk factors, thus 
enabling later assessment of risk factor in larger series 
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1.3. HISTOLOGY. 
1.3.1. Gonadal development and topography. 
In the first 4 to 5 weeks after fertilization gonadal development is similar in males 
and females ('indifferent' stage). The primordial germ cells in the yolk sac surface 
near the allantois migrate with amoeboid movements towards the gonadal ridges (see 
fig. 1.3). 
Fig. 1.3 Schematic section through mid-body region of a young embryo (Modified after Patten B.M., 
Human embryology. New York etc. McGraw-Hill Book Company, 1953) 
For about two and a half months human embryos of both sexes have a double 
set of genital ducts: the mesonephric (wolffian) duct and the paramesonephric (müller-
ian) duct (see fig. 1.4). At the time of primordial germ cell migration the genital ridges 
are situated over the ventral part of the mesonephric ducts. At about 5 weeks the 
male gonad starts to reorganize itself into a testis. The development of an ovary, how-
ever, takes place more slowly. At about six weeks irregular groups of germ cells are 
formed through penetration of mesenchymal cells, that will later in the 5th month 
be replaced by the ovarian stroma. In contrast to the testicular development, in the 
ovary the (coelomic) surface epithelium continues to proliferate and the group of germ 
cells that is formed in between are organized in primary follicles, incorporating the 
germ cells that swell up to oögonia. The oögonia undergo furious mitotic activity, 
so that at 20 weeks embryonal age their number reaches a maximum of about 7 million. 
For the understanding of the genesis of malignant ovarian tumours it is important 
to realize that what is generally called the 'germinal epithelium' in fact consists of 
coelomic, and therefore mesodermally derived cells. This epithelium is the origin of 
the largest group of ovarian tumours, the epithelial tumours, whereas the germ cell 
tumours are ultimately derived from the primitive germ cells of the embryonic gonad 
(Soetersl984). 
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Fig 1 4. Schematic diagram showing plan of lhe urogenital system before the 6th embryonal week. (Repro-
duced from Patten B.M Human embryology. New York etc • McGraw-Hill Book Company, 1953). 
In the female embryo the cranial and middle part of the paramesonephric duct devel-
op into the fallopian tubes at the time of ovarian descent to the pelvis. The mesoncphric 
duct degenerates, leaving vestigial tubules called the epoöphoron and paroophoron, 
within the broad ligament, and remnants of ducts on either side of the vagina, called 
gartner's ducts (fig. 1.5). The ovaries descend passively to the lateral wall of the pelvis, 
at the level of the anterior superior spine. They maintain their original vascularization, 
while moving from the site of early embryonal development: the ovarian arteries arise 
from the aorta just below the renal arteries. Furthermore the ovaries arc supplied 
by the ovarian branches of the uterine arteries. Venous drainage takes place through 
a plexus that communicates with the uterine plexus. Two veins arise from this plexus 
and become a single vein by the time they leave the pelvis. The right ovarian vein 
usually empties in the inferior vena cava, the left ovarian vein drains in the left renal 
vein. 
Of considerable importance for the understanding of lymphatic metastatic spread 
of ovarian tumour cells is the knowledge of the lymphatic drainage of the ovaries. 
This takes place along 3 routes: 
(1) in inguinal lymphatic vessels, (2) in lymph vessels along the external iliac arteries, 
and (3) via the para-aortic lymph vessels, including those above the renal vessels at 
the left. Eventually lymphatic fluid drains into the lumbar (or aortic) nodes. 
In conclusion, the ovaries are abdominal retroperitoneal organs in origin, and only 
secondary intra-peritoneal pelvic structures. This has consequences for the manage-
ment of ovarian cancer as will be discussed in chapter 2. 
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Fig. 1.5 Schematic diagram showing plan of developing female reproductive system. (Reproduced from 
Patten Β M., Human r;mbryology. New York etc.. McGraw-Hill Book Company, 195.1). 
1.3.2. Histological classification. 
The widely used histological classification of ovarian tumours according to the 
World Health Organi/.ation (Serov & Scully 1973) is based on the histogenesis of the 
tumours (table 1.2) 
Table 1.2 WHO classification ofovanan tumours, major groups. 
I common 'epithelial' tumours 
II sex cord stromal tumours 
III lipid (lipoid) cell tumours 
IV germ cell tumours 
V gonadoblastoma 
VI soft tissue tumours not specific to ovary 
VII unclassified tumours 
VIII secondary (metastatic) tumours 
IX tumour-like conditions 
Up to 90% of all neoplasms of the ovary are reported to be of epithelial origin 
(Malkasian et al. 1975; Katsube et al. 1982). The majority of ovarian epithelial neo­
plasms is derived from the so-called 'germinal epithelium' and stroma, although con­
clusive arguments for this hypothesis arc still lacking (Czernobilsky 1977). 
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Because of the relative rareness of non-cpithehal mahgant tumours of the ovary, 
as well as the specific treatment required for these tumours which goes beyond the 
scope of this thesis, these tumour types will not be discussed further All data in this 
thesis concern malignant epithelial tumours, unless otherwise stated 
Of the epithelial malignant ovarian tumours, the paptllarv serous cvstadenocartmo-
ma is the most common type, forming about 40 (Czernobilsky 1977) to 70oo (Malka-
sian 1975). The cells in this type of tumour resemble the secretory cells of the fallopian 
tube In contrast to benign serous cystadenomas, the malignant tumours are often 
extremely papillär with the papils projecting towards the inner space of the, often 
voluminous, cysts, filled with torbid or bloody fluid In about 30o() of these tumours 
microscopic calcifications are present (psammoma bodies). These calcified bodies 
probably reflect a specific tumour-host reaction that might be responsible for the better 
survival rate in patients presenting tumours with psammoma bodies (Aure et al 1971) 
Between 3 (Anderson 1971) and 20oo (Malkasian 1975) of the malignant ovanan 
tumours art papillär) mucinom cystadenocartmomas. They are called 'mucinous' be-
cause they resemble the mucin secreting endometrial cells and because of the rcscm-
blence of the cystic sticky 'fluid' with intestinal mucin Extraovanan lesions behave 
in the same way as pseudomyxoma peritonei, except for the malignant characteristics 
in the former 
In 5 (Malkasian 1975) to 20oo (Czernobilsky 1977) of the cases the carcinoma is 
of the endometrioid type histologically identical to endometrial adenocarcinoma or 
adenocarcinoma with squamous differenlialion Although this type of tumour is clear-
ly related to, if not deriving from, ovarian endometriosis it may be regarded as a tu-
mour of the germinal epithelium This epithelium is considered to be the source of 
endometriosis of the ovary (Hertig & Gore 1961, C/ernobilsky et al 1970) and may 
therefore, either directly or indirectly via endometriosis, give rise to endometrioid tu-
mours 
Clear cell carcinoma constitutes 5 (Kurman & Craig 1972) to \0o/„ (C/ernobilsky 
Table 1 1 WHO histological cldssification of ovarian tumours malignant common'epithelial tumours 
- Serous tumours 
(a) adenocarcinoma, papillary adenocarcinoma, and papillary cystadcnocarcinoma 
(b) surface papillary carcinoma 
(c) malignant adenofibroma and cystadenofibroma 
- Mucinous tumours 
(a) adenocarcinoma and cysladenocarcinoma 
(b) malignant adenofibroma and cystadenofibroma 
- Endometrioid tumours 
(a) carcinoma 
(b) endometrioid stromal sarcomas 
(c) mesodermal (mullenan) mixed tumours 
- Clear cell (mesoncphroid) tumours carcinoma and adenocarcinoma 
- Brenner tumours 
- Mixed epithelial tumours 
- Undifferentiated carcinoma 
- Unclassified epithelial tumours 
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et al 1970) of all ovarian carcinomas Its origin is the most controversial of all ovarian 
carcinomas It has been considered to be of mesonephnc origin (Novak et al 1954) 
as well as of germ cell origin (Teilum 1959) Since the work of Scully and Barlow 
(1967), however, it has become clear that clear cell carcinoma is most probably of 
paramesonephnc (mullenan) origin, and is closely related to endometrioid carcinoma 
Much more rare are malignant brenner tumours, associated with urothclium-hkc 
epithelial elements and with walthard cell nests (benign lesions from metaplastic ger-
minal epithelium). Benign brenner tumours are not uncommon and are often associat-
ed with other cystic neoplasms Only about 50 cases with malignant brenner tumours 
have been reported in the world (Czcrnobilsky 1977) About the same incidence rate 
is reported for carcinosarcomas (mixed epithelial tumours) and mixed mesodermal tu-
mours (mesenchymal tumours) Both are heterogenous tumours, not only often diffi-
cult to diagnose (Ramaekers et al. 1983a) but also with a very bad prognosis, median 
survival of 12 and 6 months respectively (Dehner et al 1971) 
1 3.3. Grading. 
In a 15 years overview of the Mayo Clinic experience, Malkasian (1975) showed 
the importance of the application of histologic grading for the prognosis of the patient 
and choice of treatment. Grading systems (see table 1 4) have been designed based 
on the percentage of undifferentiated cells present in the tumour (Broders 1926) and 
on the basis of the total histological appearance of a tumour (Alan & Hertig 1949). 
In a very extensive study Malkasian (1975) showed a significant difference in survival 
between the high grade versus low grade tumours in all stages, but this was most pro-
nounced in the lower stages Moreover, differences in survival rate were less apparent 
in mucinous tumours. Similar results are reported by Dembo & Bush (1981) for 430 
patients They found well differentiated serous and mucinous tumours to have a fa-
vourable prognosis as opposed to less differentiated serous tumours. Furthermore, 
higher grade is associated with a higher rate of lymph node involvement (Chen & 
Lee 1984) Sorbe et al. (1982) also reported on a study of 458 évaluable women with 
ovarian carcinoma They concluded that 'the difference in 5-year survival between 
patients with well- and poorly differentiated tumors is as large as the difference be-
tween stage I and IV'. Moreover, the presence of poorly differentiated tumours in 
stage I is a bad prognostic sign. 5-year survival in this group is only 35% Grading 
is especially important in young women in whom ovarian function should preferably 
Table 1 4 Grading systems according to Broders and Alan & Hertig 
Grade Delinition of Broders (1926) Definition of Alan & Hertig (1949) 
I 0- 25% undiflerentialed cells well-difTerentialcd 
II 25- 50"/o undifferentiated cells moderately well-differentiated 
III 50- 15% undifferentiated cells poorly differentiated 
IV 75-100% undifferentiated cells 
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be retained, well-differentiated tumours allow a more conservative approach than the 
less differentiated tumours. 
A very special category of tumours is formed by the 'grade 0\ 'borderline', 'border-
line malignant', 'potentially malignant', 'questionably malignant' tumours, or tu-
mours 'of low malignant potential' These tumours have essentially the same character-
istics as frank malignant tumours (stratification of the epithelial lining of the papillae, 
pleomorphism, atypicality, and mitotic activity > 1/hpf) except for stromal invasion. 
Especially in mucinous tumours it is very difficult to differentiate between malignant 
tumours and tumours of low malignant potential, as stromal invasion is often difficult 
to evaluate due to the formation of intruding cysts. Hart & Norns (1973), therefore, 
do not consider stromal invasion to be a mandatory criterion for the diagnosis mucin-
ous carcinoma Furthermore, they observed in their important series of 688 primary 
mucinous tumours that both atypicality and mitotic activity were inconsistent factors 
in mucinous tumours of low malignant potential 
Finally, it should also be noted that ovarian tumours of low malignant potential 
can occur in every stage of disease, upto distant metastases In a retrospective evalua-
tion of 62 patients with an ovarian tumour of low malignant potential, Nikrui (1981) 
found 30% of the serous tumours in a stage higher than stage I (11% in stage III 
& IV), whereas the mucinous low malignant tumours were seen in a stage higher than 
stage I in 9% (all m stage III & IV) In a series of 94 patients, Barnhill et al (1985) 
found 33% of all tumours of low malignant potential (17 mucinous and 77 serous) 
to be in stage III and IV. Julian et al. (1972) found ascites in 14% of his series of 
64 ovarian tumours of low malignant potential! Generally reviewing the literature, 
metastases of low malignant ovarian tumours are reported in 20 to 45% of all serous 
tumours, of which approximately 10%, have distant metastases 
As long as clear cut histological criteria for the differentiation between 'low malig-
nant potential' and frank malignancy are not available, the advice of Czcrnobilsky 
(1977) should be followed to classify these tumours as 'well-differentiated, low-grade, 
noninvasive carcinomas'. Because most cases with lower malignant potential present 
in an early stage of disease, a rather conservative approach can be advocated for most 
cases. 
Recently Barnhil et al. (1985) reported on their experience with 94 patients with 
tumours of low malignant potential Notably patients with a mucinous tumour had 
a lower 5-year survival rate than patients with serous tumours. Survival rates for all 
histological types and all stages was the same regardless whether the patients received 
adjuvant therapy (91% and 95% for post-operative chemotherapy and radiotherapy) 
or not (100%). 
A definite answer to the question whether patients with tumours of lower malignant 
potential should receive adjuvant therapy can only be answered in a prospective random-
ized trial, which has not yet been conducted. 
Although excellent survival rates are reported, the finding of residual tumour in 
5 out of 10 cases of second-look operation in the series of Barnhil et al (1985) should 
be taken serious. Notably one of these patients had no residual disease after first opera-
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Hon. We feel that surgical treatment should essentially be the same as for carcinomas, 
especially for mucinous tumours 
Apart from the grading according to histological differentiation morphological 
parameters have also proven to be associated with prognosis (Schul/ el al 1985) As 
the results of morphological assessment are often very difficult to interpret because 
of inter- and intra-obscrver variation, the use of quantitative morphometnc methods 
can be of help in gaining reproducible data 
Quantitative assessement of various morphological parameters have shown good 
correlation with prognosis in epithelial ovarian tumours (Baak et al 1981), as well 
as in dysgerminoma of the ovary (Soeters 1984) Especially in differentiation of tu-
mours with lower malignant potential and malignant tumours, morphometry can pro-
vide a powerful discriminative instrument mitotic activity index and the volume per-
centage epithelium together are discriminative al a p-level of less than 0 00001 (Baak 
1983). 
Furthermore, cytophotometnc (Erhardt et al 1985) and flow cytometric (Fricd-
lander et al 1984) assessment of DNA levels in ovarian tumours provide an additional 
objective parameter to histological grading, correlating closely with clinical follow-up. 
These methods are, however, not yet available for direct clinical use 
In conclusion, very few good reports exist regarding grading and its relation to 
prognosis Although it has been suggested that grading might be a more important 
prognostic tactor than staging (Malkasian 1975), there are few other reports to support 
this suggestion (Sorbe et al 1982) Nevertheless, especially in lower stage disease in 
young women, low grade tumours allow less extensive surgery. This is certainly true 
for tumours with low malignant potential Here again, prospective studies on the role 
of surgery and adjuvant therapy arc not available More objective criteria with estab-
lished prognostic relevance may become available in the near future. 
1 4 STAGING 
Unlike other malignancies of the female genital tract, ovarian cancer is staged on 
the basis of surgical assessment Radiological, cndoscopical and echoscopic/-graphic 
evaluation of patients presenting with complaints suspect for an ovarian tumour are 
important for (early) diagnosis and evaluation of the clinical condition, but have no 
direct significance for classification of the disease 
Classification and subsequent staging are based on histologically and cytologically 
proven extent of the disease and therefore always require surgical evaluation. Grossly, 
two main groups of stages can be distinguished (a) disease limited to the pelvic cavity 
(Stage I and II), and (b) disease spread outside the pelvic cavity (Stage III and IV). 
As can be seen in table 1.5, in the lower stages the role of microscopic spread is an 
important characteristic in the subgroups presenting with ascites, cytologically positive 
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Table 1.5 Classification ofovarian cancer, FIGO staging (1974). 
Ia Growth limited to one ovary. 
(i) No tumour on the external surface; capsule intact 
(n) Tumour present on external surface of ovary, and/or capsule ruptured. 
lb Growth limited to both ovaries No ascites*. 
(i) No tumour on the external surface, capsule intact. 
(ii) Tumour present on external surface, and 'or either capsule ruptured. 
Гс Tumour at either stage la or lb, but with obvious ascites* present or positive peritoneal washings. 
IIa Extension and/or metastases to the uterus and/or fallopian tubes. 
IIb Extension to other pelvic tissues 
He Tumour at either Stage Па or lib, but with obvious ascites* present or positive peritoneal washings 
III Growth involving one or both ovaries with extension outside the pelvis, and or positive retroperitoneal 
nodes. Tumour limited to the true pelvis with histologically confirmed malignant extension to small 
bowel or omentum. 
IV Growth involving one or both ovaries, with distant metastases от pleural effusion is present, with 
positive cytology or metastasis to liver parenchyma. 
'ascites is peritoneal effusion that the surgeon considers pathological or clearly exceeding normal amounts, 
or both 
peritoneal washing, tumour present on the external surface of the ovary and/or rup­
tured capsules. Unless the tumour is limited to the intracapsular stroma and epithelium 
of one or two ovaries (stage lai and Ibi), ovarian cancer should be regarded as a disease 
of the whole peritoneal cavity. 
Since it becomes increasingly clear that stage group III comprises patients with wide­
ly differing prognosis on the basis of the tumour load present, a more detailed subdiv­
ision of stage III - which encompasses the largest group of patients - is being consid­
ered by the FIGO Cancer Committee ( Richardson et al. 1985). In this concept stage 
Ilia should encompass patients with only microscopic abdominal spread, stage Illb 
with abdominal tumour(s) less than 2 cm in diameter before resection, and stage I lie 
with larger tumour deposits in the abdomen and/or involvement of retroperitoneal 
lymph nodes. On the other hand it is now also accepted that residual tumour AFTER 
operation is the most important prognostic factor compared with tumour size or exten­
sion PRIOR to cytoreductive surgery. 
In the evaluation of malignancies of the ovary usually the 1974 revised FIGO classi­
fication is used (see table 1.5). Other classification or staging systems include the TNM 
classification and the UICC staging system, which is based on the TNM classification. 
Currently, description of spread of disease is defined in terms of'classification', which 
means the description of the extent of disease in terms of sites involved, and 'staging', 
which means the formation of prognostic groups on basis of these sites involved. 
Unfortunately, one prognostically important item is not included in this classifica­
tion: histological grading. Fortunately, another item of prognostic significance, not 
incorporated in e.g. the classification of cervical neoplasms, has been appreciated: 
lymphatic node involvement. 
In a series of 26 patients, initially staged as 'stage Г disease, Knapp and Friedman 
(1974) found 19% having positive para-aortic lymph nodes. It should be noted that 
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Table 1 6 Pard-aorlic lymph node involvement in supposed stage I ovanan cancer 
author(s) 
Knapp & Friedman 
Delgado et al 
Piver et al 
Musumeci et al 
Knipscheer 
Chen & Lee 
Vergole 
Total 
year 
1974 
1977 
1978 
1980 
1982 
1983 
1984 
# patients 
26 
5 
5 
34 
20 
11 
4 
105 
0/ involved 
19 2 
20 0 
0 0 
147 
25 0 
18 2 
0 0 
162 
none of these patients with lymphatic spread had a tumour with intact capsule These 
findings were consistent with later studies (see table 1 6) Of special interest is that 
both Knapp and Friedman (1974) and Knipscheer (1982) reported positive lymph 
nodes in stage I disease only in patients with poorly differentiated tumours This corre­
lates well with the findings of Chen and Lee (1984), who found an increase in percent­
age of lymph node involvement with increasing histological grade for all stages 
In reviewing these data one should keep in mind, however, that all patients with 
positive lymph nodes in these scries were wrongly staged as stage I and should already 
have been assigned as having stage III disease In series where careful classification 
has been done as will be described below, the percentage of lymph node involvement 
in stage I disease will, by definition, be 0%' So aggressiveness in the approach of stage 
I patients should not only be based on the results presented here, but also on an evalua­
tion of the classification procedure used by the surgeon (cf Ozols & Young 1983) 
Classification is mandatorily based on surgical exploration and requires careful ex­
amination of all sites involved for which we propose the protocol in table 1 7 Omitting 
exploration of one or more of these sites may result in insufficient classification and 
therefore in improper staging (as illustrated in the example of lymph node involve­
ment) 
Table 1 7 Evaluation of inlra-abdominal spread procedures at staging laparotomy 
- sampling of intraperitoneal fluid 
- smears of para-colic gutters, diafragm and cul de sac 
- palpation and visual examination of the intestine 
- palpation and visual examination of liver and spleen 
- hysterectomy 
- bilateral salpingo-oophorettomy 
- supra-cohc omentectomy 
- cytoreductive surgery (tumour debulking) 
- in absence ofmacroscopic intraperitoneal spread 
О random biopsies of the para-colic gutters 
О random biopsies of the diafragmalic pentoneum 
О para-aortic lymph node sampling 
О pelviL lymph node sampling (optional) 
34 
One item that can lead to difficulties is the interpretation of the presence of ascites. 
When a large volume of ascites is present, which is often the case, or when cytological 
examination of the peritoneal washing in the absence of ascites reveals malignant cells, 
classification will not be a matter of dispute In other instances it is up to the surgeon 
to define what is ascites or not. As there is always a certain amount of peritoneal 
fluid present, with largest volumes up to 60 ml in the post-ovulatory period (Bouckaert 
1984), it can be difficult to decide whether it is ascites or not, especially in lower stages 
Maathuis (1978) showed that the total protein concentration m peritoneal fluid (c 
40 g/l) was consistently lower than in serum (60-70 g/1). Although both physiological 
fluid and ascites should be considered exsudâtes, a higher protein concentration in 
the latter, nearly corresponding with serum concentrations, might differentiate be-
tween pathological and physiological fluid Also other significant changes in the bio-
chemical profile of peritoneal fluid have been reported (McGowan et al 1973). Such 
objective entena are, however, not (yet) incorporated in the classification 
Another problem in FIGO classification (table 1 5) is that nowhere is stated whether 
rupture of the capsule pre-operatively and during the operation should be equally 
appreciated Some only speak of'ruptured capsule' if rupture has occured before oper-
ation and still stage as lai and Ibi, even if the cyst is ruptured through manipulation 
Spread of tumour cells is not likely to be influenced by the way the cyst ruptures 
Moreover, it might be assumed that through instrumentation in the opened peritoneal 
cavity tumour cells will even be more easilly spread at iatrogenic rupture than at 'natu-
ral' rupture Therefore, we consider every intra-abdominally opened cyst to be rup-
tured and classify accordingly. The value and importance of cytological sampling be-
fore spill can occur will be discussed in chapter 6. 
In conclusion: staging of ovanan cancer is still not based on an unequivocal classifi-
cation with objective criteria It is feared that proposals for a new staging system only 
add further details without prognostic significance. Nevertheless, a good staging pro-
cedure with adequate classification together with careful recording of all tumour sites 
is necessary to give better knowledge of prognostic significance of current and pro-
posed staging criteria. 
1.5 SYMPTOMA rOLOGY. 
Symptoms provoked by the 'silent lady killer' are often vague and seldom directing 
towards the diagnosis of a gynaecological tumour Barber & Kwon (1976) are still 
right in stating that 'early diagnosis is a matter of chance rather than a scientific meth-
od' This statement was based on long term experience in looking for early signs of 
malignant ovarian disease In 1968 Barber introduced the concept of the 'Post Meno-
pausal Palpable Ovary (P.M P O ) syndrome' (Barber & Graber 1968) In post meno-
pausal women every palpable ovary is suspect for malignancy, since functional cysts 
do not occur at this age. The value of this symptom is, how significant it may be, 
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limited even if a patient visits her physician for vague abdominal discomfort (the 
most frequent presenting symptom, see tabic 1 8), a vaginal examination will seldom 
follow 
Although abdominal pain and abdominal distension are the most frequent symp­
toms and occur in about half of all cases, they can hardly be called pathognomonic 
for ovarian cancer A circumscnpt swelling, that might direct towards the diagnosis 
of an ovarian tumour, is rarely felt by the patient Patients are often referred to the 
surgical department e g for appendicitis (in 10% of our patients) or to the medical 
department for gastro-intestinal examination (in 23% of our patients) 
Abnormal vaginal blood loss is the only gynaecological symptom, reported in about 
15% of all cases Uyttenbroeck (1976) postulated that this symptom is suspect for 
a secondary tumour, but from the perccnlages of symptoms in patients with primary 
ovarian malignancy (table 1 8) it can be concluded that this is also a relalivcly common 
symptom in primary ovarian cancer 
Patients' and doctor's delay, as expressed as time between first symptom and diagno­
sis, can exceed 6 months in up to 25% of the patients (Buka & McFarlane 1969) 
In 83% of the cases of our study, the diagnosis was made within 6 months Also Uytten­
broeck (1976) reported a similar figure of 76% 
In the absence of a specific syndrome, abdominal distension (ascites!) paired with 
weight loss in post menopausal women should bring the diagnosis of ovarian cancer 
in mind 
Tabic 1 8 Presenting symptoms in ovarian cancer ("„оГрориШюп) 
Author 
symptom 
abdominal pain 
abdominal distension 
abdominal mass 
gastro-int complaint!) 
urinary symptoms 
abnormal bleeding 
weight loss 
Number оГраІіепЬ 
Meigs* 
1940 
65 68 
50 
-
-
25-41 
25-30 
30-40 
154 
Malloy 
1965 
59 
46 
22 
32 
22 
17 
23 
558 
Pomerance 
1966 
30 
44 
4 
6 
2 
-
128 
Dargent 
1973 
_ 
35 
-
8 
5 
19 
-
349 
DiSaia 
1975 
50 
70 
-
20 
15 
15 
15 
Kennedy 
1981 
34 
20 
10 
10 
9 
4 
97 
this 
study 
70 
48 
8 
27 
9 
20 
II 
64 
* Two values for patients with 'solid' and 'cystic' tumours respectively 
Although untili recently early detection of ovarian disease by means of ultrasound 
examination was not regarded as feasible, recent data (Campbell et al 1982, Goswamy 
et al 1983) are very encouraging that with modern techniques the Ρ Μ Ρ О -syndrome 
will soon take on new (echoscopie) dimensions Echoscopy might be valuable in screen­
ing high risk groups (such as discussed in paragraph 1 2) for ovarian cancer in an 
early stage of disease 
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1 6 PRL-OPERATIVF EVALUATION 
Definitive diagnosis of ovarian cancer in most cases (83% in our patients) is done 
at staging laparotomy In other cases diagnosis can be made by cytological examina­
tion of ascites, obtained at paracentesis and/or of pleural effusion, obtained at pleural 
puncture Although culcentesis has been a much advised approach for obtaining fluid 
for cytological examination (Day & Smith 1975), the risk of intra-abdominal spread 
makes this approach less desirable, the same accounts for punctation of ovarian cysts 
through the abdominal wall (Busine 1984) Of course, in women less likely to have 
developed a malignancy of the ovary, such a transvesical approach might be advocat­
ed. Apart from the risk, still present, of spread of tumour cells, this is seldom a curative 
approach, since cysts readily recur. Furthermore, the false negative rate of cytologic 
examination of specimens obtained in these ways is very high, even in cases with wide­
spread tumour (McGowan et al 1966). 
The initial work up as performed in our clinic is shown in table 1 9 All examinations 
that have no direct clinical implication are omitted. Notably it is not advisable to 
do a barium enema, livcr-/spleenscintigraphy, CT-scan or lymphangiography routine­
ly. Neither of these examinations will influence surgical treatment as debulking will 
always be performed and metastatic spread to either of the sites examined by these 
procedures can also be explored surgically 
Intestinal metastases can be removed, with or without a resection of a part of the 
intestine. This does not require a preoperative barium enema, but a good cleansing 
of the bowel is essential for uncomplicated surgery and good results 
In stage I and II para aortic lymph node sampling will be performed to be sure that 
no lymph nodes are involved, whereas in stage III and IV disease (only) enlarged lymph 
nodes will be removed in the cytoreductive procedure Lymphangiography may facili­
tate finding the pathological lymph nodes, but is not mandatory; in lower stage I di­
sease a lymphangiography is optional before operation in order to be able to check 
sites to be biopsied After the operation of an unexpected ovarian tumour lymphan­
giography should be done when proper lymphadenectomy has not been possible 
Table 1 9 Pre-opcrativc evaluation 
- physical (esp pelvic) examination 
- blood BSE.hacmoglobinc, leucocytes + difT, platelets, electrolytes, liver function tests, protein, albu­
men, urea, creatinine tumour associated antigens (CLA, ΑΓΡ, hCG, OC-125) 
- ultrasound examination ofpelvis and abdomen 
- chest X-ray 
- ι ν urogram 
- abdomen X-ray 
- cystoscopy 
- paracentesis (when ascites is present) 
- lymphangiography (optional) 
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The liver can be palpated at the staging laparotomy and in the rather rare case 
of intra-hepatic metastasis a through-cut puncture can be done in order to obtain 
histological evidence. In our series we found only 1 patient (1 5%) with parenchymal 
metastases in the liver at time of diagnosis Even at post mortem examination of pa­
tients who died from recurrent disease not more than 2 cases of intra-hepatic metas­
tases (4.5%) could be found 
One of the main problems in cancer diagnosis in general, but particularly in the 
abdominally hidden ovarian tumours is that detection is dependent on the physical 
properties of the tumour: size, density and localization Imaging techniques have been 
improved to a large extent, warranting a more accurate diagnosis and monitoring 
of tumours Since the resolution of these techniques do not allow the detection of 
tumours of small size or tumours at inaccessible sites, more refined diagnostic means 
are needed 
Tumour markers allow detection of tumour at a distance, ι e irrespective of the 
physical properties of the tumour The different types of tumour markers can be classi­
fied into 5 groups a) proteins with enzymatic activity that are non-specifically elevated 
m the presence of tumour (e g galactosyltransfcrasc, GT), b) (early) developmental 
proteins that may reappear (e.g Carcino Embryonic Antigen, alpha-foetoprotein), 
c) carcinoplacental glycoproteins (Human Gonado Trophin, Human Placental Lacto­
gen), d) proteins derived from oncogene activity, associated with carcinogenesis, and 
e) tumour-associated cell surface antigens This paragraph will discuss the latter group 
of markers, since these markers are potentially directed specifically towards different 
tumour types A special group of antibodies are those directed towards tissue specific 
intra-cellular elements, the intermediate filaments Although these are not specific for 
the type of tumour, they can be helpful in establishing the tissue of origin (for review 
see. Ramaekers et al 1983b) 
Bhattacharya and Barlow (1973) were the first to detect antigens (OCAA Ovarian 
Carcinoma Associated Antigens) associated with ovarian serous cystadenocarcinoma 
by means of polyclonal antibodies against these tumours. Such polyclonal antibodies, 
however, have the disadvantage of being directed towards various epitopes or antigen 
sites, rendering them an unwanted aspecificity 
In 1975 Kohier and Milstein developed the hybndoma technique by which antibo­
dies can be produced in large quantities with such a high intrinsic specificity that only 
one or two antigen determinants, or epitopes, are recognized Such monoclonal antibo­
dies have also been developed against ovanan tumours (for overview see Kenemans 
et al. 1985). OC-125, developed by Bast and co-workers (Bast et al 1983), was the 
first to be both satisfactory specific for ovarian serous cystadenocarcinomas and clini­
cally applicable Recently a monoclonal antibody (OV-TL3) with seemingly higher 
specificity and also reactive with mucinous tumours was developed by our group (Poels 
et al 1985). 
Of the possible applications of monoclonal antibodies, those in tumour diagnosis 
are detection of malignant disease in primary diagnosis or in treatment monitoring 
by immunoserology (Bast et al. 1983, Niloff et al 1985), immunolocalisation by means 
of scintigraphy (Pateisky et al. 1985) as well as by immunopathology where monoclon-
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al antibodies can be helpful in differential diagnosis (Kabawat et al. 1983, Ramaekers 
et al. 1983). 
Computer tomographv (CT) has as yet no place in the classification of ovarian tu-
mours (Amendola et al. 1981). Kerr-Wilson et al (1984) found CT 'helpful' in just 
over half (55 5%) of a total of 41 CT scans in 30 patients This is mainly due to the 
fact that CT cannot detect tumours of a size less than 2 cm, which is often the case 
in lymph node involvement and peritoneal implants (Solomon et al 1981, Rohde & 
Steinbin 1982). Neither is CT very helpful in demarcating the tumour from other pelvic 
organs, such as the uterus (Spasokukotskaya, 1984) In a partly prospective, partly 
retrospective study, van Engelshoven (1983) evaluated 88 cases where CT scan was 
performed for suspected ovarian cancer In 11 of these cases no abnormalities were 
found Of the 60 patients with proven ovarian cancer sensitivity in the detection of 
tumour ranged from 22% (diafragmatic lesions) to 95% (pelvic mass) Specificity 
ranged from 89% (pelvic mass) to 100% (ascites, diafragmatic metastases and omen-
tum metastases) Van Engelshoven concluded that CT has no place in staging of the 
disease, but that it might be helpful in timing second-look operations CT, however, 
also fails to detect tumour rests adequately Stern et al (1983) reported 3 false negative 
results in 18 patients before second-look operation Regarding the cost-benefit ratio, 
there is an argument for the use of CT-scan only when complete debulking has not 
been possible. In such cases, CT can be done post-operatively to record the situation 
before start of chemotherapy. However, helpfulness in these cases has still to be prov-
en 
Notably, until recently the superiority of CT over ultrasound examination could 
not be established (Amendola 1981; Walsh 1978) A more recent retrospective study 
(Kerr-Wilson et al 1984) confirmed this Preliminary data from a Dutch study, howev-
er, suggest that sonography has a higher false-positive rate than CT and that CT can 
more adequately assess invasion of the tumour in surrounding tissue (Van Doorn et 
al. 1985). 
Finally, Johnson et al. (1984) have illustrated (and not more than that) that Nuclear 
Magnetic Resonance (NMR) Imaging (MRI) is possible in patients with ovarian can-
cer. In a companson of CT and MRI examination of patients with gynaecological 
tumours, both methods appeared to give similar results (Bies et al 1984) Since there 
is more contrast in the pelvis provided by the pelvic fat, MRI seems to be specifically 
suitable for scanning of this part of the female abdomen (Bryan el al. 1983) The clinical 
usefulness of this type of extremely expensive examination has still to be established 
Investigations in this field are in too preliminary a stage to allow a definitive comment. 
As in CT, it is not unlikely that MRI will prove to be too expensive for routine use 
and can add little information to commonly used diagnostics, such as ultrasound tech-
niques 
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2. Overview of treatment before 1979 
2.1. REVIEW OF THE LITERATURE 
As early as 1949 Howson and Montgomery analyzed the history of patients with gyn­
aecological malignancies, who were often seen in a late stage of disease. It appeared 
that physicians' delay was 9.6 months (mean) and in not less than half of the cases 
this was due to the fact that the doctor did not make an examination! Despite this 
early warning, ovarian cancer remains a disease of the late stages. Five-year survival 
remained essentially unchanged for decades (see table 2.1 ). 
Table 2.1 Five-year survival rates in the past 3 decades, before 1979 
Author Year /Patients Stage III'IV All stages 
Kottmeier 
Munnel 
Kent 
Rubin 
Buka 
Dargent 
Kottmeier 
Berhe 
1952 
1957 
1960 
1962 
1964 
1973 
1976 
1983 
418 
120 
349 
145 
100 
333 
4394 
495 
2 · ; 
io"; 
18°; 
io°0 
12". 
7°/„ 
I/o 
24°/0 
2S°0 
36" 0 
36% 
зг; 
19" 0 
28"/0 
13°; 
The overall 5-year survival was approximately 30%, with less than 10% of the pa­
tients surviving this period with stage III and IV disease. This constant survival rate 
is a reflection of the lack of progress in the management of ovarian cancer at that 
time. It is remarkable that especially in France the general prognosis for ovarian cancer 
is worse than elsewhere in the western world (Dargent et al. 1973) and that these poor 
results were not improved in the past 3 decades: 5-year survival for advanced ovarian 
carcinoma decreased to nearly 0 in the most recent national survey up to 1979 (Berlie 
et al. 1983)! Treatment of ovarian cancer has until the mid-seventies been a matter 
of little choice and hence of little dispute. 
Surgery 
Griffiths and co-workers (1972) were the first to introduce the concept of cytoreduc-
tive surgery (debulking). In a retrospective study of 60 patients with advanced ovarian 
carcinoma, treated between 1955 and 1965, they investigated the role of concurrent 
administration of alkylating monochemotherapy with postoperative irradiation. 
Thirty-two of the 53 patients that received 'adequate' radiotherapy had an Optimal 
operation', where cytoreductive surgery could achieve minimal residual tumour. 
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Twenty-one still had 'residual palpable disease' Only in the first group with optimal 
operation could they observe a significant improvement of survival with the addition 
of alkylating mono-chemotherapy to radiotherapy On the basis of these results Grif-
fiths in a later study established the diameter of the largest residual tumour mass as 
statistically significant at the 2 per cent level when exceeding 1 0 + 5 cm (Griffiths 
1975) 
From two retrospective studies, one in Los Angeles (UCLA) and one in Leiden 
(University Clinic) Heintz (1985) concluded that patients in whom residual tumour 
after cytoreductive surgery was less than 1 5 cm in diameter had a significantly better 
prognosis than those left with larger tumour volumes Despite the minor post-opera-
tive complications like fever and prolonged ileus after bowel surgery, Heintz strongly 
advocates extensive surgery in order to obtain optimal tumour reduction A more 
favourable prognosis justifies the risk of a higher but still acceptable morbidity on 
the basis of cytoreductive surgery as found in the retrospective study of Heintz and 
in other similar studies (Chen & Bochner 1985), although this is questioned by some 
other authors (Moore 1980) 
Chemotherapy 
In the early fifties, nitrogen mustard appeared to have some effect on ovarian tu-
mours With the introduction of a series of alkylating agents, chemotherapy for ovar-
ian carcinoma was started chlorambucil (Leukeran"), cyclophosphamide (Endox-
an l l), Thiotepa and l-phenylalanme mustard or melphalan (Alkeran ") were respective-
ly introduced between 1955 and 1965. Treatment results are very difficult to assess 
for this early period Surgery was often incomplete and tumour rests were not recorded 
There was not yet a consensus on criteria for therapy response and new cytostatic 
agents were not tested in prospective, randomized trials The alkylating agents had 
the great advantage of oral administration Melphalan was the most extensively used 
alkylating agent with 35 to 65% responders reported (Smith & Rutledge 1970). Of 
the responders 20% survived 5 years (Smith & Rutledge 1970) The choice of chemoth-
erapy versus radiotherapy was a matter of 'discretion' of the surgeon and not based 
on good clinical studies 
Radioiherapy 
Radiotherapy, first by orthovolt technique (cf Orbaan 1920) and later by the use 
of cobalt-60 megavolt technique, was certainly equal to, if not superior to single-agent 
chemotherapy A new impetus to this treatment modality was given especially by the 
introduction of a modification of the Manchestermoving strip technique - which was, 
incidentally, devised for the treatment of patients with testicular cancer - adapted 
for cobalt-60 by Delclos and co-workers (1963) 
In contrast to the open-field technique, in which the whole abdomen is irradiated 
in a number of fractions, the moving strip technique uses small horizontal segments 
(strips) which are irradiated consecutively At each session a number of strips, starting 
with one strip up to usually 4 strips of 2 5 cm wide, are irradiated When the first 
strip has received its maximum dose, the field moves upward or downward (depending 
on where the first strip is started) including the next adjacent strip It was presumed 
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that with this technique a high biological tumour dose could be reached, but when 
evaluating the open field and moving strip technique by their 'ret dose' and 'TDF 
value' (estimates of biological tolerance) both techniques appeared to have similar 
values (see for details Fuks 1975) and neither could differences m clinical response 
be detected in prospective studies (Fazekas & Maicr 1974, Dembo et al 1984) 
With cobalt-60 moving strip an even distribution to the whole abdomen can be 
obtained, but this is technically more difficult with modern linear accelerators with 
reduced penumbra producing inhomogeneity of dose distribution (Khan et al 1974) 
Effectiveness of moving strip radiation is also reduced by bowel movements and intra-
penloncally floating cells, causing escape Furthermore, more complications occur 
with the moving strip technique, especially bowel complications requiring surgery in 
6% of the patients versus 1 2% of patients treated with the open-field technique (Dem-
bo et al 1983) Finally, the open-field technique is much easier to apply and has a 
shorter duration than the moving strip technique 
In conclusion it seems that the only advantage of the moving strip technique is 
that with its introduction, the importance of irradiation of the diafragmatic domes 
was also introduced Amazingly enough, however, Delclos et al (1963) stressed this 
important point, but still incorporated liver shielding in his irradiation Conversely, 
Dembo et al (1979) recognized the consequences of this concept and did not shield 
the liver, but reduced the midplane dose to 22 5 Gy From the criticism of the efficacy 
of the moving strip technique, as summarized by Young et al (1982), it can be con-
cluded that this technique is not the approach of preference, if not obsolete 
In the past two decades a few major groups have been investigating the role of 
radiotherapy Results of the most important of these studies, notably in the Princess 
Margarclh Hospital in Toronto and the MD Anderson Hospital in Houston, will be 
summarized here (see table 2 2) 
In a prospective study, initiated by Bush in 1971, Dembo et al (1979) found an 
improved survival following abdomino-pelvic radiation, with no additional effect on 
response for chlorambucil in addition to radiotherapy Brody et al (1979) also failed 
to find an improving effect of the addition of melphalan to radiotherapy (neither be-
fore, nor after irradiation) in a prospective randomized trial 
Recently Dembo reviewed and updated the Princess Margaret Hospital experience 
(Dembo 1984) In the stage la group, patients were randomized between observation 
(27 cases) and pelvic irradiation (27 cases) In this part of the study there was an even 
distribution of the 9 relapses over both groups From this part it could be learned 
that 'pelvic irradiation is inappropriate adjuvant therapy' (sic1), confirming the con-
cept of ovarian cancer as a disease of the whole abdomen In a similar study of the 
Gynecological Oncology Group (Hreshchyshyn et al 1980) a difference between both 
arms could not be found Dembo also reports on his study in which he treated 190 
stage lb, II and III asymptomatic patients Notably, stage III patients were allocated 
to cither the pelvic irradiation + chlorambucil or to the pelvic irradiation + abdom-
inal-pelvic irradiation arm Again a great difference in overall response could be ob-
served between complete bilateral salpingo-oophorectomy and hysterectomy (BSOH) 
and incomplete BSOH 5-year survival of 62% and 21% respectively for all arms to-
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Table 2 2 Prospective randomized trials comparing radiotherapy and chemotherapy in first line treatment 
of advanced ovanan carcinoma 
Author Stages Rx Arms Results Comment 
Melphalan vs 
Pelv + strip 
Chlorambucil vs 
open field vs 
both 
Melphalan vs 
open field vs 
1 Cth + 2 RTh ν s 
1 RTh + 2 CTh 
Demboetal 1979 ΙΒ,ΙΙ + pelv vs 
asymptomatic III pelv + 
chlorambucil vs 
pelv + strip 
Smith et al 1975 Ι,ΙΙ,ΙΙΙ 
< 2 cm 
Miller et al 1975 III 
Brady et al 1975 III 
no significant 
differences 
irradiation 
alone best, 
no benefit 
from combination 
irradiation 
not significantly 
better than melphalan, 
not benefit from cither 
combination 
pelvic + abdominal 
strip irradiation 
superior, esp in 
patients with 
minimal residual tumour 
more stage I 
and IIa pts 
in melphalan group 
Chlorambucil 
given for 
only 8 weeks 
altcrdiagn 
Legend 
< 2 cm residual tumour not larger than 2 cm in diameter 
pelv pelvic irradiation 
open field abdominal irradiation with open field technique 
strip abdominal irradiation with moving strip technique 
CTh chemotherapy, ι с melphalan 
RTh radiotherapy, ι с abdominal open field irradiation 
gether. Once again, although treatment results did not differ for those in the group 
with imcomplete BSOH, the difference was marked in the group with complete BSOH. 
For all stages together 5- and 10-year survival rates were better following pelvic + 
abdominopclvic irradiation than following pelvic irradiation + chlorambucil (p 
0 007) Unfortunately, as the author already reports himself, surgical staging was not 
always well performed and chlorambucil was also administered in a low dose and 
not always adequately In a randomized trial between postoperative abdominopclvic 
irradiation with the moving strip technique and melphalan therapy, 70 versus 79 pa­
tients respectively were studied at the MD Anderson Hospital (Smith et al 1975) 
Overall 5-year survival in these stage I, II and HI patients was similar for both arms 
(71% and 72%) Because of less toxicity and lower costs, many physicians in North 
America preferred - on basis of this study - to give their patients melphalan postopera­
tively (Dcmbo 1984), nobody, however, achieved 70% 5-year survival' 
Even quite recently Schray and co-workers (1983) reported on a non-random study 
in which they treated 82 patients with disease limited to the pelvis and lower abdomen 
in stage I, II and 'selected' stage III with open field irradiation ' administered only 
to regions of demonstrable disease' after initial surgery This regimen resulted in an 
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overall 10-year survival of 53°./ (78, 60 and 24% for stages Ι, Π and III respectively) 
This high survival rate was the highest reported uptil then However, this study compr­
ised patients of whom at least 14% were improperly staged and in 13% of the cases 
not all bulk of disease could be removed Moreover, irradiation by means of a 4-
and 6-MV linear accelerator was subject to many variations So, unfortunately the 
initial status of the patients is not well documented and it may be very dangerous 
to compare these results with those from well conducted prospective randomized trials 
as previously described 
Another approach in the application of radiotherapy is preoperative irradiation, 
which is reported to enhance operability (Kjerstad et al 1977, Long et al 1967, Vaeth 
& Buschke 1969, ) as well as resulting in longer survival (Kottmeier 1962, Long et 
al 1967, Vaeth & Buschke 1969) More recent reports on preoperative irradiation 
are not to be expected because this approach has now been nearly completely aban­
doned for several reasons When irradiating preoperatively it is impossible to obtain 
a satisfactory histological diagnosis and a good classification of the disease Although 
no surgical problems have to be expected from this type of irradiation, there is always 
a risk of post-operative complications, especially when it is necessary to resect a part 
of the intestine' The need for a bowel resection can hardly be estimated before opera­
tion, but will be hampered by the radiotherapy given Moreover, the value of preopera­
tive irradiation is very difficult to assess, because it will never be known whether the 
patient was really inoperable or not' 
The role of radiotherapy in second-line therapy after chemotherapy will be very 
limited because of the high rate of patients that are not able to tolerate the planned 
radiotherapy 59% as reported by Hainsworth et al (1983) Greiner et al (1984) also 
reported that they had to interrupt radiotherapy in 67% of the patients who received 
'consolidation' therapy Hacker et al (1985) reported that 30% of the patients who 
received salvage radiotherapy required laparotomy for small bowel obstruction Un­
fortunately the response of the patients was not made clear Radiation therapy might 
well be effective in the management of microscopical residual tumour However, pro­
spective randomi/ed studies on the role of salvage radiotherapy are lacking 
As ovarian carcinoma is considered to be a disease of the whole abdominal cavity, 
it seems logical to apply radiotherapy directly to the surface of this cavity (see for 
review Rosenshein 1983) Intra-pentoneal administration of l9BAu and 32P has been 
widely used before the introduction of cobalt-60 irradiation and more modern tech­
niques in radiotherapy Problems with an even distribution in the abdomen, adhesions 
that make subsequent surgery virtually impossible and complications such as bowel 
obstruction made this approach less attractive Notwithstanding these problems, it 
has been advocated for therapy of especially early stage disease (Buschbaum & Keettel 
1975) Furthermore it has been incorporated in a protocol together with external irra­
diation intraperitoneal instillation of 1 2P proved to give satisfactory preliminary re­
sults in a regimen of intra-abdominal 3 2P followed by split delayed abdominal irradia­
tion (Hinket al 1978) 
Further developments in the field of radiotherapy have more or less been slowed 
down by the introduction of new active cytostatic agents, which will be discussed in 
chapter 3 
50 
Conclusion 
Surgical treatment of ovarian cancer in these early years was far from aggressive 
or radical. Mono-chemotherapy with alkylating agents was hardly used as an adjuvant 
chemotherapy, but mostly as a treatment of recurrent disease. In this respect not much 
progress was made. More progressive were efforts to improve radiotherapeutic ap-
proaches, which were rather successful. The concept of cytoreductive surgery was gra-
dually introduced and received an extra impetus when better chemotherapeutic 
schemes came available in the late seventies, making extensive surgery worthwhile. 
The implications of these developments will be discussed in the next chapter, report-
ing our own experience in this early period. 
2.2. EXPERŒNCE IN THE RADBOUD HOSPITAL: RADIOTHERAPY. 
2.2.1. introduction. 
Retrospectively the history and follow-up data were evaluated of 53 patients treated 
between 1960 and 1978 for ovarian carcinoma in the department of Radiotherapy. 
The aim of this retrospective study was to review the treatment in the past 2 decades. 
Lack of improvement in the treatment results reported elsewhere (see for overview 
chapter 1) called for an evaluation of our own results in order to establish a starting 
point in improving treatment. 
2.2.2. patients and methods. 
Patient characteristics are summarized in table 2.2. The age distribution shows a 
peak between 50 and 60 years. The pattern of complaints was not specific for any 
disease: abdominal pain (47%), abdominal distension (38%), abnormal bleeding or 
vaginal discharge (13%) and abdominal mass (9%). Similar results were obtained in 
a later study, reported in the next paragraph. At least partly through these atypical 
symptoms, more than 70% of the patients had complaints for longer than 3 months 
before diagnosis was made and in more than 20% this period was longer than 6 months. 
In only one case the diagnosis of malignancy was made prior to operation. Table 
2.3 shows the indications for primary surgery. Unfortunately, in 21 cases the exact 
indication could not be traced in the patient's record. 
In accordance with the literature we saw that 75% of the patients had an epithelial 
tumour of the ovary. There were 16 serous cystadenocarcinomas papilliferum and 
only 4 mucinous cystadenocarcinomas, whereas 15 tumours were not further classified 
than '(cyst-)adenocarcinoma'. This low percentage of mucinous tumours can be ex-
plained by this high number of less differentiated tumours, that may hide some mucin-
ous carcinomas. As discussed in chapter 1, mucinous cystadenocarcinomas can often 
be very difficult to diagnose. 
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Tabic 2 3 Characteristics of 53 patients receiving radiotherapy 1960-1978 
Histological classification 
Classification 
Nulliparae 
Mean age (epithelial tumours) 
Duration of patient's 
+ doctor's delay 
Previous treatment 
Indication for first operation 
epithelial carcinoma 
germ cell tumours 
gonadal stroma tumours 
not specific for the ovary 
Stage la 6 
b 2 
с 3 
lall 
Stage IIa 2 
b 8 
с 4 
Hall 
Stage III 
Stage IV 
Stage unknown 
less than 6 months 
more than 6 months 
unknown 
not treated before (primary) 
treated before (secundary) 
tumour in abdomen/pelvis 
tumour of the ovary 
myoma of the uterus 
acute abdomen 
appendicitis 
adenocarcinoma 
unknown 
40pts 
5 
7 
1 
11 
14 
18 
5 
5 
26 
554y 
32pts 
12 
9 
37 
16 
14 
11 
3 
2 
1 
1 
21 
In the period studied here grading of tumours was not systematically performed 
and could not therefore be taken into account 
Staging was done according to FIGO regulations (see chapter 1 4) In 48 patients 
the pattern of metastatic spread of the tumour was documented In 16 cases there 
were metastases in the omentum or peritoneum In not less than 5 cases there were 
clinical and radiographical signs of parenchymatous metastasis in the liver This is 
a rather high rate, considering the rareness of this localisation and the fact that in 
a later study (see chapter 2 3) we saw only 1 case of liver metastasis out of 65 patients 
Four patients presented with metastases to the lung and an equal (and again high) 
number of patients had already skeletal metastases 
In table 2 4a summary is given of the different strategies in various stages of disease 
Primary treatment, ι e the first treatment given for this disease after surgery, consisted 
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Table 2 4 Treatment strategics number of patients per stage and treatment modality 
Primary trealmcnl la 
expectant 0 
radiotherapy 5 
chemotherapy 1 
lb 
0 
2 
0 
Ic 
0 
3 
0 
IIa 
0 
1 
1 
IIb 
1 
6 
1 
He 
0 
3 
1 
111 
1 
10 
7 
IV 
1 
4 
0 
Unknown Total 
2 5 
3 37 
0 11 
of: a) expectancy, b) radiotherapy, and c) chemotherapy Thirty-seven of 53 patients 
received radiotherapy It should be noted that surgery in the period studied was hardly 
ever radical, nor complete and often unsuccessful in reducing tumour load (see also 
chapter 2 3) After failure of primary therapy, or when the original treatment plan 
was altered, secondary therapy (with the same modalities) was applied in 30 cases. 
Again, radiotherapy was the most used approach in this latter group ( 10 cases) 
In the first years of the period studied, radiotherapy was mostly given to the pelvic 
or abdominal region only Later, radiation in most instances started with a whole 
abdominal field up to 25 0-30 0 Gy In the course of abdominal irradiation, the kidneys 
were shielded after they had received 15 0 Gy and the liver was shielded after having 
received a dose of 20 0 Gy. Subsequently, an extra dose of 10 0-20 0 Gy was given 
to the pelvic region Fractions of 1 50 to 2 50 Gy were administered on 5 consecutive 
days (Monday through Friday) until total tumour dose was reached Until 1964 irradi-
ation took place with 250 kV X-ray beams with HVL = 3 mm Cu (Philips RT250) 
Table 2 5 Approaches in the administration of radiotherapy N = 53 
Co60 Abdomen + pelvis 
abdomen only 
pelvis only 
pelvis + spine 
250kV abdomen + pelvis 
pelvis only 
lower abdomen 
18MV abdomen + pelvis 
pelvis only 
Intrapentoneal isotopes 
+ external radiation* 
alone 
6 
0 
9 
1 
2 
3 
1 
0 
0 
0 
after 
surgery 
6 
2 
8 
0 
0 
0 
0 
3 
0 
2 
after surgery 
and chemother 
0 
3 
7 
0 
0 
0 
0 
1 
1 
0 
Total 
12 
5 
24 
1 
(42) 
2 
3 
1 
(6) 
4 
1 
(5) 
2 
* both patients received also external irradiation 
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Table 2.6 Tumour response to irradiation N — 53 
Tumour no more palpable 
Decrease of tumour size 
Stable disease 
Progression 
Unknown 
12 
7 
4 
13 
17 
(6 patients), from 1964 until 1978 Telecobalt beams (Philips and AECL Theratron 
780) were used (42 patients), and from 1978 onwards patients were treated with 18 
MV X-ray beams (CGR Saturne)(5 patients). An overview of the different approaches 
is shown in table 2.5. 
In the case of a dysgerminoma the target regions for radiation also encompassed 
the mediastinum and supraclavicular nodes, as these tumours are even more prone 
to lymphatic spread than epithelial ovarian tumours (Musumeci et al. 1978). 
Two patients had been treated with intraperitoneal installation of radioactive gold 
(198Au) and chromiumphosphate (-12CrP) respectively prior to external irradiation. 
2.2.3. results. 
In 19 of the 53 patients (36%) tumour reduction, defined as an decrease in tumour 
size of more than 50%, could be obtained (see table 2.6). 
Survival curves were calculated according to the actuarial method, developed by 
Berkson & Gage (1950), which was later modified by Kaplan & Meier (1972). The 
use of this method of survival description was encouraged by the UICC (1974). Be­
cause not all patients were documented completely, the following figures do not always 
refer to all 53 patients. Actuarial five-year survival for all histological types was 30%, 
as it was also for the group of epithelial tumours (see fig. 2.1). 
7 β 9 10 11 12 13 14 15 16 
Survivol in years Irom diagnosis 
Fig. 2.1 Actuarial survival curves for (·) all palicnls (N = 53) and for (O ) patients with epithelial tumours 
(N = 40). 
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5 6 7 θ 9 10 11 12 13 14 
Surv iva l in years t rom diagnosis 
Fig 2 2 Actuarial survival curves according to stages of disease О Stage I + Ha ( N = 13), Π Stage 
IIb + lie (N=12), Δ Stage III + IV (N = 23) 
Survival C/.) 
100 
1 2 3 4 5 6 7 8 9 10 
Survival in years f r o m diagnosis 
Fig. 2 3 Actuarial survival curves for ( χ ) patients who initially were treated with surgery alone (N = 5), 
(·) patients who were irradiated first after operation (N = 37), and (Π) patients who received chemotherapy 
first (N=11) 
When the disease is limited to the internal genital organs (Stage I through IIa) long 
term prognosis is better than for more advanced disease, as is shown in figure 2.2. 
In patients not pre-treated, a 5-ycar survival rate of 42% could be achieved, whereas 
only 14% of the patients that had been treated before survived a 5-year period (see 
fig. 2.3). Treatment results early in this study (prior to 1970) were similar to results 
later in this period (from 1970 onwards). The survival curves as shown in fig. 2.4 
arc only suggestive of slight improvements. 
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Survival in years trom diagnosis 
Fig 2.4 Actuarial survival curves for (·) patients treated before 1970 (N = 
from 1970 untili 1978 (N=38). 
15), and (O ) patients treated 
SIDE EFFiiCTs: nearly all patients undergoing radiotherapy suffer more or less from 
side effects, mostly of acute, but temporary nature as is shown in table 2.7. 
Complaints are usually confined to gastro-intestinal problems: nausea, vomiting 
and diarrhoea. In this period only 1 case of chronic enteritis was seen. Proctitis and 
cystitis were predominantly seen in patients who received pelvic irradiation only. Al­
though nausea is a constant feature in all radiotherapeutic approaches, vomiting oc­
curs more often in those cases where an abdominal field was combined with pelvic 
irradiation. In our small numbers, no correlation could be found between tumour 
dose and occurence of side effects. 
Fortunately, haematopoietic disturbances were rarely seen. However in two cases 
of cobalt-60 treatment bone marrow suppression, was sufficient reason to terminate 
Tabic 2.7 Side effects of '"Co-irradiation. 
Side effect. Abdominal Abdomino-pelvic Pelvic 
irradiation irradiation irradiation 
# # # 
Thrombo-/leucopenia 
Nausea 
Vomiting 
Diarrhoea 
Proctitis/cystitis 
Dermatitis 
No complaints 
1 
3 
0 
2 
0 
1 
0 
1 
9 
4 
10 
2 
0 
0 
0 
15 
3 
13 
5 
2 
2 
Known N = 
Unknown N = 
12 
0 
23 
56 
irradiation One patient had been treated before with chlorambucil; the other patient 
was irradiated first, before other therapy 
Four patients did not report any side effects. Two of these patients received a pelvic 
dose only (total dose 50.0 Gy and 80 0 Gy respectively with ^Co), two other patients 
patients were treated over the pelvis only with 18 MV (total dose 65 0 Gy) and with 
abdomino-pelvic 18 MV irradiation (total dose of 61 2 and 40 2 Gy over both regions 
respectively). 
2.2 4 discussion and tomlusions. 
Although in the long period studied here many changes in therapeutic approaches 
took place and although the group of patients is of a heterogeneous constellation, 
the overall 5-year survival of 30% and 19 tumours of 53 patients responding is not 
unlike results reported by other important institutions brom the Lenox Hill Hospital, 
Barber & Tae Hae Kwon (1976) reported an overall 5-ycar survival rate of ca 30% 
In the MD Anderson Hospital a crude 5-year survival rate of 30% was obtained if 
treated in the MD Anderson Hospital in the immediate postoperative period, and 
24% for patients referred to them after having been treated elsewhere (Smith & Day 
1979) In a randomized trial of radiotherapy alone, radiotherapy and melphalan and 
melphalan alone, Brady et al (1979) reported rather poor results for the Gynecological 
Oncology Group with an overall 3-year (') survival rate for each treatment arm of 
approximately 25% 
Of course, radiotherapeutic treatment has changed since 1960 However, despite 
the introduction of more advanced technology, especially in more appropriate and 
more effective targetting, radiobiological advances are only very slowly incorporated 
in clinical procedures (Twentyman, 1979) From our results it can be concluded that 
if such advances have contributed to the treatment of ovarian cancer patients, their 
impact was not so impressive that - within the limits of our small numbers - this 
was reflected in a significantly improved survival rate, which is in accordance with 
reports in the literature (see table 2 1) 
Interpretation of these data is hampered by the heterogeneity of the sources, incons-
istent treatment and selection of patient material In the period studied, only one third 
(49 out of 148) of the patients admitted to the St. Radboud Hospital (between 1957 
and 1977) received radiotherapeutic treatment (Year report of the Inst, of Obstetrics 
and Gynaecology, 1977) 
Furthermore, classification of the disease was not consistent during this period and 
many patients underwent an insufficient staging procedure. It can therefore be post-
ulated that many of the patients will have been understaged, which is reflected in just 
50% of the low stage patients surviving a 5 years period 
Last but not least, no standard procedure for the determination of treatment re-
sponse was followed, resulting in not less than 17 patients in whom no retrospective 
evaluation of the tumour response, other than the survival of the patients, could be 
assessed 
Radiotherapy is tolerated fairly well and side effects are usually of a mild and tempo-
rary nature Gastro-intestinal complaints can be managed quite easily 
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No case of radiation nephritis was reported. Although doses up to 20.0 Gy should 
be tolerated well (Luxton 1953; Luxton & Kunklcr 1964; Birkhead et al. 1979), it 
is still unknown what the late complications of such doses will be. A prospective study, 
however, is currently being conducted to study these late effects (Dewit & Hoefnagel 
1984). We shielded the kidneys after a tumour dose of 15.0 Gy. Although in this series 
the mean survival time is too short to evaluate late radiation effects in the kidney, 
such effects may be of considerable importance when patients with better prognosis 
are going to be irradiated (see further). 
Of special interest arc the differences in survival rate observed between patients 
who first received radiotherapy and those who first received chemotherapy (fig. 2.3). 
Smith & Day ( 1979) also observed better survival rates in patients treated postoperati-
vely with irradiation than in patients treated with chemotherapy. However, in their 
study patients received either radiotherapy or chemotherapy alone. It should be born 
in mind that our data concern patients that have 'ever' in the course of their disease 
been treated with irradiation. The fact that the highest survival is seen in cases that 
received radiotherapy because of recurrent disease after an expectant policy is in accor-
dance with the low stage disease of these patients (4/5 in Stage I or II) or the low 
malignant potential of the initial tumour in stage III (1/5). From the data presented 
here it may not be concluded that chemotherapy in the period of observation achieved 
less positive results than radiotherapy: patients presented here are a selection with 
recurrent disease, all requiring further (radiotherapeutic) treatment, whereas of the 
37 patients treated first with irradiation 'only' 22 required further therapy. 
In fact, in the study reported here a comparison should be made between the patients 
that received radiotherapy after initial chemotherapy versus initial irradiation. The 
latter group in this study, however, comprises only 2 patients,surviving 6 and 2.2 years 
respectively. 
In conclusion, results reported here can only indicate that radiotherapy may be 
effective but cannot cure advanced ovarian cancer. Radiotherapy can still have its 
place in the treatment of ovarian cancer, but whether this should only apply to low 
stage disease, recurrent disease or inoperable cases has still to be established. Although 
conclusive data cannot be provided from this retrospective study and arc unfortunately 
neither provided by prospective studies (Dembo 1984; Schray et al. 1983), irradiation 
as an adjuvant therapy in low stage disease and irradiation prior to operation of other-
wise inoperable cases, as well as in residual disease after chemotherapy should be ser-
iously considered for future evaluation. 
2.3. EXPERIENCE IN THE RADBOUD HOSPITAL: SURGERY & CHEMOTHERAPY. 
2.3. ¡. introduction. 
After the previous retrospective study on about one third of all ovarian cancer pa-
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Fig 25 Frequency of new cases ofovarian carcinoma per year from 1967 through 1984 
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year of referai 
tients treated in the St Radboud Hospital, a further retrospective study was conducted 
on all patients, comprising also those that did not receive radiotherapy, seen in the 
Institute of Obstetrics and Gynaecology of the St Radboud Hospital between January 
1st 1967 and January 1st 1979. This chapter is mainly concerned with the staging 
and surgical aspects of treatment in the 67 patients seen in this period. Many epidemio­
logical data and patient characteristics have already been discussed in chapter 1 and 
will not be reported here again. 
2.3 2. patients and methods. 
The clinical prevalence of ovarian carcinoma is rising over the period studied, as 
can be seen from figure 2.5. In order to show the continuing trend of rising incidence, 
which started in earlier years, data of recent years arc added too. Forty-nine out of 
the 67 patients received initial therapy in our institute, whereas 18 patients were re­
ferred Thirty-one of the patients described here were also encompassed in the study 
reported in chapter 2 2 1 as they (also) received radiotherapy 
Data were processed with the Statistical Package of Social Sciences on a PDP 11 
computer (Digital, Maynard, Ma ,USA) As in the previous chapter, survival rates 
were calculated according to the actuarial method, which allows the use of the data 
from patients that were still alive at the end of the study (Kaplan & Meier, 1972) 
The histological distribution according to WHO entena (Scrov & Scully 1973) is 
shown in table 2.8. Seventy-seven percent of the tumours were of epithelial origin, 
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Tabic 2.8 Distribution of histological types of tumours, classified according to WHO criteria N = 67 
Serous cystadenocarcinoma 29",, 
Mucinous adenocarcinoma 12°,, 
(cyst-)adenocarcinoma 2Q°0 
other epithelial tumours 15'% 
Dysgerminoma 3% 
other germ-cell tumours 6% 
Gonadal stroma tumours 12°ó 
Not ovarian specific 3% 
which is slightly less than the 85% reported in the literature of this period (Malkasian 
1975; Speckhard 1972). In this, the commonest type of ovarian tumours, serous cyst-
adenocarcinomas are usually 3 to 4 times more frequent than mucinous adenocarcino-
mas, as we too found in our material. 
In 83% of the cases diagnosis was made at laparotomy, whereas 6% of the cases 
were found at laparoscopy, which is reported to be useful in the evaluation of an 
abdominal mass, being of possible malignant nature (Rosenoff 1975). In a further 
8% of the cases diagnosis was made on cylological examination of ascites obtained 
at paracenthesis. In one case diagnosis was made on cytological examination of pleural 
effusion. 
The indications for operations are listed in table 2.9. It is rare to find an explicit 
indication of malignancy before operation. 
For 60 of the 67 patients the actual examinations for screening before operation 
are known and are listed in table 2.10. Of the routine laboratory tests BSE had been 
recorded for 33 patients with a mean of 42 mm in the first hour (range 3 - 120 mm). 
Because classification has not been done consistently over the period of the study, 
stages were assessed retrospectively. Of those 30 cases where the stage of the disease 
had been recorded, 6 stages appeared to be wrong at réévaluation. For 4 patients 
insufficient data were available to determine the extent of the disease. Table 2.11 shows 
the stage distribution (staging according to FIGO criteria, see chapter 1.4). 
Table 2 9 Indications for initial operation. N = 67 
Ovarian tumour 58"^ 
Lower abdominal tumour 29°ó 
Acute abdomen 3% 
Appendicitis 3% 
Leiomyoma of the uterus 2% 
Adenocarcinoma 2°ó 
Otherwise/unknown 5"/0 
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Tablc2 10 Examirulions performed at screening Ν —60 
X-ray chest 
X-ray abdomen 
ι ν Urogram 
Barium enema 
Li\er- spleen scan 
Cystoscopy 
Lymphscintigraphy 
Total bone scan 
Sonography 
X-ray stomach + small intest 
CT-scan 
Mammography 
Paracenlhesis 
Lymphangiography 
90"
o 
72"„ 
67% 
4ί% 
35"/,, 
\i\ 
15% 
15". 
'1°,, 
12% 
3"o 
3"„ 
3% 
2"„ 
Oncological treatment is based on treatment plans (in experimental designs 'proto­
cols') First of all it is important to realize in evaluating therapy results that the out­
come of therapy not only depends on the way treatment is administered, but also 
on the way it is planned We distinguish treatment according to the intention with 
which it is planned the primary treatment plan is the first strategy proposed for the 
treatment and consists usually of surgery in its first phase and chemotherapy or radio­
therapy in the next phase Only those modalities of therapy that are included in the 
initial plan of treatment can be regarded as 'primary' or 'first line' When after some 
time other or further therapy appears to be required a secondary plan can be initialized 
and so on Ovarian cancer is especially notorious for the fact that primary treatment 
often cannot be completed and/or that due to recurrent disease new strategies have 
to be explored In our series 6 out of 67 patients were treated according to no less 
than 4 consecutive plans of treatment (see table 2 13) 
Fig 2 11 Distribution over FIGO stages 
Stage 
la 
0) 
(•О 
lb 
Ic 
(la 
Hb 
He 
III 
IV 
Total 
N 
16 
5 
9 
0 
1 
3 
7 
2 
28 
6 
61 
0 
25 
0 
2 
5 
11 
Τ 
44 
10 
100 
61 
In 2 of our patients no curative therapy was feasible. Of the remaining 65 patients 
62 were operated initially. Twenty-eight patients received chemotherapy and 16 pa­
tients received radiotherapy in the first treatment plan (see table 2.12). Forty-seven 
patients also received further treatment after the primary treatment plan. 
Table 2.12 Primary treatment plans. 
Planned first line therapy carried out after diagnosis. 
11 patients of this group were still alive at the end of this study. 
9 patients died after this first treatment plan. 
47 patients received further therapy. 
Phase I Phase II Phase III Number: 
surgery 
surgery 
surgery 
surgery 
surgery 
chemotherapy 
palliation 
chemotherapy 
radiotherapy 
chemotherapy radiotherapy 
2 
22 
24 
15 
1 
3 
67 
Table 2.13 Consecutive treatment plans (number of patients). 
Secondary Rx Tertiary Rx Quaternary Rx 
surgery only 
chemother. only 
radiolher. only 
combination 
palliation 
6 
21 
9 
9 
2 
surgery only 
chemother. only 
radiother. only 
combination 
palliation 
surgery only 
chemother. only 
radiother. only 
combination 
palliation 
47 23 
follow-up: 
8 withdrawn from study alive 
16 died 
23 received further therapy 
follow-up: 
4 withdrawn from study alive 
13 died 
6 received further therapy 
follow-up: 
all 6 dead 
Table 2.14 Distribution over FIGO stages for (A) patients that were treated according to a primary treat­
ment only and for(B) patients that were treated according to four consecutive plans. 
Stage A One treatment plan 
# N = 20 
В Four treatment plans 
# N = 6 
I + IIa 
Ilb + c 
III + IV 
unknown 
10 
1 
7 
2 
62 
Tabic 2 15 Nature of operations for ovarian cancer according to the time of operation (number of patients) 
Operation* First operation Second operation 
biopsy 17 8 
debulking 47 10 
unknown 4 0 
* biopsy . cystectomy, tumour biopsy and'or aspiration malignant effusion, no further therapy 
debulking . operation aimed at the removal of as much tumour as possible 
From table 2.14 it can be concluded that there is no relation between stage of the 
disease and the number of treatment plans that are given. In both the group of patients 
that received only therapy according to the primary treatment plan and the group 
that received therapy according to more than one plan a similar stage distribution 
is seen. 
SURGERY: standard procedure in the surgical treatment of ovarian tumours is a hystero-
salpingo-oöphorectomy in combination with a (supra-colic) omentcctomy and sam-
pling of (suspect) lymph nodes. Intestinal resection should be done if necessary to 
accomplish complete cytoreductive surgery. However this was not always carried out 
in the period studied here. 
Table 2.15 lists the nature of operations done in the first treatment plan versus 
those done in the fourth treatment plan. In the latter 'late' operations a (complete) 
cytoreductivc surgery was less often attempted. The two cases that were found to be 
inoperable at the time of first operation were both stage III patients. Of the patients 
undergoing a cytoreductive operation 45% were stage III and IV and 30% were in 
stage la. 
Table 2.16 Procedures in first and second operations (number of patients). 
Procedure First operation Second operation 
N = 64 N=18 
hysterectomy 
right ovariectomy 
left ovariectomy 
right salpingectomy 
left salpingectomy 
omentectomy 
appendectomy 
intestinal resection 
bladder resection 
removal abdominal meta's 
others 
27 
48 
46 
40 
41 
12 
3 
1 
0 
4 
10 
63 
ГаЫс 2 17 Residual tumour dfler first operation (number of patients) 
Diameter of largest residue In the pelvis In the abdomen 
no residual tumour 
few, smaller than 2 cm 
multiple, smaller than 2 cm 
larger than 2 cm 
tumour rests of unknown size 
unknown whether there was 
residual tumour 
24 
1 
0 
11 
26 
2 
33 
0 
5 
10 
12 
4 
Total number 64 64 
From table 2.16 it can be concluded that there was actually no standard procedure 
for surgical treatment in the period studied Not only were internal genital organs 
often left in situ, but omentectomy was performed in only 19% of the first operations 
(20% of the first operations for disease staged higher than stage la; in these former 
cases omentectomy is mandatory) 
Not surprisingly, in secondary operations it is relatively more often necessary to 
perform major surgery such as intestinal resection than in first operations. 
In 24 cases (39%) all macroscopic lumour could be removed at first operation How­
ever, when residual tumour was still present after operation the largest diameter of 
the tumour rest was usually larger than 2 cm. Unfortunately in many cases the measur­
ements of the residual tumour were not recorded (see table 2.17) 
CHFMOTHbRAPY. in the period studied the most important cytostatic agent used was 
chlorambucil. Of the 28 patients who received chemotherapy in the primary treatment 
plan, 24 were treated with chlorambucil (2-15 mg d.d ), 10 received cyclophosphamide 
in cycles (100-300 mg d.d.), 4 melphalan in cycles (6-20 mg d.d ) and in 6 patients 
Thio-Tepa was installed intrapentoneally For 4 patients the exact agent administered 
was not recorded. 
Because of the various treatment schemes and inconsistency in therapy no evalua­
tion could be made of the role of cytostatic drugs in this patient material. 
RADIOTHFRAPY: patients studied in this retrospective study are partially desenbed in 
chapter 2.2.1 With regard to this study, 34 patients received radiotherapy, of whom 
one was treated with intraperitoneal radioactive пСтР prior to external irradiation 
The total lumour dose varied between 30 and 65 Gy and was higher than 45 Gy in 
more than half of the cases Fifty percent of the cases received abdominal irradiation 
plus pelvic irradiation, 27% were irradiated in the pelvis only and in 15% of the cases 
only the abdomen was irradiated 
2.3 3 results 
RbSPONSF Because of the lack of unanimity in describing response to therapy in former 
years, the response had to be deduced from the patient's records. We succeeded in 
64 
Table 2 18 Clinical response according to therapy in primary treatment (number of patients) 
Therapy 
chemotherapy 
radiotherapy 
both 
Clinical 
CR 
3 
5 
1 
response 
PR 
4 
4 
0 
SD 
8 
2 
0 
Ρ 
8 
1 
1 
Total 
23 
12 
2 
doing so in 37 cases, in the rest of the cases sufficient data were not available. 
Clinical response and the period that responses lasted are given in tables 2 18 and 
2.19. Clinical complete remission (CR) is defined as no clinically detectable tumour. 
In a partial remission (PR) there is tumour reduction of more than 50%, lasting for 
more than 1 month Stable disease (SD) implies a reduction of less than 50% but not 
more than 25% increase in tumour size Progression occurs when the tumour si/e in­
creases by more than 25% and/or when new metastases or and/or ascites occur(s). 
All responses were evaluated after the primary treatment plan Response rate for 
chemotherapy is less favourable than for radiotherapy. As can be seen from table 
2 20 this is due to the high percentage of low stage disease in the latter group of patients. 
Seventy-four percent of the patients receiving chemotherapy were m stage III + IV, 
against 33% of the patients receiving radiotherapy that had stage III or IV disease 
SURVIVAL: five-year survival rate for all patients is 32%. Patients in stage III + IV, 
however, have only a 3-year survival of 6%. The most common histological group 
of tumours, the epithelial carcinomas, show a lower survival rate than all patients 
together (see fig 2 6). 
Table 2 19 Duration of remission according to therapy in primary treatment (number ofpaticnts) 
Duration of remission 
Therapy 1-6 mos 7-12 mos 12 mos unknown Total 
chemotherapy 2 2 1 2 7 
radiotherapy 0 2 2 5 9 
both 0 0 1 0 1 
Table 2 20 Therapy in primary treatment plan according to stage (number of patients) 
Therapy 
Stage chemotherapy radiotherapy chemo-/radiotherapy 
la + Ha 2 5 I 
Ha + с 4 3 0 
III 16 2 1 
IV 1 2 0 
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S u r v i v a l in years f r o m diagnosis 
Fig. 2.6 Survival curves for (O ) all palients (N = 62), and (·) patients with epithelial tumours (N = 46) 
Survival curves according to the actuarial method are shown in figure 2.7 for the 
various stages. Survival for stage lib and lie do not differ from survival rates for 
stages III + IV. Only in early stages I + IIa does the 5-year survival rate approximate 
80%, whereas this is nearly 0% in the high stage group. 
Survival rates for patients in whom no debulking operation was possible at first 
operation were similar to those for patients in whom a debulking operation could 
be performed (see fig. 2.8). 
Survival rates for patients who received only radiotherapy after surgery in the first 
S u r v i v a l (0/o) 
100 
1 2 3 4 5 6 7 8 9 10 
Survival in years f r o m diagnosis 
Fig. 2.7 Actuarial survival curves according to various stages of epithelial tumours. · · Stage I + IIa (N-
12), D · Stage lib + lie (N = 6), О • Stage III + IV (N = 27). 
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Survival m years f r o m diagnosis 
Fig 2 8 Actuarial survival curves for (O ) patients in whom a debulking operation could be achieved (N — 
43), versus (·) patients in whom no tumour reduction was attempted (N = 14) 
treatment plan were better than those of patients who received chemotherapy (see 
fig. 2.9). 
SIDE EFFECTS: because of the retrospective nature of this study side effects of especially 
chemotherapy could not be traced for all patients over the whole period. This is partly 
due to the fact that the mono-chemotherapy used in this period was often given by 
the referring specialist or even by the general physician. In 39 patients the side effects 
1 2 3 4 5 6 7 8 9 10 
S u r v i v a l in years f r o m diagnosis 
Fig 2 9 Actuanal survival curves for (·) patients who received only radiotherapy (N=16) and for those 
(O ) who received only chemotherapy (N = 28) after surgery in the first treatment plan. 
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had not been recorded or there was no chemotherapy given In 6 patients who were 
irradiated no side effects had been recorded (sec tables 2 21 & 2 22) 
Especially chemotherapy caused considerable complications, notably in the haema­
topoietic system One 67 year old patient with a serous cystadenocarcinoma was treat­
ed with 6 mg chlorambucil d d for one year After that year she appeared to have 
a chronic lymphatic leucaemia 
Side effects of radiotherapy mainly concerned the digestive tract Nearly all patients 
suffered from diarrhoea In only 2 cases therapy had to be stopped due to myelosup-
pression 
Table 2 21 Side effects of mono-chemotherapy in 27 patients 
myelosuppression 
alopecia 
nausea 
vomitting 
mucositis 
no side effects 
# 
17 
4 
10 
5 
1 
3 
% 
63 
15 
37 
19 
4 
11 
Table 2 22 Side effetls of radiotherapy in 25 patients 
myelosuppression 
nausea 
vomitus 
diarrhoea 
proctitis 
enteritis 
no side effects 
# 
2 
16 
15 
21 
5 
1 
3 
υ/ 
/о 
8 
64 
60 
84 
20 
4 
12 
2 3 4. discussion 
Treatment in the period from 1967 untili 1978 has been subject to many changes, 
as indicated in chapter 2 2 In this chapter the treatment of ovarian cancer, with special 
emphasis on surgical treatment in our hospital has been evaluated In this period no 
standard surgical treatment was available This is reflected in the many different surgi­
cal procedures. First of all it is striking that in more than half of the cases the uterus 
was left in situ The same can be said of the non-afflicted ovaries, that were also left 
in situ in most instances Furthermore, an extremely low number of omentectomies 
(less than 20%) has taken place It is of utmost importance to remove the omentum 
completely (inclusive the supra-cohc part) as-
a) the omentum is a preferential site for metastasis (Baglcy et al 1973), so omentectomy 
is at the same time a therapeutic, diagnostic (staging!) as well as a preventive measure 
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b) the omentum is one of the larger producers of ascites when metastases occur (recur-
rent disease ') 
c) the omentum is the cause of massive adhesions post-operatively, which can interfere 
with further chemo- or radiotherapy 
By leaving the omentum in situ further therapy may be hampered and early recur-
rence of disease is provoked. 
Treatment of ovarian cancer starts with surgery. It is known by now that the amount 
of tumour left behind after first operation is directly related to prognosis (Griffiths 
1972, Dembo 1984). In 47 cases operation was regarded feasible, in 17 cases no debulk-
ing was attempted Regarding the survival curves for both groups of patients, no differ-
ences can be observed (fig. 2 8) It can be postulated that prognosis does not worsen 
when tumour as well as internal genital organs are left to be removed at a second 
operation after chemo- or radiotherapy, as compared with initial debulking Also Neyt 
(1983) concludes that irrespective of whether debulking up to residual tumour with 
rests smaller than 2 cm has taken place before or after chemotherapy has been initiated 
survival can be improved. In contrary to the current opinion that reduction up to 
residual tumour less than 2 cm (1 cm) in diameter at first operation is essential (e.g. 
Dembo 1984), also Cohen et al. (1983) reported no difference in results of second-look 
operations in 73 surgically évaluable patients with either complete or incomplete de-
bulking from a multiple arm randomized study. 
For the assessment of prognosis and for the evaluation of treatment results it is 
essential to document the tumour status prior to chemo- or radiotherapy Residual 
tumour after (attempted) debulking operation should be documented with exact metri-
cal measurements The still common practice of describing tumour size in terms of 
agricultural products (si/e of pea, almond, egg, orange, coconut etc.) is, apart from 
being unscientific, objectionable because it hampers adequate decision making in the 
management of ovarian tumours. 
From table 2.12 and table 2.13 it can be concluded that most patients received their 
first chemotherapy after operation cither in a first treatment plan, or in a second 
treatment plan. In the course of the treatment plans the chemotherapy-radiotherapy 
ratio tends more and more towards radiotherapy Radiotherapy is mostly given in 
second line therapy 
When radiotherapy, however, is given firstly after surgery, this treatment yields bet-
ter survival rates than chemotherapy (sec fig 2 9) This is due to the fact that 8 of 
the 12 patients (with known stage) who were only irradiated post-operatively were 
in stage I and II, whereas of the 23 patients who received only chemotherapy after 
operation just 6 were in these lower stages. The poor survival of patients who received 
chemotherapy is therefore a reflection of the high risk status of these patients. Al-
though radiotherapy was given to either low stage patients or to patients with late 
recurrent disease, others have advocated also protocols for high(cr) stage disease (Lew-
is & Blessing 1977, Dembo 1984) 
It is of special interest that stage of the disease was no indication for the number 
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of treatment plans to which the patient would be subjected Notably half of the patients 
that were treated according to four subsequent treatment plans were in stage I and 
II Conversely, 35% of the patients that received only one treatment plan were in stage 
III and IV This gives reason for caution when explaining the proposed treatment 
to a patient One should not be tempted to predict the course of therapy, especially 
statements like 'this will take six courses of chemotherapy' or 'we will see whether 
you will be cured after the following 5 weeks of radiotherapy' should be avoided 
Ovarian cancer is a disease with a nearly endless sequence of hospitalization, out-
patient follow-up, operations and evaluations Without scaring the patient, a realistic 
prospect can be offered in terms of e g 'We are going to perform at least 2 operations, 
at which second operation we will evaluate response to therapy After this second 
operation we will decide together whether further therapy is necessary or feasible' 
Offer the patient land marks to clamp to, but also prepare for eventual second line 
therapy (further unexpected - treatment plans). 
It is of concerning interest to note that 5-year survival rate for stages I + Ha is 
also less than 80% Partly this will be due to improper staging procedures, resulting 
in under-staging From the high number of treatment plans that had to be designed 
for this group of patients it can also be concluded that this relatively low survival 
rate is also due to ineffective management Ineffective in this respect means incomplete 
surgery (apart from other staging procedures), no or improper adjuvant therapy, im-
proper follow-up 
In summary, improvement of treatment can be expected from better planning of 
treatment, paired to new treatment approaches Especially in view of the rising inci-
dence of ovarian cancer and the relatively poor results obtained in low stage disease 
it seems important to pair the development of new treatment strategics to strategies 
aimed at detection of the disease in a curable phase 
2 4. CONCLUSION 
From the beginning of the seventies onwards, the concept of cytoreductive surgery 
was introduced This concept became especially important since the introduction of 
more active (combination) chemotherapy, which renders a better prognosis for pa-
tients with minimal residual tumour after first (9) operation Better post-operative 
therapy makes extensive surgical staging and treatment worthwhile 
The development of active chemotherapeutic schemes also caused radiation therapy 
to lose importance. However, problems specifically related to the treatment of low 
stage disease and resistant tumour after therapy have not been solved unequivocally. 
Therefore application of radiotherapy, as well as of single agent chemotherapy, may 
eventually prove to be useful for strict indications. 
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New approaches in the managcmenl of (detected) disease will be discussed in the 
next chapters 3, 4, 5 and 6 Pre-treatment management is not within the scope of this 
thesis, but prospects will be discussed in chapter 7. 
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3. Introduction of cisplatin 
3 1 CIS-PI ATINUM IN COMBINATION WITH LOW DOSE 
ADRIAMYCIN AND CYCLOPHOSPHAMIDE IN ADVANCED OVARIAN 
CARCINOMA. 
R H M VfcRHbiJEN*, L BLfcx**, D J T H WAGENER*** & Ρ KFNEMANS* 
'Institute for Obstetrics and Ciynaecology, Internal Medicine, "Division of Endocrinology and ***Divi-
sion of Medical Oncology.Sint Radboud University Hospital, Nijmegen, The Netherlands 
3.1 I. Summary. 
Between February 1979 and August 1981 20 patients with advanced ovarian carci­
noma have been treated according to a mitigated РАС-V protocol cis-platin 20 mg/m2 
d 1 -5, adnamycin 35 mg/m2 dl and cyclophosphamide 400 mg/m2 d 1, q 28 days. Sixteen 
patients were évaluable with objective, measurable tumour parameters. Minimal fol-
low-up time was 2 years Overall response rate was 50% (8/16) with complete response 
in 12.5% (2/16). Median duration of complete response was 40+ months, of partial 
response this was 16+ months Two year survival rate was 9/16 Patients who had 
a complete dcbulking prior to РАС-V therapy or had not been treated before re­
sponded best (5/6 and 6/7 respectively) Thirteen patients indicated experiencing sub­
jective improvement in their condition. Haematological, renal or neurological toxicity 
never caused threatening problems 
In conclusion, a chemotherapy regimen containing a mitigated dose of adnamycin 
and cyclophosphamide next to full dose cis-platin yielded good tumour and patient 
response without severe toxicity 
3.1.2. Introduction. 
Surgery plays a primary role in the combat against ovarian carcinoma; 'dcbulking' 
has proven to be essential for the success of further therapy and a favorable prognosis 
(1,2) The poor survival, however, of the large group of patients in stage III and IV 
poses an especially compelling argument for a better approach with cytostatic agents 
With cis-platin (cis-diamminedichloroplatinum, DDP) opportunities were created 
for the improvement of treatment results (3-7) However, especially toxicity of additive 
cytostatic agents limited both objective and subjective tolerance for these regimens. 
Ehrlich et al (5) reported a response rate of 61% (39% complete response) for the 
so called PAC-I scheme versus 76% (35% complete response) for the РАС-V scheme 
in first line therapy Treatment with a mitigated scheme containing cis-platin (P), adna-
Reproduced with permission from Fur J Gynecol Oncol 6 116-120,1985 
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mycin (A) and cyclophosphamide (С) was evaluated in our institute. With mitigation 
of the latter two agents we aimed at improving tolerance of patients in poor condition. 
3.1.3. Patients and methods. 
Twenty patients with histologically proven epithelial carcinoma of the ovary - recur­
rence of stage lib, stage III or IV - were eligible for entering this study. Treatment 
took place from February 1979 to August 1981, allowing a minimal follow-up time 
of 2 yrs (evaluation on October 1, 1983).Three patients who did not attain 3 courses 
(1 early progression, 1 early death and 1 patient who refused further therapy) were 
excluded. One patient was not évaluable because she moved overseas. Thus 16 patients 
were available for evaluation for response and toxicity (see table 3.1). Nine patients 
had been prctreated with either alkylating agents or sequential therapy with radiother-
apy and alkylating agents. 
In all instances staging of the disease according to FIGO criteria had been done 
by laparotomy and eventually by lymphangiography, computerized tomography or 
echography of the abdomen and pelvic cavity. In 6 patients the tumour load could 
be reduced to items smaller than 2 cm in diameter at first operation (complete debulk-
ing) prior to the chemotherapy. In 3 patients such tumour reduction was only possible 
after 3, 4 and 6 РАС-V courses respectively. Three patients on whom no debulking 
operation was attempted were referral cases from other hospitals after initial operation 
there. 
Chemotherapy consisted of: cis-platin (P) 20 mg/m2 iv on Days 1 through 5; adria-
mycin (A) 35 mg/m2 iv on Day 1 and cyclophosphamide (C) 400 mg/m2 iv on Day 
1, q 28 days. This means a 30% reduction of the dosage of adriamycin and a 46% 
reduction of the dosage of cyclophosphamide, when compared with the original PAC-
V regimen (5). 
Results of therapy - in terms of complete response, partial response, no change 
Table 3.1 Pretreatment patient characteristics. 
mean age (range) 52 (32-70) yr 
Stage (No. of patients ("/„)) lib 3(19) 
III 11(69) 
IV 2(12) 
Histological diagnosis: serous cystadenoca. 11 (69) 
(No.ofpalients(°0))mucinoubcysladenoca l ( 6) 
adenoca. 4 (25) 
No. of patients for first line PAC-V ("„) 9 (57) 
No. of patients for second line PAC-V (%) 7 (43) 
Delay from initial diagnosis to PAC-V(range) 7 2(1-15 5)mos 
for first line (range) 3 0 (1-14) mos 
for second line (range) 10.4 (5-15.5) mos 
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and progression - were evaluated according to WHO criteria (8,9). Sometimes re-
sponse to treatment was already clear from lethal progression or regression of a non-
invasively measurable parameter. Both complete responses and two of the six partial 
responses were verified with a so called second-look operation (SLO): laparoscopy, 
when there was no evidence of disease, followed by laparotomy. 
3.1.4. Results. 
Pretreatment characteristics of the 16 évaluable patients are listed in table I. Eight 
of 16 patients (50%) achieved an objective remission, whereas in 1 patient the disease 
remained stable during treatment. In 2 of these 8 patients clinical, histopathological 
and cytopathological criteria for complete response were fulfilled. 
Patients who had a complete debulking prior to therapy with РАС-V had a response 
of 5 out of 6 (83%) with a complete response in 2 patients (33%). Also the three patients 
in whom a complete debulking could be achieved during treatment attained a partial 
response. Of the seven patients who had no (complete) debulking none attained rem­
ission. 
The 2 patients with a complete response are still in remission at 31 and 36 months 
from first record of complete response (38 and 42 months respectively from the first 
day of treatment). The median duration of partial remission was 16+ months, 2 pa­
tients still being in remission for 34 + and 39 + months from the first day of treatment. 
Minimal follow-up time after therapy is 2 year (see table 3.2). 
Table 3.2 Results of treatment and prognostic factors, grouped according to response 
age 
initial prior pnor complete 
stage radioth. chemoth. debulking 
no. of 
objective subject. 
response* 
(months) 
response* 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
51 
52 
34 
32 
44 
62 
70 
55 
59 
54 
61 
54 
51 
42 
67 
38 
III 
III 
III 
lib 
HI 
III 
III 
IK 
lib 
IV 
III 
lib 
III 
IV 
III 
III 
-
-
+ 
-
+ 
-
+ 
— 
+ 
+ 
+ 
+ 
+ 
+ 
initially 
initially 
initially 
initially 
after 3 с 
after 6 с 
initially 
after 4 с 
-
-
-
-
initially 
-
-
-
10 
6 
8 
5 
7 
9 
8 
5 
7 
5 
4 
6 
5 
4 
3 
3 
CR(42 + ) 
CR(38 + ) 
PR(39 + ) 
PR(34 + ) 
PR(I6) 
PR(16) 
PR(IO) 
PR(4) 
SD(8) 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
-
' CR = complete response, PR = partial reiponse, SD = stable disease, 
Ρ - progression (Duration of response in months from start РАС-V Rx) 
' + = subjective improvement of condition, + = subjective stable condition, : deteriorating condition 
76 
At the time of evaluation 4 of the 8 patients who attained remission were still alive. 
Of those with no change or progressive disease none was alive at the time of evaluation. 
The 2 year survival rate is 56% (9 out of 16). Figure 1 shows the actuarial survival. 
Apart from the objective tumour response, the subjective response of the patient 
is noteworthy. Thirteen out of 16 patients indicated an improvement in their condition 
and tolerated chemotherapy well (see table 3.2). Only 3 patients did not find relief 
from РАС-V therapy. 
toxicity. 
Haematological and renal toxicity parameters, as they occurred on the first day 
of each cycle are given in table 3.3. Although in 9 patients courses had to be postponed 
or adjusted due to marrow toxicity, РАС-V therapy was never stopped for this reason. 
In 3 patients leucopenia (wbc less than 2xl09 cells/1) occurred during or shortly after 
a course. 
Anaemia required transfusion of packed cells in 8 patients a total of 29 times. 
Severe hypocalcaemia was never seen. Two patients developed epileptiform insults 
which showed no direct relation with РАС-V therapy. 
In 3 patients serum creatinine was raised above 100 μιτιοΐ/ΐ, in one case even above 
150 μπιοΐ/ΐ. Although it is well known that cis-platinum may cause severe renal dys­
function clinically apparent renal dysfunction was only seen after mechanical obstruc­
tion by the tumour of one or both of the ureters, and improved after release of the 
obstruction. 
All patients developed alopecia. This was always reversible, sometimes already dur­
ing treatment. 
Audiometrie assessment revealed a subclinical hearing loss in the high frequencies 
for 2 patients. Only 1 patient experienced subjective deafness. 
All patients experienced nausea. 
Survival (0/o) -
100-
80-
60-
4 0 -
2 0 -
ACTUARIAL SURVIVAL 
f r o m date of diagnosis 
РАС-Y treated patients 
february1979 - October 19Θ3 
- 1 1 1 1 1 1 1 1 1 1 1— 
θ 12 16 20 24 28 32 36 40 44 4 8 
Survival in months f r o m diagnosis 
Fig 3 1 Overall actuarial survival 
i . / .5. Discussion and conclusion. 
Even in first line therapy patients with ovarian carcinoma are virtually always in 
a very poor condition on admission. But especially in previously treated patients toxi­
city tolerance has often dropped to zero when referred to an oncological centre. We 
chose to mitigate the bone marrow depressive agents in an otherwise effective combina­
tion chemotherapy (5) in order to obtain a relatively mild regimen, which would not 
be selflimiting, neither by subjective nor by objective intolerance. 
The РАС-V scheme as used in our clinic yielded a good response rate (50%) in 
first and second line therapy together. Overall response in patients receiving first line 
therapy was even better: 86% (6 out of 7) with 29% (2 out of 7) surgically proven 
complete responses ! These results compare well with those of Ehrlich et al. (10) with 
44% complete response. In the latter study, however, only 20% of the second-look 
operations performed were negative ! The suboptimal condition of patients referred 
for second line therapy is reflected in a 22% partial response rate with no complete 
responders. 
Table 3.3 Values for haematological amnd renal parameters as measured on the first day of every course 
(i.e. 3 weeks after the prccecding course). 
loxicily no of 
patients 
no. of 
courses 
Haematological* 
leucocytes grade 
not documented 
platelets grade 
not documented 
haemoglobin grade 
not documented 
Renal** 
creatinine grade 
not documented 
0 
1 
2 
3 
0 
1 
2 
0 
1 
2 
3 
0 
1 
2 
6 
5 
3 
11 
4 
1 
2 
9 
2 
3 
8 
8 
12.5 
37.5 
31 
19 
69 
25 
6 
12 5 
56 
12.5 
19 
50 
50 
58 
26 
6 
3 
3 
83 
6 
2 
5 
55 
27 
5 
4 
5 
71 
16 
9 
60 
27 
6 
3 
3 
86 
6 
2 
5 
57 
28 
5 
4 
5 
74 
17 
9 
* patients are grouped according to the lowest value recorded 
** patients are grouped according to the highest value recorded 
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The overall 2 year survival of 56% is already above the range for median survival 
obtained by others (11) 
Furthermore, the importance of cytoreductive surgery is also confirmed in our re­
sults none of the 7 patients in whom tumour rests remained with a diameter larger 
than 2 cm did attain remission (see table 3 2), whereas 83% (5 out of 6) of those 
with minimal residual tumour prior to РАС-V treatment attained remission Even 
debulking m a later stage, after several courses, can result in (partial) responses, as 
has been reported also by others (12) 
Courses have been tolerated subjectively well, neither did we see life threatening 
complications following this mitigated regimen It should be noted that, although we 
lowered the doses of bone marrow depressing adnamycin and cyclophosphamide, we 
did not delimit the maximum additive dosage of cis-platin 
In conclusion, a good tumour and good subjective response could be achieved with 
a relatively mild combination chemotherapy (РАС-V) with minimal toxicity 
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3 2 INVENTORY OI COMBINATION CHLMOTHCRAPY RFGIMFNS 
As discussed in chapter 2 1, until the late seventies ovarian cancer cytostatic treat­
ment mostly comprised one (alkylating) agent Together with the introduction of the 
concept 'combination chemotherapy', already used in haematological malignancies 
and other solid tumours, also new drugs were being developed Notably hexamethyl-
melamine (HMM) and cisplatin (DDP) were introduced as active agents, especially 
in combination with other cytostatic agents This coincidence gave a tremendous impe­
tus to the conversion from single agent chemotherapy to combination chemotherapy 
If HMM had not been such an active agent against ovarian cancer, the first report 
which showed positively the superiority of a combination of agents (i с HMM, cyclo­
phosphamide -CTX-, methotrexate -MTX-, and 5-fluorouracil -5FU-) over single 
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agent therapy (ι с melphalan -LPAM-) would have been forgotten by now (Young 
et al 1978) Although this Hexa-CAF combination appeared to be more toxic than 
LPAM, dose modifications because of bone marrow toxicity were frequently required 
in the latter treatment ' Both response rate (75% vs 54%) and survival rates were 
significantly better for Hexa-CAF 
In this chapter we will discuss primarily first line treatment as the first treatment 
plan offered to a patient will be most important for her prognosis 
Tables 3 4, 3 5 and 3 6 show the results of studies reported in the literature regarding 
Table 3 4 Results from the literature оГ SINGLE AGENT chemotherapy in first line treatment 
Drug # patients , response* Author 
ηυη-aìk) latmg 
ADR 
5HJ 
MTX 
МММ 
DDP 
alkylating 
LPAM 
Chlorambucil 
CTX 
12 
12 
34 
24 
10 
10 
12 
54 
13 
22 
9 
18 
541 
37 
70 
61 
23 
72 
17 
16 
38 
72 
64 
130 
388 
10 
335 
35 
115 
21 
56 
50 
33 
27 
17 
10 
30 
42 
32 
13 
50 
67 
22 
47 
54 
11 
30 
30 
40 
59 
25 
47 
40 
38 
24 
50 
60 
43 
31 
22 
14 
64 
de Palo 1977 
Stanhope 1977 
Smith 1978 
Smith 1975 
Young 1975 
Karnofsky 1949 
Wilson 1969 
Wharton 1979 
Bruckner 1981 
Gcrshenson 1981 
Hall 1981 
Cohen 1983 
Tobias 1976 
Young 1978 
Bruckner 1979 
Park 1980 
Turbow 1980 
Trope 1981 
Israel 1982 
Harvey 1982 
Sturgeon 1982 
Vogl 1982 
Omura 1983 
Brodo\sky 1984 
Tobias 1976 
Young 1974 
Tobias 1976 
Edmonson 1979 
MRC1981 
Decker 1982 
Carmo-Pereira 1983 
* Percentage response clinical as well as surgico-pathological complete and partial remissions together 
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Table 3 5 Results from the literature with COMBINATION CHEMOTHERAPY WITHOUT CIS-PLA-
TIN (DDP) in first line treatment 
Combination # patients % response* author 
ADR-CTX 
ADR-MTX 
CTX-HMM 
MTX-TSPA 
CTX-MTX 
5FU-MTX 
5rU-LPAM 
LPAM-5FU-ActD 
CTX-5FU-ActD 
ADR-CTX-HMM 
CTX-5FU-HMM 
CIX-5FU-MTX 
5rU-LPAM-MTX 
CTX-5FU-HMM-MTX 
HMM-LPAM 
36 
61 
24 
41 
16 
72 
70 
20 
14 
21 
22 
48 
48 
21 
55 
16 
31 
132 
240 
40 
13 
31 
28 
37 
88 
97 
36 
36 
71 
83 
56 
49 
63 
50 
36 
67 
32 
25 
31 
33 
78 
63 
52 
35 
19 
75 
54 
42 
36 
65 
50 
51 
Edmonson 1979 
Alberts 1979 
Turbow 1980 
Parker 1980 
Schwartz 1981 
Omura 1983 
Trope 1981 
Schwartz 1980 
Bruckner 1981 
Barlow 1980 
Barlow 1982 
Park 1980 
Park 1980 
Park 1980 
Mangioni 1981 
Posada 1985 
Israel 1982 
Brodovsky1984 
Klaassen 1979 
Young 1978 
Mcndiola 1980 
De Palo 1981 
Carmo-Pereira 198 
Sturgeon 1982 
Neyt 1981 
Omura 1983 
* Percentage response clinical as well as surgico-pathological complete and partial remission together 
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Fig 3 2 Reported response rate for different numbers of agents in a scheme The horizontal lines give 
the mean response rate over all studies · Alkylating agent, О non-alkylaling agent, χ (containing) DDP, 
D not containing DDP 
Table 3 6 Results from the literature with CIS-PLATIN (DDP) CONTAINING COMBINATION che-
motherapy in first line treatment 
Combination # patients 70 response* author 
ADR-DDP 
CTX-DDP 
DDP-Chlorambucil 
ADR-CTX-DDP 
ADR-DDP-HMM 
ADR-DDP-Leuk 
ADR-CIX-DDP-5Í-U 
ADR-CTX-DDP-HMM 
ADR-CTX-DDP-5FU-
HMM-MTX 
36 
15 
98 
48 
19 
20 
32 
26 
97 
54 
91 
36 
40 
35 
31 
64 
25 
20 
6 
26 
35 
18 
24 
51 
46 
85 
21 
18 
37 
84 
29 
75 
80 
44 
35 
74 
75 
56 
50 
69 
78 
71 
83 
75 
80 
75 
32 
88 
75 
67 
38 
54 
63 
66 
74 
96 
62 
81 
55 
51 
79 
65 
Vogll976 
Bruckner 1981 
Cohen 1983** 
deGramontl984 
Wernz 1982 
Israel 1983 
Barker 1981 
Griffin 1981 
Bolisl981 
Mangioni 1981 
Omura 1982 
Budd 1982 
Sturgeon 1982 
Williams 1982 
Ehrlich 1983 
Cohen 1983 
Ehrlich 1983 
Mcehrpohl 1984 
Vcrhcijcn 1985 
Carmo-Pereiral982 
Barker 1981 
Pouillart 1981 
Brctaudeau 1982 
Young 1981 
Greco 1981 
Vogl 1982 
Harvey 1982 
Hernandez 1983 
Cohen 1983 
Ncyt 1984 
Young 1982 
* Percentage response clinical as well as surgico-pathological complete and partial remission together. 
** Deducted from 4 arms together of a multiple arm study 
Table 3 7 Companson of response rates for various chemotherapeutic regimens in first line treatment 
Single agent 
non-alkyl 
Single agent 
alkylating 
Combination Combination 
without DDP with DDP 
# patients in literature 230 2101 1491 1237 
Overall response 32% 48% 45% 63% 
Range response 10-67% 11 64% 19-83% 32-96% 
* Response clinical as well as surgico-pathological complete remission together 
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single agent chemotherapy, combination chemotherapy without DDP and chemother-
apy with DDP respectively. Table 3.7 summarizes the results from the three previous 
tables for four groups as single agent therapy is divided in alkylating and non-alkylat-
ing agents. Overall treatment results for alkylating agents are better than for non-
alkylating agents. Combination chemotherapy without DDP is in general not superior 
to single agent therapy, but incidental higher response rales than with the latter regi-
mens have been reported. A real improvement has come with the introduction of DDP 
in combination chemotherapy: not only is the mean response rate much higher than 
for other regimens, also these DDP containing schemes are the first to give consistent 
better treatment results in all trials. 
Apart from the introduction of active agents in combination, the factual number 
of agents also has an effect on the efficacy of the treatment. Although the mean re-
sponse rates for regimens with 1,2 or 3 agents do not differ much, much higher response 
rates are reported by individual authors when the number of agents is rising. Improve-
ment can be seen when 4 drugs arc used (fig. 3.2 ). From fig. 3.2 it can also be seen 
that DDP consistently scores in the high response rate ranges. 
Unfortunately reports from the literature vary in e.g. the kind of patients that are 
eligible for a study, in prognostic factors, in treatment schemes and especially in criteria 
for assessment of response. Therefore no statistical assessment is done for the data 
presented here. As there is still no consensus regarding treatment and the assessment 
of tumour response, the results from the various studies are not very comparable. 
In every study a reduction takes place from the total number of patients that are 
admitted to the investigating hospital to the eventual number of évaluable patients 
(fig. 3.3). First of all, arbitrary exclusion criteria in the study design exclude some 
of the patients from entering the study. It should be noted that these criteria differ 
from study to study, forming a bias for comparison. Futhcrmorc, when patients are 
eligible for a study, personal and management factors may cause them not to be consid-
ered for entering. Of all patients that have been entered a certain number will be lost 
to follow-up or not available for evaluation by the standards set for the study. Since 
- apart from this latter reduction - reports on trial results never mention the quantity 
of loss of patients that could potentially be treated, it can only be estimated that about 
70% of all patients will eventually be évaluable for a certain study. 
Before cure rate can be assessed, however, a further reduction takes place. Since 
clinical assessment of response is too subjective, only (more) objective surgico-patho-
logical evaluation can give representative results. Many microscopical complete re-
sponders are definitely not cured, regarding the lower 5-year survival rates published. 
Of the 5-year survivers again only a part will be cured without (late) relapses. Many 
reports cannot even mention 5-ycar survival rales becauses the pressure to publish 
does not allow sufficient follow-up time. 
It is clear that a compilation of treatment results as given in this chapter can only 
give an estimate of a trend. The high variation in results reported is not only due 
to factual variation in efficacy of the various regimens, but is also due to reductive 
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o//pa//en/s 
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5-year survivers 
cured 
Fig. 3.3 Histogram representing the theoretical constitution of a clinical study. The number of évaluable 
patients is only a part of the total number of patients as a result of arbitrary and non-tumour related 
reduction (arrows). 
Response in this reduced group is assessed clinically and less often surgico-pathologically. No information 
is available on the number of patients that will really be cured. 
factors irrespective of the treatment given. 
Since the important study of the Netherlands Joint Study Group for Ovarian Cancer 
(Neyt 1983) the multitude of different chemotherapeutic regimens is now condensing 
on the combination of cisplatin. hexamethylmelamine, adriamycin and cyclophospha-
mide (CHAP), the combination without hexamethylmelamine (CAP) or without both 
hexamethylmelamine and adriamycin (CP). Since the 5-day courses of CHAP-V 
proved superior to the Hexa-CAF scheme (Neyt et al. 1984), some investigators regard 
this former scheme or its single day variant as standard therapy for comparison with 
other active combinations. 
Although CHAP-V yields a consistent respose rate of 79% with 30% surgically veri-
fied complete remissions, these good results are paired to a relatively severe toxicity. 
Apart from 55% of the patients who have moderate renal toxicity (for which the criteri-
on is the serum creatinine exceeding 1.26-2.5 times the pre-treatment values),a very 
high percentage of 35% of the patients develop a moderate, and 4% a severe peripheral 
neurotoxicity. In the first Dutch trial with CHAP-V, doses of all constituent agents 
except cis-platin had to be reduced in all patients. Furthermore, these 5-day courses 
constitute a very demanding therapy for the patient (Neyt et al. 1984). In table 3.8 
three combinations, commonly used in the Netherlands are compared as to their re-
mission inductive capacity and toxicity. The promising and relatively simple combina-
tion of cis-platin (60 mg/m2 on Day 1) and cyclophosphamide (1100 mg/m2 on Day 
1) appeared to be relatively toxic with notably a high renal toxicity, despite good pre-
and post-hydration (Israel et al. 1983; Ten Bokkel Huinink 1984). Furthermore, in 
an ongoing prospective Dutch study, comparing CHAP-V and CP, complete remission 
rates seem to be similar for both regimens but partial remission rates appear to be 
much higher for the CHAP-V scheme (Ten Bokkel Huinink 1984). 
Unfortunately a (prospective) trial comparing CAP and CHAP has not yet been 
N4 
Not documented data influenced by unknown factors 
Documented data influenced by partly known factors 
Table 3 8 Comparison of treatment results* (response: clinical complete + partial remmision) and toxicity 
of three commonly used regimens containing cis-platin. 
Combination Cumulative response Toxicity** 
number of rate haemato- neuro- nephro- dose*** 
patients % logical logical logical reduction 
ADR-CTX-DDP 535 68 + - - + 
(PAC) 
ADR-CTX-DDP- 342 72 + + + + + + + + 
HMM (CHAD/P) 
CTX-DDP 39 75 + / + + + + + + + + 
(CP) 
* compilation of results reported in the literature, see also table 3.6 for references. 
**-: ±0%, + ±250£, + + : +50oo, + + -1-: ± 7 5 0 / и , + + + + . ± Ι00
ο>Γall patients 
*** incl. refusals and postponements. 
conducted. Since the former regimen is reported to have considerably less toxic effects 
(Ehrlich et al. 1983;Verheijen et al. 1985) and response rate for this kind of chemother­
apy is only a few percent lower than for CHAP it is very desirable to compare these 
two regimens. This is even more tempting since 1 day courses with РАС-V appeared 
to be equally effective in comparison with 5 day courses with РАС-V (Ehrlich 1983; 
Omura et al 1982; Bolis et al. 1981; Budd et al. 1982). Thus it would be more than 
just informative to find out whether this short, well tolerated scheme could yield as 
good results as have been obtained with CHAP-V treatment. To give conclusive evi­
dence of superiority or equality of PAC-I treatment, such a prospective trial should 
include CHAP-I treatment vs. PAC-I. 
In the meantime new derivatives of cis-platin which appear to be less nephrotoxic, 
and perhaps also less neurotoxic, JM8 (carbo-platin) and JM9 (iproplatin) (Evans 
et al. 1983) are now being tested for their effectiveness in the treatment of ovarian 
cancer. Carbo-platin is currently being studied in an EORTC randomized prospective 
trial comparing CHAP-V to CHAC-I, in which latter regimen cis-platin is replaced 
by carbo-platin. Regrettably this study design will only allow definite conclusions 
when CHAC-I appears to be superior to CHAP-V. When it is shown to be less effective 
one cannot exclude the possibility that this is due to the shorter duration of treatment 
in these single day courses. 
In summary, the superiority of the use of more than one drug over single (alkylating) 
agents in the treatment of advanced ovarian carcinoma is well established. This does, 
however, not necessarily mean extension to 4 or more drugs. 
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3 3 CONCLUSION 
Efforts to improve therapy results are currently based on the concept of a) aggressive 
surgery, and b) pharmacokinetically optimal drug regimens Despite all these efforts, 
however, long term results still have not improved substantially Data from our own 
study reported here cannot be more than suggestive for an improvement in short term 
survival (first 2 years of followup) but in the end survival rates are very likely to remain 
the same as they were before the introduction of the two concepts mentioned above 
It is not unlikely that the lack of long lerm improvemenls is due to the fact that 
we still do not know whether the patients who are in (short time) remission should 
be treated for consolidation after primary chemotherapy In view of the fact that 1 mm1 
of tumourous tissue can still contain 106 malignant cells it is difficult to reach a point 
where one can be sure that no malignant cells arc left This 'zero point', however, 
is the only criterion on basis of which therapy can be stopped 
Various approaches and regimens have been designed to improve efficacy of 
(chemo-)therapy after first operation, but we do not know the risk factors in patients 
who benefited from these therapies and who came into remission Unfortunately, the 
majority of patients in remission will sooner or later relapse long term survival remains 
unchanged 
We do not know whether patients in remission should be treated or not But, as 
short term survival has improved, not only do more reports on late toxic effects of 
cytostatic agents emerge, but also tumour growth in chemotherapy sanctuaries, such 
as the cerebrum (Mayer 1979, Behnam et al 1984), which had been very rare before 
because of short term survival, is more likely now Since long term side effects of 
chemotherapy are still not well known it seems advisable to stop treatment with cyto­
static agents as early as possible 
If it is decided that further treatment should be given its nature is by no means 
clear Current ongoing trials with intra- peritoneal high dose chemotherapy for pa­
tients with only microscopic disease after combination chemotherapy might give an 
answer minimally to the question of the role of this kind of'postjuvant' therapy (Ten 
Bokkel Huinink et al 1983) One of the issues of the next chapter will be, whether 
clinically important tumour cells can be identified in an in vitro assay This might 
be important in order to select candidate patients for further 'postjuvant' therapy 
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41 SUMMARY 
Current and future clinical applications of the Human Tumour Clonogemc Cell 
Culture (HTC1) system are presented Advanced gynaecological cancers, especially 
ovarian, endometrial and cervical carcinomas, require extensive systemic chemother­
apy The HTC3 system seems to be an adequate instrument for individualized chemo-
sensitivity testing in order to choose proper cytostatic treatments, that is, maximum 
tumour cell kill with minimal sidc-cffccts Furthermore, this system helps in assessing 
the response after treatment by detection of remaining clonogemc, and thus viable, 
tumour cells 
Other clinical applications of the system include grading of the tumour and recogni­
tion of the histologic type Thus the HTC1 provides a potential tool m diagnosis, treat­
ment and follow-up of gynaecologie malignancies 
4 2 INTRODUCTION 
Although surgery and radiation play major roles in the treatment of patients with 
gynaecologie malignancies, chemotherapy is effective in attacking advanced or recur­
rent malignant disease in gynaecology (Willson et a l , 1981, Young, 1980, Deppe 1980). 
Patients with ovarian cancer and advanced endometrial or cervical cancer derive spe­
cial benefit from recent developments in systemic multiple drug chemotherapy Despite 
some high response rates published recently, in particular up to 90% in ovarian cancer 
(Vogel et a l , 1979). cytostatic treatment has its limitations. 
Practically, problems arise in administering proper doses at proper time (intervals) 
and in choosing the proper patients, in part because of the limits set by the severe 
and often life-threatening side- effects on bone marrow, heart, gastro-intestinal tract, 
nervous system and renal function (Von Hoff, 1979, Krakoff, 1979, Rozencweig et 
Reproduced with permission from Europ J Obstet Gynec Reprod Biol, 17 43-51,1984 
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al 1980) All cytostatic agents produce side-effects in one or more of these systems 
The major challenge in current oncological management is to attain a cure at the cost 
of the lowest possible toxicity. 
Basically, problems in chemotherapy start in selecting the proper cytostatic ap­
proach Development of new regimens is still based on pragmatic considerations and 
empirical data, obtained in trials, that refer to experience in treatment of a group 
of patients rather than to the situation of the individual patient Developing new cyto­
static regimens requires participation of patients ι e , a number of patients who arc 
requested to participate in a trial, therefore receiving treatment yet to be proved effec­
tive 
At the bedside of each cancer patient the clinical investigator is reminded of his 
limitations Each time he is confronted with his inability to predict whether this tumour 
of this particular patient will respond to one or more drugs, he must choose one of 
many options Employing a multiple-drug therapy, he will not be able to assess which 
is (are) in fact the effective agent(s) 
Such problems are prominent in the management of ovarian cancer. However, they 
are also encountered in treating advanced endometrial and cervical carcinoma (Will-
son et a l , 1981, Young, 1980,Stehmanctal., 1979) 
Clearly there exists an urgent need foran in vitro method to choose and individualize 
treatment During the last 10 years several assays for chemoscnsitivity testing have 
been developed (Table 4 1) Of the methods using laboratory animals, the most labor­
ious is the implantation of a peritoneal diffusion chamber (Heekman, 1968, Selby 
et al , 1980) Othermethodsstudy the effect oftreatment at the cellular level Labelling 
techniques (Bloomfield et a l , 1980), incorporation studies (Volm and Kaufmann, 
1970), search for receptors (Crcasman et al , 1981 ), and dye exclusion tests (Weisenthal 
and Marsden, 1981) are metabohcally oriented assays Most successful in chemoscnsit­
ivity testing are tests that look at the effect oftreatment on cell growth, either qualitati­
vely (ι e , morphologically (Limburg and Brachetti, 1981) of quantitatively (Salmon, 
1980a, Courlenay and Mills, 1978) The latter methods involve cell cultures, the princi­
ple focus of this paper 
Tabic 4 1 Assays for chemoscnsitivity 
Assay Method 
(A) Directly in tissue receptors 
(B) In vivo subcutaneous implantation 
peritoneal diffusion chamber 
subrenal capsule implantation 
(C) In vitro cell metabolism labelling of cytostatic agents 
uptake of RNA DNA precursors 
How cytometry 
(D) In vitro cell growth cell morphology 
colony formation 
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4 3 HUMAN TUMOUR CELL CULTURES. 
In the mid-fifties Puck and Marcus (Puck and Marcus, 1955) were able to establish 
an in vitro tumour model A decade later several in vitro culture systems for human 
tumour cells were developed (Di Paolo, 1963, Limburg and Krahe, 1964, Bruce and 
Lin, 1966) The main aim of this development was to solve the problem of individual 
chemotherapy selection by an in vitro chemosensitivity test An individual patient's 
tumour cells in culture were incubated with cytostatic agents, after which their che-
motherapeutic effect was recognized by the inhibition of uptake of metabolic precur­
sors or by inhibition of growth. The concept behind these cultures is that, although 
most cells in a (malignant) tumour are not cycling, a few cells do replicate and maintain 
their reproductive potential These cells with proliferative properties have been called 
'stem cells' (Buick, 1980) These 'stem' or 'clonogenic' cells may be the origin of colo­
nies in culture The morphological and biological characteristics of these cells, howev­
er, remain to be defined and it is still impossible to demonstrate which cells of a tumour 
cell population will give rise to colonies in vitro. 
Bruce in 1966 was the first to test cytostatic agents in a soft agar culture of normal 
and malignant haemopoietic cells It was not until the late seventies that Hamburger, 
Salmon, Alberts and co-workers extended to solid tumours the clinical applicability 
of their Human Tumor Stem Cell Assay (HTSCA) by quantification of sensitivity 
(Salmon et al., 1978) and later by demonstrating an in vitro-in vivo correlation that 
was 99% accurate in predicting lack of clinical response (resistance) and 62% m predict­
ing efficacy for individual ovarian cancers (Alberts er al, 1980) 
The general procedure of the most commonly used test, the HTSCA (Human Tumor 
Stem Cell Assay), which, because of the controversies surrounding the concept of tu­
mours 'stem' cells, may better be called 'Human Tumour Clonogenic Cell Culture', 
runs as follows Tumour material, be it the tumour itself, metastases or malignant 
effusions, is disaggregated mechanically and/or enzymatically in order to obtain a 
single cell suspension. After washing and centrifugation, ahquots of the tumour cells 
arc incubated with a number of drugs for 1 h After further washing to free the cells 
of chemotherapeutic drug, ahquots of 5 χ 10s cells are plated in a two-layer soft agar 
medium, and incubated for 2-3 weeks at 37"C and at 6% CO2 After this period, the 
number of colonies, which are assumed to derive from the clonogenic cell population 
in the tumour, are counted. Various criteria have been drawn up to define in vitro 
sensitivity Salmon and associates (Salmon et al., 1980) use the number of colonics 
growing at different drug concentrations and determine a 'sensitivity index' from the 
drugconcentration curve Von Hoff and associates (Von Hoffet al , 1980) use the 
decrease in colonies formed after incubation with a single drug concentration, com­
pared with the number of colonies formed in the control plates In a variation of this 
assessment, the relative decrease is determined at different drug concentrations (Ozols 
et a l , 1980a). As Clark (Clark and Von Hoff, 1981) has already pointed out, neither 
of these take into account the colony size, which may prove to be an important factor 
Use of this Human Tumour Clonogenic Cell Culture system as a clinical service to 
assist the clinician in individual chemotherapy selection requires automation of the 
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counting of colonies This is possible with the introduction of the Omnicon " automatic 
colony-counling system (Bausch & Lomb Ine , Rochester, NY, U S.A ) (Kressner et 
a l , 1980, Herman et al., 1983a) 
Automatic colony counting provides data on colony size distribution as well as on 
the number of colonies counted in 6 size categories Thus it is possible to study and 
quantitate some morphological characteristics of in vitro colony growth for various 
tumours 
4 4 APPLICATIONS oi HTC1 
4 4 1 chemosensitivity testing 
As noted above, this was the first clinical application of the in vitro human tumour 
cell culture system Possibilities of predicting sensitivity or resistance of an individual 
patient's tumour to drugs have already been discussed above It should be emphasized 
that individual chemotherapy selection reaches beyond 'sparing' the patient unneces-
sary and unsuccessful chemotherapy (Selby and Raghavan, 1981) by elimination of 
those drugs that arc expected to contribute only to the side-effects, but fail to be eflec-
tive, a more effective full course of chemotherapy can be pursued 
The clonogenic cell culture system can also be used in screening for possible new 
drugs for cancer therapy (Salmon, 1980b, Salmon et a l , 1981, a,b) Some of the more 
than 1000 new compounds that arc investigated yearly at the US National Cancer 
Institure are presently being tested using the Human Tumour Clonigenic Cell Culture 
system (Venditli, 1981) It should be noted that this system provides most reliably 
a negative selection, i.e., a selection of the non-effective compounds Automation and 
the accompanying quantitation of the colony scoring may enhance its efficacy 
Especially in view of the screening of such a large number of putative cytostatic drugs 
both the high in vitro-in vivo correlation (Alberts et a l , 1980) and the required repro-
ducibility of the automated system (Herman et a l , 1983a) make it a useful instrument 
44 2 detection of viable disease 
As the soft agar two-layer media are highly selective for tumour cells (MacPhcrson, 
1973), growth of stromal or inflammatory tissue is generally not seen Sometimes, 
however, minimal growth occurs when non-malignant tumour cells are cultured We 
saw colony growth (defined as 5 or more colonies per plate) in a case of granulosa 
cell tumour and in one borderline malignant serous tumour of the ovary The meaning 
of such observations requires further investiga ton of cell and colony growth character-
istics in agar Apart from such rare cases, the I luman Tumour Clonogenic Cell Culture 
system is highly specific and selective for the detection of malignant cells (Herman 
el a l , 1983b) At the first combined diagnostic-therapeutic laparotomy the question 
of microscopic metastatic disease can be raised in early stages without obvious tumour 
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Table 4.2 
Colony formation Cytology Histology 
(5 col/plate) 
Serous papillary cystadenocarcinoma of the ovary + + 
Adeno-acanthoma of the uterus + - + 
Second-look operations are done when complete remission after therapy is expected. 
In both situations, random biopsies and peritoneal washing may not present the 
pathologist with sufficient representative material. And even if tumour cells can be 
demonstrated morphologically, the biologic potential of these cells cannot be assessed 
by cytological or histological examination. In vitro culturing is a convenient way to 
detect remaining viable cells. 
Our data suggest that the Human Tumour Clonogenic Cell Culture system may 
provide a more sensitive detection of malignant cells than cytological examination. 
Others (Steel, 1981) have not reported colony growth when cytology was negative. 
We did, however, see colony growth combined with negative cytology twice, out of 
a total of nine specimens of cytologically non-malignant effusions (Table 4.2). In these 
cases, the in vitro observation had been confirmed by concurrent histological examina-
tion of biopsies taken after peritoneal washing. Morphologic features displayed by 
the colonies after 2 or 3 weeks growth in culture are comparable to the slides of the 
biopsies (Fig. 4.1 and 4.2). 
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Fig. 4.1 Histological appearance (PAS-stain) of cystadenocarcionoma of the ovary 
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4.5. DISCUSSION 
The relative advantages of the Human Tumour Clonogenic Cell Culture system 
in individual chemotherapy selection are still being discussed (Ozols et al., 1980b; Edi-
torial, 1982; Tveit et al., 1981), though its potential as an important tool in oncological 
management cannot be denied. A major problem in H T C at the moment consists 
of a relatively large proportion of false-positive (sensitive) predictions of the effect 
of chemotherapy in vivo (Salmon et al., 1978; Alberts et al., 1980). However, the possi-
bility of reducing side-effects of drug treatment in order to enhance the therapeutic 
ratio is still achievable, thanks to the high reliability of HTC prediction of tumour 
resistance. 
Certainly the mechanisms of tumour growth in vitro, especially the nature of the 
clonogenic cells, are still unclear. The low plating efficiency, i.e., the small number 
of cells that can form colonies, seems to be a disadvantage. It has been suggested 
that a culture method in which so small a proportion of the cells grow can never be 
a representative (and therefore reliable) method. However, a low proportion of colony-
forming cells in vitro may reflect a low proportion of clonogenic (stem) cells in the 
tumour cell population. In practice, colonies in culture do not differ morphologically 
from the primary tumour material and the in vitro-in vivo correlations in chemosensiti-
vity testing are very good. Enhancement of the plating efficiency, e.g., in the Courte-
nay-Mills method, has not been shown to give equal or better in vitro-in vivo correla-
Fig. 4.2 Colony grown from tissue of the tumour shown in Fig. 4.1. This colony contains cells that resemble 
the malignant cells seen by histological examination. 
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lions in primary human tumours. Similarly, improvement of the plating efficiency 
by using enzymatic disaggregation methods produced no improvement in the predic-
tive performance of HTC3. 
Comparison of a radiolabelled precursor incorporation test (Lelieveld and Mulder, 
1981) and nude mice xenografts (Rice et al., 1980) with a plating efficiency-improving 
variant of the culture method described in this paper (Tveit et al., 1981) could not 
demonstrate improvement in selection of cytostatic agents. 
Regarding the HTC3 application in detection of viable disease, it offers an extra 
dimension in diagnosis. Cytological or histological examination can at best indicate 
morphologically intact malignant cells. Whether these cells are also 'viable' in the sense 
of retaining reproductive potential cannot be assessed microscopically. Behaviour of 
borderline malignancies is also controversial in itself. It will be worthwhile to correlate 
in vitro growth characteristics with eventual malignant behaviour of the lesion. Au-
tomation will provide more data on in vitro colony growth, thus enhancing applicabili-
ty of the HTC3. 
Apart from the application mentioned already, other potential applications still 
under investigation are noteworthy. Especially in ovarian cancer, the grade of malig-
nancy is highly significant for the prognosis (Malkasian et al., 1975). The introduction 
of a suitable grading system (Broders, 1926) added a new dimension to tumour diagno-
sis, although it is based on a rather subjective interpretation of the percentage of mi-
toses. Parameters of in vitro growth, such as speed of colony formation, colony size 
distribution and plating efficiencies, may be more reproducible than histological grad-
ing. Exact comparative evaluation of both quantitative and qualitative methods of 
grading with regard to prediction of clinical behaviour has still to be done. 
Definition of histologic type can also be extremely difficult, especially in poorly 
differentiated or anaplastic tumours of the gynaecologie tract. Colony size distribu-
tions may show discriminative patterns, correlating with histological differences. Re-
search in this area also requires the introduction of automatic assessment of colony 
properties. 
4.6. CONCLUSION 
Using the Human Tumour Clonogenic Cell Culture system in chemotherapy selec-
tion, risks of chemotherapy will be diminished, leaving space for adequate treatment 
with effective drugs. More economical screening for new drugs is possible. Detection 
of viable disease as a diagnostic possibility of the HTC3, especially after treatment 
(second-look), may be an important addition to cytological and histological examina-
tion. 
The present and proposed applications of the HTC3 system are as follows: 
- screening for new anti-tumour drugs; 
- individualized chemosensitivity testing; 
- detection of viable disease; 
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- grading and staging, 
- recognition of hibtologicdl type 
Other diagnostic procedures in this system which are decisive in choosing the right 
therapy and in estimating prognosis are still under investigation It is clear that the 
Human Tumour Clonogenic Cell Culture system can offer more than in vitro drug 
testing 
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4.8 UPDATE OF REVIEW AND PERSONAL EXPERIENCE 
In five years time, from 1977 untili 1982, Human Tumour Clonogenic Cell Culturing 
(HTC3) has been tremendously propagated as a clinical test for chemosensitivity. It 
soon became clear, however, that clinical applicability was hampered especially by 
the low number of tumour specimens that actually showed colony growth, although 
few investigators were prepared to publish data on these limitations on basis of their 
own experience (Bertoncello et al. 1982). 
In vitro growth enhancement was attempted in order to optimalize growth condi­
tions. First of all the Salmon & Hamburger soft agar culture system was introduced 
initially as a system with enriched media for culturing of myeloma cells from bone 
marrow. The background of the addition of most of these enrichments were empirical 
early results in human tumour cloning (Pike & Robinson 1970). It later appeared that 
some of the constituents in fact inhibit growth in at least some tumours (Kodama 
et al. 1978; Hamburger 1980). 
On the other hand addition of growth stimulating agents such as insulin and hydro­
cortisone (Kern et al. 1984), cell-free ascites (Uitendaal et al. 1983), a feeder layer 
of peritoneal macrophages (Welander 1982), or epidermal growth factor (Pathak et 
al. 1982) have been investigated without substantial improvement in colony formation. 
Also altering the physical conditions of the cultures e.g. in combination with biochemi­
cal changes in the media (Hug et al. 1984) as well as changes in oxygen concentration 
(Gupton & Eberle 1984) have been investigated, without resulting in cultures that 
can be routinely used in the clinic. 
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Table 4 3 Criteria for lumour growth in the Human Tumour Clonogenic Culture System. In the literature 
a range of definitions appears for the three criteria on which in vitro growth is based (1) the lime at which 
colonies appear, (2) the minimum number of cells per colony required, and (3) the minimum number of 
colonies per culture dish Criteria arc shown as used in studies partly on ovanan carcinoma, mostly in 
scries with various lumour types 
Cnlenon Threshold References 
range authors reporting minimum - maximum 
1. Day of evaluation 7-29 Alberts et al. 1980 Williams et al. 1983 
2 Number ofcells per colony 20-50 Kernetal. 1982-Von Hoff et al. 1981 
3. Number of colonies per dish 5 30 Cowan et al. 1983-Salmon et al 1977 
At least as important as the problems of culture conditions are the problems related 
to differences in interpretation of in vitro growth by the various authors. Variation 
in criteria for colony growth are summarized in table 4.3. Recently, the role of growth 
dynamics in the assessment of in vitro colony growth has been put forward first by 
our group (Kirkels et al. 1983) in the study of the time course of colony growth, and 
later by other groups who investigated the role of changes in colony volume and area 
over time in the establishment of growth (Thomson et al. 1984; Alley et al. 1985). 
It became clear that colony growth could not be assessed by simply counting the 
number of'colony-like structures' after a fixed period of time. 
While searching for optimal conditions for colony growth in the soft agar assay 
it also soon became clear that, although the system is most apt for basic research 
and valuable in the establishment of e.g. anti-tumour activity of new drugs (Shoemaker 
et al. 1985), clinical applications such as individual chemotherapy selection is still not 
feasible (Lieber 1984). It is therefore not surprising that only one major prospective 
trial has been published in which results of treatment on basis of the outcome of the 
clonogenic assay are evaluated. In a cooperative study Von Hoff (1983) cultured tu-
mour specimens from 1145 patients, of which 246 were évaluable for in vivo - in vitro 
correlation in single drug clinical trials. The true positive prcdictiveness (for response) 
was 60% and the true negative prcdictiveness was 85% (for lack of response). Von 
Hoffs results were reproduced in a few other, much smaller, prospective studies, as 
summarized in table 4.4. 
Since clinical applicability was not immediately feasible, further prospective clinical 
trials were not inititated. Instead, some groups developed new tests that are potentially 
Table 4 4 Prospective studies relating in vivo results of chemotherapy and in vitro prcdictiveness by the 
use of the Human Tumour Clonogenic Cell Culture System. 
Author 
Von Hoffet al. 1983 
Alonso et al. 1984 
Ajanietal. 1984 
# of patients 
246 
50 
28 
True + 
60% 
65% 
86% 
True-
85% 
90% 
81% 
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Table 4 5 Samples from gynaecological malignant tumours cultured in the Nijmegen HTC1 laboratory 
during the period 1 9 81 untili 1 I 85 
Origin of tumour Number of samples Samples infected 
solid effusions solid effusions 
tumours /washings tumours /washings 
ovary 
endometrium 
cervix 
fallopian lube 
vulva 
trophoblast 
breast 
Total 
73 
13 
22 
1 
9 
2 
1 
121 
88 
19 
23 
1 
-
2 
-
133 
11 
2 
1 
0 
2 
1 
0 
17 
13 
5 
4 
0 
-
1 
1 
23 
easier to apply but based on the experience in soft agar cloning (Von Hoff 1984). 
Some even combined several modes, such as DN A-precursor uptake test and the clon-
ogenic assay (Hildcbrand & Kern 1984), or other tests as summarized in table 4 1 
On the other hand it should still be kept in mind that the predictiveness for chemo-
sensitivity as shown in the soft agar assay is still superior to other tests, such as a 
mono-layer assay and a biochemical test (tntiated nucleotide incorporation)(Wilson 
et al 1984), as well as the tntiated thymidine uptake test and the biological subrenal 
capsule ('Bogden') assay Recently Eidtmann et al (1985) compared the Volm DNA 
precursor uptake test with the double layer soft agar chemoscnsitivity test and con-
cluded that the Volm assay is more practical to apply but that the stem-cell assay 
is 'desirable' because it allows for testing of a battery of cytostatic agents. Again from 
this study it was also concluded that simplification of the test method, together with 
an increased take rate, would be necessary A more basic approach towards the soft 
agar assay is needed to establish the applicability of this test, which provided promising 
preliminary results 
Our own experience is based on the specimens listed in table 4 5 Apart from ovarian 
carcinoma, various types of gynaecological tumours were cultured Endometrial carci-
noma offers good cloning ability Unfortunately, since only small, low stage tumours 
are treated with surgery, the volume of the tumour is often not enough to generate 
a sufficient number of cells for culturmg From the few cultures that could be obtained 
the soft agar system seems to be a suitable assay to test e g hormones, such as medroxy-
progestcrone-acetate. Cervical carcinoma is often difficult to culture due to bacterial 
contamination since these tumours are mostly ulcerating into the vagina infection 
seldom occurs evidently, but neither do we see much colony growth Although Parker 
et al (1985) have been able to culture adequately cervical carcinoma specimens, these 
tumours are not suitable for cloning in soft agar in our experience 
In view of the problems related to in vitro - in vivo correlations, our studies focused 
on characterisation of in vitro growth and on the parameters for detection of (clinically 
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relevant) in vitro tumour cell growth The proposed applications in paragraph 4 6 
have therefore been translated into the main questions, dealt with in the folowing 
chapters-
1. Do the tumour cells that grow in vitro, and are thus accessible for further study, 
form a clinically relevant part of the tumour, that is to say does the soft agar assay 
select for malignant growth9 
2 Can additional information be obtained by the assessment of the time course 
of colony formation, rather than single time point counts, that is to say can the criteria 
for detection of in vitro growth be improved7 
3 Having established that the tumour cell cultures provide representative malig­
nant growth (1) and that we may apply the time course of colony formation in the 
detection of this growth (2), does in vitro growth correlate with the clinical status 
of the patient, that is to say can growth in vitro predict the clinical course9 
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5. Human tumour cloning 
5.1 INTRODUCTION. 
From the previous chapters it can be concluded that several problems in the manage­
ment of ovarian carcinoma remain still unsolved notably the choice of the right cyto­
static agent(s) as well as risk assessment for patients with minimal disease in lower 
stages or after chemotherapy are still a matter of discussion 
Conventional treatment encompasses surgery and chemotherapy according to em­
pirically established schemes This approach, however, could not result in significantly 
improved treatment results and, therefore, required a new approach The Human Tu­
mour Cloning System (HTCS) reportedly yielded excellent in vitro-in vivo correlations 
for chemosensilivity. Since most experience was obtained in malignant myeloma and 
ovarian carcinoma it was decided to study the applicability of this assay in our institute 
for ovarian carcinoma 
Unfortunately, soon after our first initial experience with the HTCS, rather severe 
criticism was directed towards the HTCS It was doubted whether the established tech­
nique could really tell one something of the tumour fraction, responsible for malignant 
growth in the patient. Also our own preliminary results could not immediately repro­
duce the good results on in vitro growth reported from the United States. 
We wondered whether the method of evaluation was correct It did not seem logical 
to try to assess a biological process like in vitro tumour cell growth in one single obser­
vation Others suggested that the low cloning efficiencies, ι e the number of colonies 
formed per plated cells, could be enhanced This would make the test more suitable 
for routine clinical use The low cloning efficiency, however, is likely to be an intrinsic 
property of malignant cells, since only a very few cells constitute 'stem cells', or more 
appropriately called 'clonogenic cells'. 
Therefore, we questioned whether it would be useful to try to enhance growth in 
a culture method not yet fully understood, thus introducing more elements that could 
cloud the picture. Without changing the assay itself, we tried a more differentiated 
way of evaluating colony growth by means of temporal growth patterns, first intro­
duced by our group 'I he concept of this method of in vitro growth evaluation will 
be dealt with in chapter 5 4. 
Fortunately an automated colony counter, Ommcon" FAS II, was placed at our 
disposal by Bausch & Lomb Inc. (Rochester, NY) This was a prerequisite for the 
use of temporal growth patterns, since these required large sets of culture dishes to 
be plated and to be counted Counting so many dishes would be very fatiguing for 
a human observer, making results less reliable. In an in-use evaluation of the Omm­
con
1
' we could establish the reproducibility of this automated counter and showed 
that manual counting ofcolonies indeed gave a higher variability. 
We did not only investigate a method of evaluation which potentially does more 
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justice to the biological properties of proliferating colonics in vitro. We were also inter­
ested in knowing whether it was clinically relevant to study clonogenic cells from which 
colonies arose Since this assay could be used to detect 'viable' tumour cells and in 
vitro cytostatic drug effects could be assessed on the basis of colony growth inhibition, 
it seemed a prerequisite to establish the relevance of the cells in vitro to clinical behav­
iour of the tumour. 
It was recently made clear by Friedlander et al. (Cancer Res 44· 397, 1984) that 
cellular D N A content was relevant to prognosis in ovarian cancer We therefore corre­
lated D N A content of the cells plated in soft agar to their in vitro growth potential. 
This study will be discussed m chapter 5 2 
5.2. CF! I DNA CONTENT - CORRELATION WITH CLONOGFNICITY IN THE HUMAN TUMOUR 
CLONING SYSTEM (HTCS) 
RH M VntnHjiN12, W F J FF1T73, J Ι M BfcCK'.FMJ DumuYM-3, G Ρ VOOYS', Ρ KINFMAVS2, С J 
HbRMAN4 
' Inst of Pathology, 2 Inst of Obstetrics and Gynaecology. 1 Depl of Urology, St Radboud Hospital, 
Catholic University. Nijmegen, and 4Dept of Pathology, SSDZ. Delft, THE NFTHFRLANDS 
5 2.1. Summary 
Thirty-six ovarian and renal cell tumours were analyzed by flow cytometry (FCM) 
for D N A content and in parallel were assayed for colony formation in the Human 
Tumour Cloning System (HTCS) While 15/19 (790/<)) tumours with an abnormal (an-
euploid) D N A stemline formed colonies in the HTCS, only 2/17 (12/o) of diploid tu­
mours formed colonies All samples contained tumour cells as assessed by routine 
cytological examination The capacity to form colonies in the H l CS was not correlated 
in these tumours with grade or stage of disease or tumour type. The level of aneuploidy 
expressed as the F C M D N A index did not correlate with the cloning efficiency in 
HTCS These findings suggest that tumour growth in the H T C S reflects a biologically 
important potential, related m at least some tumours to an abnormal D N A stemline 
5 2.2 Introduction 
In 1977 the Human Tumour Cloning System (HTCS) was introduced by Hamburger 
and Salmon (1977a-l-b) as a technique for selective in vitro growth of cells from solid 
tumours which could then be studied in vitro for their chemoscnsitivity. Other clinical 
applications for this assay have also been proposed, including detection of viable di­
sease at first- and second-look operations in patients before and after chemotherapy 
Reproduced with permission from Int J Cancer 35 653-657,1985 
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(Verheijen et al 1984), as well as in urinary specimens or bladder biopsies in follow-up 
of patients after treatment for transitional cell carcinoma of the bladder (Kirkels et 
al 1982,1983,1985; Hermanetal. 1983a) These applications are based on the concept 
that only clonogenic tumour cells grow in this double layer soft agar assay (Macpher-
son 1973). 
Flow cytometric DNA analysis is another method of recognizing tumour cells, by 
detection of an abnormal DNA stemhne (Herman 1984, see for nomenclature. Hidde-
man et al 1984). An abnormal DNA slemline is related to the stage of disease in 
ovarian cancer (Friedlander 1983) and is also a major and independent prognostic 
determinant in ovarian cancer Patients with tumours with a normal DNA stemhne 
survive significantly longer than those with an abnormal DNA stemhne (Friedlander 
1984a+b) In renal cell carcinoma tlow cytometric studies reported that the DNA 
content of these tumours was indicative for the clinical course of the patients (Otto 
1984), although other investigators could not establish a relation between prognosis 
nor stage of the disease and DNA distribution (Schwabe 1983) 
Reports on the relation between DNA content and clonogemcity of primary human 
tumours in vitro are scarce. Morasca (1983) reported a change in DNA content in 
consecutive passages in tissue culture of 15 cases of ovarian cancer Hostmark (1984) 
found equal colony formation in aneuploid (2'3) and diploid (3/6) tumours of transit­
ional cell carcinoma of the bladder The purpose of this study was to establish the 
relationship between DNA content and cloning ability in a larger series of human 
solid tumours, in which DNA content has been shown to be of clinical importance 
(Hermanetal 1984) 
5.2 3 Material and methods 
5.2 3 1 Tumour material 
Samples were taken from 11 solid malignant ovarian tumours, 12 solid renal cell 
carcinomas and from 13 malignant effusions or abdominal washings from patients 
with ovarian cancer. Samples were collected and transported stenlely to the tissue 
culture laboratory All samples were processed for DNA analysis and in vitro culture 
within 6 hours from collection 
5 2 3 2 Preparation of single cell suspensions 
Tumour cell suspensions were prepared as required for the HTCS, using the method 
described in detail by Slocum et al (1981) In brief, tumour tissue was minced and 
incubated in a slowly revolving magnetic rotor with collagcnasc Type II (40 mg of 
227 units/mg; Worthington, Freehold, NJ) and DNase Type I (0 5 mg of 3085 Kunitz 
units/mg, Sigma, St Louis, Mo.) for 2 hours at 37"C and subsequently washed with 
McCoy's wash (Gibco, Paisley, Scotland). Then, the homogenate was sieved in consec­
utive steps through a 150-200μ metal sieve, a 40-60μ nylon sieve and a 25-gauge needle 
Cells from effusions were not treated enzymatically but were rcsuspended in McCoy's 
wash after centnfugation. Cells were counted in a Burker-Turk haemocytometer. The 
cell concentration was adjusted to ЗхІО6 nucleated cells per ml McCoy's wash 
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Air-dried Papanicolaou stained smears of the cell suspension used for plating the 
cultures and for flow cytometric DNA analysis were examined by an experienced cyto-
pathologist (G.P.V.) and compared with the original specimens of the tumours and 
effusions or washings. In this way it was shown that the tumour cell suspensions pre­
pared did indeed contain malignant cells. 
5.2.3.3. Cloning in soft agar 
Plastic 35 mm petri dishes were seeded with 5xl05 nucleated cells in double-enriched 
CMRI.-1066(Gibco, Paisley, Scotland) with 0.3 % agar on a bottom layer of enriched 
McCoy's medium with 0.5% agar, as described by Salmon (1978), except that condi­
tioned medium was not used. The cultures were incubated at 6% CO^ in humidified 
air at 37 C. 
Eighteen to 24 dishes were plated from each sample to allow frequent colony count­
ing, without having to return the counted dishes to the incubator. Thus risk of infection 
was reduced. Colonies were counted with an automated colony counter (Omnicon", 
Bausch & Lomb Inc., Rochester, NY) (Herman et al., 1983b). Counting of the dishes 
at intervals of 2 to 3 days resulted in Temporal Growth Patterns (TGP) on which 
growth assessment was based (cf. Fig. 5.1). When the number of colonies rises with 
a consistent trend to more than twice the lowest count recorded before peak growth, 
at a peak of at least 30 colonies, criteria for growth are met (Kirkels et al. 1983). 
5.2.3.4. Flow cytometric DNA analysis 
From all samples с 2x1ο6 nucleated cells were taken from the cell suspensions pre­
pared as described above. After cenlrifugation at room temperature, the cells were 
resuspended in 70% ethanol at — 20'C during vigorous vortexing. As internal standard 
Chicken Red Blood Cells (CRBC) fixed in 70% ethanol were added to the tumour 
cell suspension up to a concentration of 10% (Tannenbaum et al., 1978; Hamilton 
et al., 1980). As an external standard Human Lymphocytes were used for daily calibra­
tion of the flow cytomctcr. After removal of the fixative, cells were stained with propi-
dium iodide (A grade, Calbiochem-Behring Corp., La Jolla, Ca.) in a 0.15 M sodium 
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phosphate buffer (pH = 7.40). Cells were incubated for 10 minutes with RNase (Sigma, 
St. Louis, Mo.) at 37 С and stored in the dark. 
Flow cytometric analysis was performed using a cytofluorograph 50 H (Ortho In­
struments. Westwood, Mass.) equipped with an Argon ion laser (Spectra Physics, 
Mountain View, Ca.) as previously described (Tannenbaum 1978, Fowlkes 1976). 
Data were stored on a PDP 11/34 computer (Digital Equipment Corp., Maynard, 
Mass.) and subsequently the cell cycle distribution was analysed by the method of 
Baisch(1975). 
The normal human G, DNA index in our laboratory is 2.60-2.70 times the fluores­
cence intensity of CRBC's. In the determination of an abnormal DNA stemline the 
following criteria were used: 
a) when only one G, peak occurs, the sample was regarded to contain an abnormal 
DNA stemline when the peak deviated more than twice the standard deviation (sd) 
from the mean of all G, peaks in the samples used for this experiment. 
b) when a 'shoulder' or second peak was observed (cf. fig. 5.2) which extended to 
more than 10% (about twice the sd) from the first G, peak, the sample was considered 
to contain an abnormal DNA stemline. 
c) in the case of higher level aneuploidy a percentage of S + GjM greater than 20% 
is suspect for - but cannot prove- the presence of an abnormal DNA stemline. 
The degree of aberration in DNA stemline was quanti ta ted by the DNA index which 
represents the relative DNA content of the aneuploid tumour G, cells in comparison 
to the reference cells (CRBC as internal standard after calibration with Human Lym­
phocytes as external standard) (Jacobsen 1983). 
5.2.4. Results 
Examples of DNA histograms obtained in this study are shown in fig 5.2. Of the 
17 samples with a normal DNA distribution, 2 samples (one breast carcinoma meta­
static to the ovary and one renal cell carcinoma) (12%) showed growth in the HTCS. 
On the other hand, 15 out of 19 samples (79%) that had an abnormal - aneuploid 
- DNA distribution grew in soft agar culture (Significant difference in Chi-square 
test: X 2 = 13.67, ρ < 0.002). Because of the possible difference between cells recovered 
Table 5 1 Relationship between in vitro growth and DNA content: specimens showing growth in vitro/total 
number of specimens. Τ = solid tumours E; F = malignant effusions or peritoneal washings. 
DNA content Growth in vitro 
ovarian ca. renal cell total 
Τ E/F carcinoma growth 
Τ # * 
Normal (diploid) 0/4 1/9 1'4 2/17 12 
Abnormal (aneuploid) 6/7 3/4 6 8 15/19 79 
*p<.002,X 2=13 67 
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Table 5 2 Relationship between stage of disease in ovarian tumours (FIGO slaging), DNA content, and 
growth in the HTCS 
Stage # Samples # Aneuploid # Growth in vitro* 
lai 
Ian 
Ic 
III 
IV 
metastatic 
* All aneuploid 
1 
3 
1 
16 
2 
1 
0 
I 
0 
9 
1 
0 
0 
1 
0 
8 
1 
1 
Table 5 3 Relationship between stage of disease in renal cell carcinoma (Robson et al 1969), DNA content 
and growth in the HTCS. 
Stage # Samples # Aneuploid # Growth in vitro 
I 
II 
IVb 
' All aneuploid 
from effusions or washings and those derived from solid tumours, results for both 
types of samples are listed separately in table 5.1. There appeared to be no difference 
in the distribution of normal and abnormal DNA stemline, nor in the in vitro growth 
potential between solid tumours and effusions or washings. 
Of interest was one patient from whom cells were recovered in ascites prior to che­
motherapy which appeared to be of a normal DNA stemline and did not show growth 
in HTCS. After 6 courses of poly-chemotherapy (cis-platin, adriamycin and cyclo­
phosphamide), cells of an abnormal DNA stemline were detected in the peritoneal 
washing at second-look operation. Also, in vitro growth occured. This finding correlat-
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Fig 5.3 Correlation of DNA index as a measure of level of aneuploidy (ordinate) with cloning efficiency 
(CE) is soft agar (abcissa). Cloning efficiency is expressed as colonies produced per 100 nucleated cells 
plated (r = 0 29) 
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cd with only a partial remission with microscopic tumour rests 
The degree of abberation in DNA stcmline, as indicated by the DNA index, did 
not show a correlation with cloning efficiency, as expressed by the number of colonies 
formed per 1OQ plated nucleated cells (fig 5.3). Therefore, only the presence or absence 
of an abnormal DNA stemhne correlates with the presence or absence of colonies 
in HTCS. 
5 2 5 Discussion 
The present study demonstrates that for two types of primary human tumours, ovar­
ian tumours and renal cell carcinoma, the presence of an abnormal (aneuploid) DNA 
stemhne in the tumour highly correlates with the tumour's ability to form colonies 
in soft agar In the present material, the level of aneuploidy, expressed as DNA index, 
was not correlated with the number of colonies formed in agar, measured as cloning 
efficiency. 
A number of studies, summarized by Herman et al (1984), have demostrated a 
correlation between the presence of an abnormal tumour cell DNA stemlinc (aneu­
ploidy) and a more aggressive tumour course. In contrast, the relationship between 
tumour colony formation in agar and the clinical behaviour of the tumour has been 
a subject of controversy (Sclby et al 1983). The nature of colonies formed from prima­
ry human tumour expiants and especially their cell(s) of origin have been discussed 
in terms of the stem cell theory of growth (Mackillop et al 1983) In this context, 
the present study is encouraging in that it relates tumour colony growth in vitro to 
a well-documented biological parameter of tumour behaviour, aneuploidy as deter­
mined by FCM analysis. 
The role of diploid and aneuploid subfractions of tumours in maintaining the tu­
mour remains unclear It is reported that tumour cell lines derived from primary hu­
man tumours or malignant effusions of patients with ovarian cancer contain only 
cells of an abnormal DNA stemhne after serial passages (van Haaften-Day 1983). 
On the other hand Friedlander с s (1984c) demonstrated that the DNA content of 
ovarian carcinoma xenografts maintain the same DNA content as the original im­
planted tumour, although there was a considerable intramural variability in the S-
phase fraction Some studies (Claflin 1982) show that explanting of animal tumour 
to monolayer culture results in the loss of the aneuploid fraction with persistent growth 
in vitro of only the diploid tumour cells Other studies (Wake 1982) find exactly the 
opposite, with only the aneuploid cells persisting in vitro The present data lend sup­
port to the concept that in some way the aneuploid fraction plays a role in maintaining 
the growth of a tumour in which both diploid and aneuploid fractions are present. 
Unfortunately, because of limitations of working with primary human tumours in 
soft agar culture, the ploidy level of the cells comprising the colonics could not yet 
be determined. 
The interpretation of the FCM data in the present study presents several problems 
It would be interesting to know the relative proliferative fractions (S phase) of the 
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diploid and aneuploid populations of the tumour cells In addition, it would be inter­
esting to know if the two diploid tumours which showed colony formation were truly 
pure diploid tumours Alternatively, a small aneuploid fraction of tumour cells could 
have been missed because of the limited sensitivity of single-parametric FCM analysis 
This sensitivity is in the range of 0 1-1 0% of the total cell population analyzed (Her­
man, unpublished data) Λ possible solution to both of these problems may be offered 
by the recent development (Ramaekers 1984) of a two-parameter technique for analyz­
ing the DNA distribution of tumour cells while excluding from analysis stromal and 
inflammatory cells present in the tumour cell suspension 
The most interesting point of discussion raised by the present study is the relative 
information content of FCM and the HTCS relevant to patient management An ini­
tial hypothesis could be that, given the work and time involved in HTCS culturing, 
FCM screening of tumour cell suspensions could identify those specimens suitable 
for extensive culturing for in vitro chemotherapy testing Conversely, the use of HTCS 
to identify viable tumour after therapy seems to be independent of the presence of 
an aneuploid fraction by FCM analysis since dead cells preserve their analyzable DNA 
content for relatively long periods Finally the possible relationship between DNA 
index, reflecting the level of aneuploidy, and the temporal characteristics of growth 
in the HTCS deserve further study and correlation with the clinical course of the pa­
tients. 
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5 3 TlMfc COURSL Oí OVARIAN TUMOUR GROWTH IN SOFT AGAR CULTURE 
R H M Verhcijcn'2 W Ь J F-cil?1, Ρ Kencmans2, G Ρ Vooys', С J Herman4 
'inst orPdtholog>,2Insl of Obslelrics and Gynaecology and 3Dcpt ofUrology.St Radboud Umvcrsily 
Hospital, Nijmegen, 4Dcpt of Pathology. SSDZ Delft, THE N FTH ERLAN DS 
5.3.1. Summary 
Single time point assessment is usually used in the Human Tumour Cloning System 
as the only parameter for in vitro growth. This does not seem to give a fair expression 
of the dynamic biological properties of tumour growth and time dependent effects, 
e g of cytotoxic drugs. We studied the time course of colony formation in temporal 
growth patterns (TGP) and compared this method of growth evaluation with conven­
tional single time point assessment in 57 samples of ovarian tumours cultures in the 
HTCS A first advantage of the use of TCP's is that more cultures become évaluable, 
as this assessment over time can detect a rise in the number of colonies in dishes where 
colony-like clumps have initially been seeded Thus only 28 of the cultures were évalu-
able for single time point assessment, whereas 57 were available for TGP evaluation 
Growth was more often seen at TGP evaluation (14/57) than at single day assessment 
(8/57) Evaluation of growth over the course of time potentially allows detection of 
sensitivity to drugs. Furthermore TGP's reflect the dynamics of biological growth 
These features cannot be studied in single time point assessment. 
5 3.2. Introduction 
The Human Tumour Cloning System (HTCS) (Hamburger & Salmon 1977) was 
introduced as a chemosensitivity test for individual patient's tumours, especially in 
ovarian cancer (Alberts et al 1980, Von Hoíf et al. 1980, Ozols et al 1980) Also 
an application in detection of persisting viable tumour following therapy has been 
advocated (Herman et al 1983a, Verheijen et al 1984) 
A weak point in this test is the definition of in vitro tumour cell growth, which 
has always been based on variable criteria without much rationale more than 5-30 
colonies (Cowan & Von Hoff 1983, Salmon 1980) after 7-29 days in culture (Alberts 
et al 1980, Williams et al 1983) constitute growth. Colonics are defined as clusters 
of cells with a minimum diameter of 60μ and/or containing at least 20-30 cells (Kern 
et al 1982, Von Hoff et al 1981) In vitro drug effects are measured as a decrease 
or increase of the number of colonies at only one specific time point as compared 
with control growth 
Assessment of growth, based on single day colony counts, ignores the fact that col­
ony development of different tumours under different conditions may follow different 
patterns of temporal growth (Kirkcls et al 1983) Counting colonies in the dishes 
Reproduced with permission trom Brit J Canter 52 707-712,1985 
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frequently over a period of time provides valuable information on the processes of 
soft agar colony growth that are missed in the usual growth determination 
This study reports on the additional information in the assessment of time course 
of colony formation that may be obtained beyond colony counts at a single time point 
5 3 5 Material and methods 
5 3.3 1 Tumour material 
Ovarian carcinoma cells were obtained from solid tumours, ascites or peritoneal 
washings from 25 patients with histologically proven ovarian carcinoma. Twenty-two 
of 25 patients suffered from Stage III or IV disease Twenty four of the 25 patients 
had an epithelial tumour, one patient had a granulosa cell tumour 
A total of 57 samples were obtained from these 25 patients Growth assessment 
was done for samples that were plated immediately after reception (43 samples) as 
well as for samples that were plated after incubation in a water bath with McCoy's 
Wash (Gibco, Paisley, Scotland) as a control in chcmosensilivity tests (14 samples) 
Thus 57 temporal growth patterns were available for growth assessment for non drug 
treated cultures All cultures that were not lost due to infection were eligible for this 
study 
5 3 3 2 Culture method 
All material was cultured in a double layer soft agar culture system as described 
in detail by Hamburger & Salmon (1980) In brief, tumour tissue was minced and 
incubated with collagenase Type II (1000-1500 units/ml, Worthington, Freehold. NJ) 
and DNasc Type I (100-150 Kumt/ units/ml, Sigma, St Louis, MO) for 2 h at 37 C, 
washed with McCoy's wash, sieved through a 150-200μ metal sieve and further 
through a 70-100μ nylon sieve and a 25 gauge needle Cells from effusions were not 
treated enzymatically but were resuspended in McCoy's wash after centnfugation 
Of the cell suspension, 0 1 ml was counted in a Burker-Turk hacmocytometer The 
cell concentration was adjusted to 3xl06 cells/ml McCoy's wash 
For in vitro drug tests with adriamycin and cis-platin, cells were incubated for 1 
h in drug solutions made up in McCoy's wash to approximately 10o/
o
 of the in vivo 
attainable peak plasma level The cells for the control groups were incubated with 
McCoy's wash alone omitting the cytostatic drug. 
Plastic 35 mm petn dishes were seeded with SxlO4 nucleated cells in double-enriched 
CMRL-1066 (Gìbeo, Paisley, Scotland) with 0 3% agar over a bottom feeder layer 
of enriched McCoy's medium with 0 5% agar, as described by Hamburger & Salmon 
(1980), except that conditioned medium and mercaptoethanol were not used 
5 3 3 3 Growth assessment 
Eighteen to 24 dishes were plated from each sample to allow frequent colony count-
ing without having to return the counted dishes to the incubator, thereby reducing 
the risk of infection Colonies were counted with an automated colony counter (Omni-
con", Bausch & Lomb Ine , Rochester, NY, USA), the operating characteristics of 
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which have been published elsewhere (Herman et al. 1983b). Briefly, this instrument 
accepts as colonies round, relatively dense, homogeneous objects greater than 60 μ 
in diameter and counts these objects in 6 size categories. Sixty micron is the cut-off 
point adopted by all users of the automated colony counter untili now. 
One point evaluation: Day 21 counts 
Single point colony counts were performed on pairs of dishes after a period used 
by many authors of 20 to 22 days in culture (further called 'Day 21 counts'). Cultures 
with a mean of 30 colonies or more per dish were considered as positive for in vitro 
growth. However, when more than 30 structures were counted by the Omnicon" on 
Day 1, reflecting cell clumps seeded, cultures were regarded as not évaluable for in 
vitro growth by Day 21 counts. 
Dynamic evaluation: temporal growth patterns 
Temporal growth patterns (TGP's or growth curves) were obtained by counting 
pairs of dishes at intervals of 2 to 3 day s for 4-6 weeks. 
As a criterion for growth a minimum of 30 colonies had to be reached. Furthermore, 
the increase had to be consistent over 3 consecutive counts and an arbitrary cut-off 
point was used of 100% increase in the number of structures/colonies counted, either 
after the initial first day count or after a fall in the growth curve, reflecting deterioration 
of seeded clumps. 
In addition to the number of colonies at peak growth the number of days in which 
peak growth was reached was calculated from the time of plating. 
5.3.4. Results 
All 57 cultures were évaluable for TGP's while only 28 cultures were also évaluable 
by Day 21 counts. This lower number in the latter evaluation method is due to high 
Day 1 counts, indicating the presence of cell clumps at the start of the culture period, 
which makes them non-evaluable at a later stage. Data obtained from both methods 
Table 5 4 Comparison of the two methods of in vitro growth assessment for temporal growth patterns 
and single day counts the number of growth positive, growth negative, and not évaluable samples arc com-
pared. Not évaluable specimens by single day counts are those with more than 30 cell clumps counted 
on Day 1. 
Evaluation of in vitro growth by 
temporal growth pattern 
growth no not 
growth évaluable 
Evaluation of in vitro growth 
by single day counts 
growth 
no growth 
not évaluable 
6 
3 
5 
14 
2 
17 
24 
43 
0 
0 
0 
0 
8 
20 
29 
57 
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of growth assessment are compared in table 5 4 In 23 out of 28 (82%) of the cases 
évaluable by both methods, the two types of evaluation gave the same results as to 
the presence or absence of growth 
At Day 21,8 samples showed more than 30 colonies Thus, by single day assessment 
growth was detectable in 14% of all cultures, and in 35% of the évaluable cultures 
When assessed by temporal growth patterns, 14 cultures, ι с 25% of all cultures, 
met the criteria for growth In 6 cases growth assessed in this way corresponded with 
more than 30 colonics at Day 21 
In 2 cases of'positive' Day 21 counts but negative growth curves, temporal growth 
patterns showed marginal fluctuation around 30 colonies resulting in just less than 
30 'colonies' on Day 1 and just more than 30 'colonies' counted on Day 20 However, 
there was no consistent increase in the number of colonies counted over time 
On the other hand, in 3 cases where growth was seen in the growth curves, Day 
21 evaluation was negative with less than 30 colonies counted One sample showed 
early peak growth at 12 days in culture Two other samples showed late growth after 
the 21st day in culture 
Notably 5 of the 14 cultures positive for growth according to the temporal growth 
pattern were not évaluable by Day 21 evaluation due to seeding of clumps 
The mean time to reach peak growth for ovarian carcinomas in this study was 19 8 
days with a wide range of 8-37 days 
Table 5 5 Growth in conlrol cultures and cultures prc-incubatcd with adnamycin (ADR) and cis-pldtin 
(DDP) as assessed with single time point Day 21 counts (D21) and in temporal growth patterns (TOP) 
for ovarian carcinoma 
η e not évaluable, + growth, no growth 
Sample Control ADR DDP 
number 
D21 TOP D21 TGP D21 TOP 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
η e 
+ 
η e 
+ 
η e 
+ 
η e 
+ 
η e 
-
+ 
-
-
-
-
+ 
+ 
-
+ 
η e 
+ 
η e 
-
infected 
+ 
not tested 
-
+ 
-
-
-
-
+ 
-
-
+ 
+ 
-
η e 
-
infected 
+ 
η e 
-
+ 
+ 
-
-
-
+ 
— 
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Fig 5 4 Temporal growth patterns in soft agar culture of an ovarian carcinoma control culture ( ) 
and after one hour incubation with adriamycin ( ) and cis-platin ( ) Adriamycin effect is seen as an 
early relative inhibition with subsequent 'catch up' Cis platin has no effect on the temporal growth pattern 
initially possibly a late stimulatory effect 
Fach point in this figure represents mean + / - SF as computed by the automated colony counter 
c o l o n íes 
per p late 
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Fig 5 5 Temporal growth patterns ol soft agar culture of an ovarian carcinoma m a control culture (--) 
and alter incubation with adriamycin (—) and cis platin ( ) This tumor sample showed sensitivity for 
adriamycin whereas cis-platm showed early inhibition with catch-up to control colony number by Я0 
days 
Each point in this figure represents mean + /- SF as computed by the automated colony counter 
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In addition, growth in soft agar was assessed after preincubation of the tumour 
cells with adnamycin and cis-platinum (Table 5 5). The present data compare only 
presence or absence of colony growth as assessed by Day 21 counts versus temporal 
growth patterns Data analysis techniques for determination of in vitro chemosensiti-
vity using temporal growth patterns are being developed Many curves are lost to 
evaluation in single day growth assessment Similar numbers of growth positive curves 
are obtained in both methods of growth evaluation (10 vs 8 for Day 21 and TGP 
growth assessment respectively) 
In fig 5 4 a control curve and a curve obtained from a drug (adnamycin) treated 
culture of an ovarian carcinoma arc shown Evaluation of the culture on basis of 
single point assessment after a period of 21 days, the culture would have shown a 
stimulation of 240% for adnamycin Only in the TGP a delay in peak growth can 
be appreciated In this case growth after incubation with cis-platin is equal to control 
growth 
A second chcmosensitivity test (Fig 5 5) shows a persistent reduction in the number 
of colonies after adnamycin incubation Again, the number of colonies attains a simi-
lar level as the control curve after incubation with cis-platin, but after a marked lag 
time which cannot be detected by single time point assessment 
5 3 5. Discussion 
Growth of tumour cell colonies in soft agar is commonly determined on the basis 
of the presence of a minimum number of'colony like structures' after a fixed culture 
period In chcmosensitivity testing especially this approach is not entirely satisfactory 
because one has to rely on the outcome of only one observation that may not be 
representative of dynamic tumour cell growth 
It is argued that pattern of growth is not a constant feature of any tumour type 
or specimen Not only the number of colonies grown after a certain period of time, 
but also growth rate, lag time before growth starts, time required for peak growth, 
and total number of colonies formed may be intrinsic properties unique for each tu-
mour which can be variably influenced by culture conditions and cytotoxic drugs. 
These mechanisms may explain why some patients respond to chemotherapy with 
agents that, by Day 21 evaluation, were not regarded as active in vitro and vice versa 
Excellent in vitro in vivo correlation when single time point evaluation was used 
have been reported (Von Hoffet al 1983) I his correlation, however, only regards 
the predictive value for resistance As the sensitivity of this assay is approximately 
60% (Alberts et al 1980) it is unacceptable as a routine laboratory test for chcmosensi-
tivity 
Use of TGPs has three potential advantages Firstly, evaluation of the time course 
of colony growth reflects the biological quality of in vitro growth Two other features 
concern the quantitative evaluability of cultures TGP evaluation may allow assess-
ment of sensitivity to specific drugs, where single time point assessment fails to disclose 
any effect Of course the clinical relevance of differences observed in patterns over 
time can only be concluded from a prospective study, comparable to those performed 
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for single time point assessment (Von Hoffet al 1983) Finally, more cultures become 
évaluable for growth 
By the use of temporal growth patterns essentially all cultures are évaluable for 
growth, unless they are infected Even when clumps are initially seeded, it is still possi-
ble to evaluate the rise or fall in 'colony-like structures' counted over time In single 
time point evaluation it is not thought feasible to subtract the many cell aggregates 
of less than colony size present in culture (Umbach & Spit/er 1983) 
Clumps would either remain constant or deteriorate In the latter case, swelling 
of the dying cells may cause small clumps to 'grow' and make them detectable by 
automated counting Consequently, cell death would cause disaggregation of the 
clumps A decrease in the number of colonies is often seen after an early initial increase 
in the temporal growth pattern Colonies formed in the meantime, conversely, increase 
the number counted after the dip, allowing detection of growth 
Still, additional criteria such as total area of colonies as proposed by Thomson et 
al (1984) may prove to be useful In the study of primary human tumours, of often 
poor quality, this method may have the disadvantage that when deterioration occurs, 
swelling of the cells will cause the total area to increase This will not be fully corrected 
by the disaggregation of the clumps, clusters or colonies A combination of the use 
of both total area and number ot 'objects' greater than a certain biologically acceptable 
lower limit (e g 60μ) might prove to give optimal information on in vitro tumour 
cell growth 
The disadvantages in the use of TGP are mainly of a logistical nature The main 
problem concerns the availability of tumour material Often small biopsies or body 
fluids containing only a few tumour cells are offered for culture This may give rise 
to problems in plating a growth test with as many as 24 dishes used by us. and even 
more frequently to problems for chemosensitivity testing with at least 18 dishes for 
each drug and control Despite this requirement, more cultures prove to be évaluable 
for growth when using temporal growth patterns than in single time point assessment 
While it is necessary to reduce the risk of infection, counting new dishes each time 
allows a fair interpretation of the growth pattern since the criterion of consistent in-
crease over 3 countings is used Thus it is very unlikely that dish to dish variability 
will be interpreted as consistent growth 
1 he growth positive rate of 25% as assessed by TGPs in this study seems to be 
lower than reported generally for ovarian carcinoma cultures (Williams et al 1983) 
This is explained by the rigid criteria tor colony growth used in this study as opposed 
to a low threshold for colony formation of e g 5 colonies used in large studies (Sand-
bach et al 1982, Cowan & Von Hoff 1983) as well as a low number of cells (20) for 
a cell aggregate to be called a 'colony' by others (Kern et al 1982, Bertelsen et al 
1984, Alonso 1984) It should be noted especially that in the concept of TCP's it is 
not enough to see a sufficient number of colonies on ANY day, but that temporal 
increase should be consistent and reach 100% 
The fact that the mean time to peak is 20 days shows that Day 21 count seems 
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to be well timed. However, the great range in time to peak shows that the right lime 
for evaluation cannot be predicted for individual cultures for single time point assess­
ment 
In conclusion, the use of TGPs may not make soft agar cultures available for routine 
use as a chemosemtivity test but this type of growth assessment can point out sample 
to sample variability in growth patterns and therefore show the right time for evalua­
tion, potentially with additional parameters to conventional evaluation 
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6. Patterns of in vitro colony formation and clinical 
correlations in ovarian cancer. 
61 SUMMARY 
Since the Human Tumour Clonogemc System (HTCS) is a selective culture system 
for malignant growth, the correlation between tumour growth in vitro and clinical 
follow-up was investigated in 37 patients with ovarian cancer For the in vitro evalua-
tion Temporal Growth Patterns (TGP) were used, as opposed to single time point 
counts The predictive value of tumour growth in vitro for therapy response was inves-
tigated in 19 patients from whom 25 samples of malignant effusions or washings were 
taken at the time of cytoreductivc surgery Only 4 samples showed growth in the TGP 
all these patients showed progression By single time point evaluation no in vitro 
growth was detected This growth rate of 16°,, contrasted with 80% of these samples 
that showed malignant cells at cytological examination In 23 cases of a second-look 
operation cytological examination of peritoneal lavage was positive in 1 case out of 
10 with tumour rest, whereas one other case showed growth in vitro both by TGP 
and single time point evaluation Furthermore a total of 30 attempted chemosensitivity 
tests resulted in 4 cases with 8 tests évaluable for in vitro in vivo correlation TGP 
correlated in 7/8 tests with in vivo response Single time point counts correlated cor-
rectly in 2/8 cases because of less évaluable test and failure to predict sensitivity It 
is concluded that the role of HTCS in the detection of minimal disease has still to 
be established Both for this diagnostic purpose as well as for chemosensitivity testing 
the use of Temporal Growth Patterns for the evaluation of in vitro colony growth 
may result in more évaluable cultures and provides potentially a better parameter 
for in vitro growth than single time point assessment 
6 2. INTRODUCTION 
Since the establishment of selective tumour cell growth in a double layer soft agar 
assay (Mcpherson 1973, Hamburger & Salmon 1977) this assay has mainly been used 
as a test for individual patients' drug selection (Alberts et al 1979, Von Hoffet al 
1983) as well as in screening of new drugs (Shoemaker el al 1985) Besides chemosensit-
ivity testing, however, additional applications of the double layer soft agar culture 
method are feasible Growth of a patient's primary tumour specimen in vitro might 
be of prognostic significance Furthermore, since the system is selective for malignant 
tumour growth, the assay may also be used for the detection of minimal disease at 
the time of evaluation of therapy results (Herman et al 1983) 
We recently introduced a dynamic assessment of in vitro growth by the use of Tem-
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poral Growth Patterns (TGP) (Kirkels et al 1983, Verheijen et al. 1985c) This method 
of evaluation was investigated for the three applications mentioned here 
Especially in ovarian cancer management the issues of prognosis, chemotherapy 
selection and therapy evaluation are difficult to assess Firstly it is still not possible 
to distinguish between patients with a favourable prognosis, and those with an unfa­
vourable prognosis at the time of detection of the tumour Secondly, chemotherapy 
fails in a considerable number of cases, mainly because we cannot predict whether 
a patient will react to a given treatment. Thirdly, failure of chemotherapy can often 
only be observed as a residue of microscopic tumour We therefore evaluated the po­
tential role of in vitro cultunng in the assessment of prognosis, chemotherapy selection 
and detection of minimal disease using techniques that consider the biological dynam­
ics of in vitro growth 
6 3 MATFRIAI AND MFTHODS 
6 3 1 Patient material. 
Eighty-five tumour samples were obtained from 36 patients with ovarian carcinoma. 
Characteristics of these patients are listed in table 6.1. 
Patients in the presumed study period were treated with several combinations of 
chemotherapy that contained cisplatin : РАС-V (Verheijen et al 1985b), PAC-I (cf. 
Ehrlich et al. 1979), CHAP-V (cf Israel et al. 1983) and CP courses (cf Neyt 1983) 
(P = cis-platin, A = adriamycin, С = cyclophosphamide, and H = hexameihylmcla-
mine) Treatment results were evaluated on basis of the clinical condition and non­
invasive follow-up, or, if complete remission was expected, at second-look laparotomy. 
Surgico-pathological examination was required to assess Complete Remission (CR) 
which is defined as no residual tumour found in random biopsies, peritoneal washings 
or smears of the diafragm, para-colic gutters and cul-de-sac Partial Remission (PR) 
can be 'microscopic', i.e when only microscopic tumour deposits are found in random 
biopsies and/or cytological specimens, or 'macroscopic' when macroscopic suspect 
lesions are seen which constitute less than 50% of the residual tumour after debulking. 
Stable Disease (SD) is defined as a tumour-reduction of less than 50% but more than 
25% of the tumourload left behind at second-look operation Progression (P) means 
less than 25% decrease of tumour load. 
Nineteen patients with a total of 25 samples of malignant effusions were available 
to assess the prognostic value of in vitro growth at the time ofcytoreductive surgery 
F-or 23 patients with a second-look operation, abdominal fluid was obtained for 
testing colony forming ability. 
In 4 patients results of in vitro chemosensitivity testing according to temporal 
growth patterns could be correlated to the clinical response to the drugs tested 
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Table 6.1 Patient characteristics. 
Histological classification 
Grading 
Classification 
Treatment after 
cytoreductive surgery 
End of follow-up 
serous cysladcnocarcinoma 
adenocarcinoma 
mucinous cysladcnocarcinoma 
endometrioid carcinoma 
clear cell carcinoma 
mixed mesodermal sarcoma 
borderline malignancy 
not documented 
grade 0 
grade 1 
grade 2 
grade 3 
not documented 
Stage I - I I 
Stage III 
Stage IV 
not documented 
РЛС-І 
PAC-V 
CP 
CHAP-V 
other 
none 
Died 
withdrawn alive 
not documented 
II 
II 
3 
2 
2 
1 
1 
5 
1 
8 
8 
II 
8 
7 
24 
1 
4 
11 
1 
6 
4 
7 
7 
20 
14 
2 
I pts. 
6.3.2. Tumour material. 
Tumour specimens were transferred under sterile condition from the operating the­
atre to the department of pathology. A pathologist immediately examined the tumour 
specimen and prepared samples from the most suspect areas of the tumour, which 
were consequently transferred to the culture laboratory under sterile conditions. Adja­
cent parts of the tumour were taken for pathologic examination. 
Effusions or washings were collected in sterile containers where preservative free 
héparine (Calparine11, Bournonville, Almere, NL) was added (1000-5000 IU/ 100ml). 
A sample of each specimen was taken for routine cytological examination. 
In total from 36 patients we obtained 40 samples of solid tumours and 46 samples 
of malignant effusions or peritoneal washings. 
6.3.3. Cloning in soft agar. 
For preparation of double layer soft agar cultures the method described by Ham-
burger et al. (1983) was used. In brief, tumour tissue was minced and incubated in 
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a container with a slowly revolving magnetic rotor with collagenase Type II (40 mg 
of 227 units/mg, Worthington, Freehold, NJ) and DNaseType I (0 5 mg of 3085 Kun-
itz units/mg; Sigma, St Louis, Mo ) for 2 hours at 37 С and subsequently washed 
with McCoy's wash (Gibco, Paisley, Scotland). Then, the homogenate was sieved in 
consecutive steps through a 150-200μ metal sieve, a 70-100μ nylon sieve and a 25-gauge 
needle Cells from effusions were not treated cnzymatically but were rcsuspended in 
McCoy's wash after centnfugation Cells were counted in a Burker-Turk haemocyt-
ometer. The cell concentration was adjusted to 3xl06 nucleated cells per ml McCoy's 
wash 
For chemosensitivity testing cells were incubated for one hour in drug solutions 
made up in McCoy's wash to approximately 10% of the in vivo attainable peak plasma 
level. The cells for the control groups were incubated with McCoy's wash alone, omit­
ting the cytostatic drug 
Plastic 35 mm petn dishes were seeded with 5xl05 large nucleated cells in double-
enriched CMRL-1066 (Gibco, Paisley, Scotland) with 0 3% agar on a bottom layer 
of enriched McCoy's medium with 0 5% agar, as described by Hamburger & Salmon 
(1980), except that conditioned medium was not used The cultures were incubated 
at 6% C 0 2 in humidified air at 37 'C 
Eighteen to 24 dishes were plated from each sample to allow frequent colony count­
ing, without having to return the counted dishes to the incubator, reducing the risk 
of infection. 
6 3 4 Evaluation of in vitro growth. 
Colonies were counted with an Omnicon" (Bausch & Lomb Ine , Rochester, NY) 
automated colony counter (Herman et al 1983b) Counting of the dishes at intervals 
of 2 to 3 days resulted in Temporal Growth Patterns (TGP) on which growth assess­
ment was based. Growth is checked visually at examination of the dishes with a Leitz 
inverted microscope 
All cultures were évaluable for in vitro growth assessment by the use of temporal 
growth curves unless infected or otherwise lost for examination However, to be évalu-
able by single day counts, cultures have to be seeded with less than 30 'colony-like' 
clumps, as assessed by counting the dishes the day after plating 
As a criterion for growth a minimum of 30 colonies had to be reached Furthermore, 
the increase had to be consistent over 3 consecutive counts and an arbitrary cut-off 
point was used of 100% increase in the number of structures/colonies counted, either 
after the initial first day count or after a dip in the growth curve, reflecting deterioration 
of seeded clumps 
To compare clinical results with in vitro growth as evaluated both in the above 
described temporal growth pattterns as well as by single time point evaluation, the 
latter procedure is also performed between day 18 and 23 on dishes that did not contain 
clumps initially. The presence of clumps was assessed on the first or second day in 
culture by automated 'colony' counting, when less than 30 'colony like' structures' 
were seen, it was assumed that clumps would not interfere with the evaluation of 
growth. More than 30 colonies counted after 3 weeks constituted growth 
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The slope of the temporal growth curves - indicating the growth rate - was calculat-
ed as an additional parameter describing the drug inhibitive effect The slope is the 
rate of colony growth This is expressed as the percentage of the minimum number 
of colonies before peak growth is reached, divided by the number of days from the 
time of plating to the time of peak growth Arbitrarily the cut-off point for chemo-
sensitivity is set at 70% decrease in slope, conform the 70% decrease in colony count 
used in single day assessment 
6 4 RESULTS 
6 4 1 In vitro growth before therapy as indicator ojprognosis 
The outcome of in vitro culture and cytological examination of ascites and abdom-
inal washings, obtained at or around cytorcduclive operation, was compared with 
the eventual surgico-pathological response of the patient and the results are presented 
in table 6 2 Eight of the 10 samples of patients that were going to have a partial 
remission or stable disease had tumour cells identified at cytological examination Of 
these samples none showed growth Conversely, 4 out of 11 samples of patients that 
later showed progression showed growth in vitro When assessing in vitro growth by 
single day counts no growth was seen in any of the dishes. 
Table 6 2 Correlation between the outcome of cytological examination and culture ofpentonedl washings 
or ascites, obtained at or around cytoreduclive surgery and subsequent surgico-pathological response to 
therapy 
D21 = growth assessed on basis of single time point counts on the 21 st day in culture 
TGP = growth assessed on basis of temporal growth patterns (see text) 
Response 
Rcsponders 
Non-responders 
Number of 
patients 
11 
8 
Number of 
samples 
14 
11 
Cytology 
# + ( évaluable) 
10(13) 
10(11) 
Colony growth 
# + ( # évaluable) 
D21 TGP 
0(14) 0(14) 
0(11) 4(11) 
6 4 2 In vitro growth at second-look operations 
In 23 patients clinical complete remission was verified surgico- pathologically at 
a second-look operation Findings at these operations are shown in table 6 3 13 com-
plete remissions, 9 partial remissions, no stable disease and one case of progression 
were seen In total 14 évaluable in vitro cultures of peritoneal lavage could be obtained 
From the 13 patients with a surgico-pathological remission, 7 samples of peritoneal 
washings were obtained for in vitro culture which subsequently showed no growth 
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Figure 6 1 The temporal growth pattern of the one sample of a peritoneal washing, obtained at second-look 
operation, that showed growth The number of colonies (ordinate) is counted on several time points during 
culture (abcissa) Each point in this figure represents mean + / - SE as computed by the automated colony 
counter. 
From 9 patients with a partial remission, 6 évaluable samples were obtained for 
in vitro growth testing. Remarkably, one specimen showed growth in vitro (fig. 6.1), 
but cytological examination could not give a definite diagnosis since only 'suspect' 
cells were found. Of the 6 évaluable samples for cytological examination from these 
patients in partial remission, 1 specimen appeared to contain tumour cells. 
One sample was obtained from a patient that showed progression: cytological exam-
ination could demonstrate the presence of tumour cells, but no in vitro growth occured. 
Table 6 3 Correlation between the outcome of cytological examination and in vitro culture of peritoneal 
washings or ascites, obtained at second-look operations, and surgico-pathological response to therapy 
D21 = growth assessed on basis of single time point counts on the 21st day in culture 
TGP = growth assessed on basis of temporal growth patterns (see text). 
Response Number of patients Cytology Colony growth 
# + ( # évaluable) # + ( # évaluable) 
Complete remission 
Partial remission 
Progression 
Total 
13 
9 
1 
23 
0(13) 
К 6) 
К i) 
2(20) 
D21 
0(4) 
1(3) 
0(1) 
1(8) 
TGP 
0( 7) 
1( 6) 
0( 1) 
1(14) 
6.4.3. In vitro chemosensitivity testing. 
As in vitro chemosensitivity tests on basis of temporal growth patterns require much 
material, in 3 years time only 30 samples were received with sufficient cell material 
for testing a total of 94 drugs. Twenty-six samples were lost because of infection or 
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Figure 6.2 Temporal growth patterns of chcmosensitivity tests, showing growth curves for control cultures 
(·), adriamycin treated cultures (Δ) and for cis-platin treated cultures (O )· Each point in these figures 
represents mean + / SE as computed by the automated colony counter. 
Four differenl samples of ovarian carcinoma. 
lack of growth in the control plates. Thus 4 samples were évaluable for in vitro assess-
ment of chcmosensitivity for 20 drugs in total. Temporal growth patterns for the stan-
dard non-incubated plates, control plates incubated with medium without the addition 
of cytostatic drugs and drug treated plates are shown in fig. 6.2. As adriamycin and 
cis-platin are the most commonly used drugs (besides cyclophosphamide, which is 
inactive without in vivo activation) only results for these 2 drugs are shown in the 
temporal growth patterns. Three patients had stage III disease (abdominal spread) 
and one patient had pleural metastases and was therefore assigned stage IV. 
Two main drug effects on temporal growth patterns in vitro can be distinguished. 
Firstly, the shape of the curve of controls and drug treated cultures may be similar 
with only differences in the maximum colony counts (cf. fig. 6.2a). Conversely, the 
shape of the curve may also be altered, resulting in delayed peak growth with a similar 
(cf. cisplatin curve in fig. 6.2c) or increased (cf. adriamycin curve in fig. 6.2b) maximum 
colony count. 
In addition the slope was calculated for the assessment of in vitro growth inhibition 
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Figure 6.3 In vitro response to chemotherapy as measured by the changes in slope in drug treated cultures 
in comparison with control cultures, relation with in vivo response. 
(fig. 6.3). In comparison with control curves, there was a less steep slope (regression 
in growth rate) in the adriamycin curves for two stage III patients that attained a 
surgico-pathological partial remission. The adriamycin curve in the case of a stage 
IV patient with progression showed a steeper slope than the control curve. In cisplatin 
treated dishes similar results were obtained. 
In determining in vitro sensitivity a cut-off point was used of 70% decrease in slope 
or number of colonies for TGP and single time point evaluation respectively. TOP 
evaluation resulted in 7/8 tests predicting the response correctly, whereas single time 
point evaluation could predict response in 2/8 tests. This lower number was due to 
the fact that 4 tests were not évaluable by single time point counts and 2 tests failed 
to recognize sensitivity as detected in the TGP. 
6.5. DISCUSSION 
6.5.1. Detection of viable disease. 
Since the HTCS is based on selective growth of tumour cells (Mcpherson 1973) 
the assay might first of all point out viable tumour, i.e. tumour that retained its vital 
proliferative capacity. At first operation for ovarian carcinoma usually bulky disease 
is present. However, in early stage disease and at second-look operations for the evalu-
ation of chemotherapy response, often minimal disease in the form of microscopic 
implants on the peritoneum is present. 
In early stage ovarian cancer it is very difficult to establish the exact stage, which 
is one of the most important determinants of prognosis. Extensive search for intra-
abdominal spread is necessary, including biopsy of para-aortal lymph nodes. If such 
operations with high morbidity could be simplified or at least be completed by the 
detection or exclusion of malignant cells in specimens taken from the peritoneal surface 
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by smears, washings or through ascites if present, this would greatly enhance the accu-
racy of staging. When looking at the sensitivity of both cytological examination and 
in vitro culture of peritoneal fluid in the presence of bulky disease, cytological examina-
tion appears to detect malignant cells in 80% (20/24) of the cases, whereas colony 
growth is seen in 16% (4/25) of the cases. In our small series, only specimens from 
patients that later showed progression gave rise to colony growth in vitro. 
From these data it could be concluded that in the presence of bulky disease HTCS 
is not valuable nor necessary in detecting viable tumour cells. However, as we discussed 
in chapter 4, culture techniques have to be improved in order to make the double 
layer soft agar culture system applicable for clinical use. In our laboratory, we had 
to cope with many teething problems: inadequate culture media, which have to be 
prepared and shipped under strict conditions, humidity that has to be retained without 
provoking fungal or bacterial contamination. Such circumstances have led to periods 
of overall growth failure that sometimes lasted for months. Therefore negative culture 
results are difficult to interpret and conclusions should not be drawn too hastily. 
A second-look operation is per definition a surgico-pathological evaluation of a 
clinical complete remission and, therefore usually minimal residual tumour, if any, 
is to be expected (Schwarz 1983). In only one case ( 17%) with partial remission (tumour 
reduction of more than 75%) where definite cytological diagnosis was possible, malig-
nant cells could be recovered in the peritoneal lavage. Again in one case (17%) - which 
was a different sample that had no positive cytology! - colony growth was seen in 
the HTCS. Ozols et al. (1984) report a 'growth rate' of 50% of all peritoneal lavages 
at second-look operation. Whether or not residual tumour was present is, however, 
not stated. Moreover, when growth is defined as a colony count of minimal 30 at 
single time point assessment (which is used by these authors) only 17% shows colony 
formation! 
In second-look operations HTCS is still at a low level of sensitivity in detecting 
tumour cells. But here positive growth may have implications. Cytological examina-
tion in these cases with minimal residual tumour appears to be much less sensitive 
than in cases with bulky disease. Mangioni et al. (1979) and River et al. (1980) found 
in 32 and 18% respectively positive cytology as the only indication of disease at second-
look laparoscopy. However in these cases no extensive biopsiing has been done. Cyto-
logical examination of peritoneal washings fails to detect minimal disease in most 
cases. This might also have consequences for patients with stage I and II disease with 
reportedly about 30% positive cytology at the time of first operation (Keettel et al. 
1974; River et al. 1978; Creasman and Rutledge 1971), who may therefore be under-
staged. Whether HTCS can point out high risk patients with low stage disease or mini-
mal residual tumour after chemotherapy can only be concluded from a sufficient 
number of patients with sufficiently long clinical follow-up. 
6.5.2. Chemosensitivity tests 
It has been claimed that the evaluation of drug tests in the HTCS at a single time 
point in culture yields good in vitro - in vivo correlations with respect to the prediction 
of drug resistance (Alberts et al. 1981 ; Von Hoffet al. 1983). Apart from pharmacokin-
etic problems related to period of drug incubation, the use of cytostatic agents in vitro 
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in absence of the in vivo metabolism, and those related to the testing of combinations 
of drugs, it appeared that assessing the decrease in colony growth in drug treated 
dishes as compared with control dishes in a single observation after a fixed period 
of time can lead to misinterpretation (Kirkels et al. 1983; Thomson et al. 1984). 
Since colony growth over time is not a consistent process which is the same for 
every tumour sample a uniform period of time after which colonies should be counted 
cannot be given. Also drug effects may give a range of changes in the temporal growth 
patterns, which cannot be detected by examining the dishes just once over time. As 
a parameter for these changes, such as prolonged lag time, delayed peak growth, catch-
ing-up effect, we calculated the slope of each curve and correlated drug effects on 
these slopes to clinical response to drugs that were tested. The results of in vitro -
in vivo correlation were similar for tests evaluated by slope of the TGP and by single 
time point assessment. However, since cultures where clumps have initially been seeded 
can also be evaluated when there is a consistent increase over time of colonies in the 
control dishes, more cultures were évaluable for chemosensitivity testing when using 
the TGPs (Verhcijcn et al. 1985c). 
Although results obtained in chemosensitivity testing using the TGP as endpoint 
are encouraging, the number of évaluable tests (4 out of 30) is still small and disap-
pointing for reasons mentioned earlier. Excluding peritoneal washings at second look 
operations, which procedure is meant for detection of minimal viable disease and not 
for chemosensitivity testing, this means that eventually 4 out of all 62 samples (6%) 
give évaluable drug tests. This is much less than the success rate of groups that are 
very experienced in testing ovarian cancer, such as the San Antonio group: 52 % of 
their samples are évaluable, resulting, however, in 5.5 % of all drug tests showing 
sensitivity (Clark & Von Hoff 1983). In contrast to this high number of évaluable 
samples, the number of sensitive tests is extremely small in comparison with our own 
results as shown in fig 6.3. A likely explanation is that on one hand our criteria for 
in vitro growth, based on TGPs, are more strict and that on the other hand TGP 
evaluation allows the detection of growth inhibition more easily in the few adequate 
samples that are left for evaluation. 
From the clinical correlation in our few experiments it seems likely that growth 
seen in these tests really consists of tumour cell growth. Moreover, from a number 
of samples that showed growth in vitro we isolated colonies as described previously 
(Verheijen et al. 1985d) and found colonies positive in immunofluorescence with a 
monoclonal anti-body highly specific for ovarian carcinoma, OV-TL3 (Pocls el al. 
1985). Finally, colony growth in the HTCS as detected in TGPs highly correlates with 
the presence of tumour cells with an abnormal (aneuplo'id) stemline (Verheijen et al. 
1985a). Especially this latter finding strongly suggests that indeed a clinically relevant 
tumour fraction is being studied, since it is well known that the presence of an abnormal 
stemline in a tumour is an important prognostic factor (Friedlander et al. 1983; see 
for review: Friedlanderetal. 1984). 
In conclusion the role of the HTCS in detecting viable disease at first operation 
cannot yet be determined but it is likely to obtain enough cells for in vitro drug testing, 
which yield a good in vivo - in vitro correlation when slope of the TGP is used as 
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parameter. TGP evaluation results in more évaluable chemosensitivity tests than can 
be obtained with single time point evaluation. The first results of colony growth from 
samples obtained at second-look operations were encouraging. The HTCS may prove 
to give additional prognostic information to other conventional cytological methods 
of tumour cell detection, which are neither sensitive enough to give definite conclu-
sions. Temporal growth patterns are preferably used for evaluation of cultures, since 
both experimental data and theoretical considerations suggest their superiority over 
single time point evaluation. 
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7. General discussion 
Ovarian carcinoma is one of the malignancies that has profited most from recent 
successes in the field of oncological management. In this thesis an inventory is made 
of the achievements and new developments that contribute to a better understanding 
of the following main problems: 
a) diagnosis and prognostication 
b) selection of treatment 
c) evaluation of treatment results. 
On basis of the results obtained with the Human Tumour Cloning System (HTCS) 
in this study the potential contribution of this assay to each of these fields will be 
discussed. 
Diagnosis and prognostication: 
Early Detection 
Early diagnosis of malignant disease offers the potential of a favourable outcome. 
This applies especially to fast growing tumours like ovarian carcinoma which is usually 
detected in a late and advanced stage. Early diagnosis requires, first of all, the defini-
tion of a high risk group and, secondly, specific and sensitive methods of detection. 
In the case of ovarian carcinoma the relative contribution of risk factors is difficult 
to determine due to lack of adequate case control studies (see Prentice et al. 1984) 
that can identify the importance of the various risk factors. Possible methods of early 
detection include ultra sound (Campbell et al. 1982), monoclonal antibody guided 
serum detection (Kenemans et al. 1985), systematic examination of adnexa at all ab-
dominal operations as well as a regular pelvic examination (Barber & Graber 1968). 
In view of the low number of positive cultures that we observed on examination of 
peritoneal washings (chapter 6) the role of the HTCS in early detection will be very 
limited. 
Staging and Grading 
With the discovery of more and more early stage disease, adequate staging of the 
disease is essential in order to select treatment with the prospect of cure. In view of 
the many false negative cytological examinations at second-look operation, when there 
is only minimal disease (Mangioni et al. 1979;Piveretal. 1980; Yoshimuraetal. 1984; 
Copeland et al. 1985), it can be argued that peritoneal washings arc also of relative 
value at the time of first operation for minimal disease. Although cytological examina-
tion of peritoneal fluid is reported to be more often positive for malignant cells in 
the situation of first operation, random biopsies and smears from the peritoneal sur-
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face as well as para-aortic node sampling seems to be superior in detecting microscopic 
disease (Piver 1983). 
Although in vitro growth appeared to be of prognostic significance in our patients 
who underwent cy toreductivc surgery, it was not indicative of the stage of the disease. 
Therefore, the HTCS cannot be used in determining microscopical dissimination of 
peritoneal disease. 
With respect to staging of advanced disease it has been suggested that two subgroups 
should be distinguished in stage III disease on basis of PRE-operative tumour load 
(diameter) (Richardson et al. 1985). From the time of Griffiths' study (1972) onwards 
it has generally been accepted that the volume of POST-operative residual tumour 
is one of the main determinants of prognosis. An international classification should 
therefore be based on this knowledge. On the other hand, it might well be that macros-
copically and microscopically similar tumours in the same stage will develop, and re-
spectively respond to (chemo-)therapy differently. It may be that on basis of certain 
criteria indeed different prognostic groups, independent of tumour stage can be distin-
guished. 
Prognostication 
The soft agar assay as described in this study might potentially be used to assess 
the malignant nature of a tumour. Human tumour cloning correlates well with the 
finding of an abnormal DNA-stemline (as shown in chapter 5.2), which feature is 
appreciated as an important prognostic factor, not only in advanced ovarian cancer 
(Friedlander et al. 1984a) but also with regard to borderline malignancies, which are 
difficult to assess. More sharply defined objective features of tumours will also be 
helpful in defining the grade of malignancies, especially when they balance on the 
verge of malignancy and non-malignancy. Together with flow cytometric (Friedlander 
et al. 1984b) and morphometric (Baak et al. 1985; Dietel et al. 1985; Erhardt et al. 
1985) examination of tumours, the HTCS potentially offers an additional parameter 
of malignancy. From our experience with tumour cloning of samples obtained at the 
time of cytoreductive surgery it is concluded that colony formation is suggestive for 
a future progression of the tumour. The present thesis also indicates that the use of 
the HTCS for the purpose of prognostication requires optimalization of cloning condi-
tions and subsequently a prospective study. Both requirements have still to be met. 
Selection of treatment 
Cytostatic Drug Selection 
Considering the results of conventional chemotherapeutic treatment schemes, there 
seems to be a plateau in the achievement of response or - more important - of survival 
(cf. fig. 3.2). Whatever effort is made, approximately 80% will not respond and thus 
succumb to the disease. Probably the critical phase that determines prognosis is the 
first phase at the time of diagnosis in which the right treatment should be chosen. 
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Although the sources of new, promising cytostatic agents and methods of administra-
tion are not yet exhausted, new approaches are necessary 
On one hand the HTCS improves the detection of new effective cytostatic agents 
in the rather conventional screening tests, such as used by the National Cancer Institute 
(NCI) Already, the HTCS has shown to be complementary to the screening routinely 
used for activity against P388 and L1210 cells compounds that would have otherwise 
been missed by the latter NCI screening system have been identified by the HTCS 
(Shoemaker et al 1985). 
On the other hand, the HTCS was presented as a new approach in cancer treatment, 
namely in tailoring cytostatic treatment by means of individual chemosensitivity test-
ing Enthousiasm, however, faded away when neither the method itself, nor the results 
obtained with it could be reproduced uniformly. One of the main drawbacks - apart 
from the, often low, culturabihty of the tumours was the irrational way the cultures 
were analyzed. Kirkels from our group (1983) started to acknowledge the time factor 
in the establishment of in vitro growth We consequently developed the use of temporal 
growth patterns into a method of growth detection (chapter 5 3 + 6) This dynamic 
concept was also later adopted by the group of Salmon & Meiskens (Thomson et 
al 1984) and by the group of Lieber (Lieber et al 1984) It should be noted that this 
concept is not only applicable to tumour cell cultures- also in bacteria cultures it has 
been shown after several decades of routine clinical use in more continuous monitor-
ing, that different organisms - like different tumours - may respond in specific ways 
to antibiotic treatment (Greenwood 1983). 
Until now no clinical study on individual chemosensitivity testing using temporal 
growth patterns or similar dynamic concepts has been conducted It is, however, ex-
pected that soon this concept will be incorporated m the large scale, multi-centre 
screening study of the NCI mentioned earlier (Lieber pers comm ) Although the pre-
sent study shows several advantages of the use of temporal growth pattern evaluation, 
culturabihty as determined by this method remains low and also should it be noted 
that chemosensitivity tests based on this concept require a substantial number of tu-
mour cells 
Patient Selection 
The HTCS may not only be used to select cytostatic agents for patients, but also 
- reversely - to select patients that benefit from therapy In this report the HTCS 
appeared to be a potential solution to the problem posed by selection of patients for 
salvage treatment In our own small series of 23 second-look operations for ovarian 
carcinoma we were able to establish the difference in culturabihty as a selective factor. 
Theoretically it can be argued that patients in a surgical partial remission with only 
microscopic disease can be divided into two groups based on the culturabihty of the 
residual tumour cells. In theory these two groups - 'growers' and 'non-growers' -
might react differently on cytostatic treatment. With current knowledge it cannot be 
predicted which group will react best A prospective study that correlates the HTCS 
parameter and/or other independent objective parameters to the outcome of salvage 
treatment has not yet been conducted The necessity of such a study is shown by the 
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fact that so far none of the approaches in salvage therapy have proven to prolong 
survival (Berek 1985) 
Evaluation of treatment results 
Evaluation of therapy results should essentially try to define the cure rate in ALL 
patients admitted to a hospital As shown in fig 3 3 only part of all patients will be 
eligible for systematic and scientific evaluation and even in this group we are unable 
to assess the cure rate since we do not have the means of defining 'cure', which is 
our ultimate goal The terms in which response or remission are defined (see glossary) 
give an impression of exactness In a model study in which oncologists had to assess 
the size of simulated nodules, lesions on chest X-rays and hepatic enlargements, Warr 
et al (1984) found a false categorization of partial responders up to 18 4%. This is 
indicative for the relative value of clinical response assessment 
In ovarian cancer treatment, however, response is assessed surgically at a second-
look operation, which should lead to an objective and accurate decision of the re-
sponse When large tumour rests are present the case is mostly not difficult, although 
it is, even then, often difficult to decide whether there is a partial remission, stable 
disease progression Warr's suggestion of abandonning the clinical criterion 'minimal 
response' ( = stable disease) should therefore be extended to the corresponding surgical 
criterion 
The mam problem, however, is how to decide between complete remission and (mi-
croscopic) partial remission Extensive biopsying is necessary to exclude microscopic 
disease Unfortunately, cytological examination of peritoneal washings often fails to 
detect tumour cells which appear to be present upon histological examination of the 
random biopsies. In the last chapter of this thesis it is shown that the HTCS can be 
an additional method for the detection of microscopic disease It is suggested to com-
bine both cytological examination and in vitro culture of peritoneal washings for the 
detection of residual tumour However, unless this proves to be effective in the future, 
the second-look operations will have to be extensive oncological procedures Until 
now this is the only method for accurate therapy evaluation 
In conclusion 
Many improvements in the HTCS - some of which have been developed in the 
present investigation - have made this assay ready for clinical studies in order to prove 
its potentials in both the field of therapy selection and in that of evaluation of treatment 
results 
Whether the introduction of the HTCS is the new approach with which it was hoped 
to improve cure rates for ovarian cancer patients by selection of proper chemotherapy 
is doubtful. In order to improve the cure of patients research should be focussed on 
early tumour detection and on the selection of salvage therapy that can stabilize a 
remission and on the selection of patients to be considered for this type of therapy 
On basis of the present investigation it is concluded that the HTCS should be consid-
ered as additive value in these approaches 
References 
Baak J Ρ A , Fox H Welke patiënten met een borderline ovariumtumor overlijden''Ned Tijdschr Gcncesk 
129 1704, 1985 
Barber H R К , Graber E A The Ρ Μ Ρ О -syndrome Cancer 22 357-365, 1968 
Berek J S Salvage therapy in ovanan cancer In A Ρ M Hcinl7 cl al , Current concepts in gynecological 
oncology, Boerhaavc course june 12-14, Leiden University of Leiden, 1985, pp 201-209 
Bertoncello I , Bradley Τ R , Campbell J J , Day A J , McDonald I A , McLeish G R , Quinn Μ A , Rome 
R , Hodgson G S Limitations of the clonal agar assay for the assessment of primary human ovarian 
tumour biopsies Br J Cancer 45 803-811,1982 
Campbell S , Goessens L , Goswamy R , Whitehead M Real-time ultrasonography for determination of 
ovarian morphology and volume A possible early screening test for ovarian cancer9 Lancet ι 425-426, 
1982 
Copeland L J , Gershcnson D M , Wharton J Τ , Atkinson Ε N , Sncige N , Edwards С L , Rullcdge F N 
Microscopic disease at second-look laparotomy in advanced ovarian cancer Cancer 55 472-478, 1985 
Dietel M , Bodecker R , Arps H , Bahnsen J , Hobel F Borderline-tumoren des Ovars Neue Aspekle 
zur morphologischen Prognosebestimmung Geburtsh u Fraucnhcilk 45 213-219,1985 
Erhardt E , Auer G , Bjorkholm E , Forsslund G , Mobcrger В , Silfvcrsward С , Wickscll G Zcttcrbcrg 
A Combined morphologic and cytochemical grading of serous ovarian tumors Am J Obstel Gynecol 
151 356-361, 1985 
Fnedlandcr M L , Hedley D W , Taylor I W , Russell Ρ , Coates A S , Tattcrsall Μ Η Ν Influence of cellu­
lar DNA content on survival in advanced ovarian cancer Cancer Res 44 397-400, 1984a 
Friedlander M L , Russell Ρ , Taylor Ι W , Hedley D W , Tatlersall Μ Η Ν Flow cytomylric analysis of 
cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy Pathol­
ogy 16 301-306, 1984b 
Greenwood D The alteration of microbial growth curves by antibiotics Proc 4th Ini Symposium on 
rapid methods and automation in microbiology and immunology June 6-9, 1984, Berlin. S12 
Griffiths С Τ , Grogan R H , Hall Τ С Advanced ovanan cancer primary treatment with surgery, radio­
therapy, and chemotherapy Cancer 29 1-7,1972 
Kenemans Ρ , Verheijen R H M , Leloux A M , Poels L G Prospects and applications of monoclonal anti­
bodies in gynecological oncology Eur J Obstel Gynecol Repr Biol 19 340-346,1985 
Kirkels W J , Pelgrim О E , Hoogenboom A M M , Aaldcrs M W , Dcbruyne F M J , Vooijs G Ρ , Herman 
С J Patterns of tumor colony development over lime in soft-agar culture Int J Cancer 32 399-406, 
1983 
Lieber M M Soft agar colony formation assay for in vitro chemotherapy sensitivity testing of human renal 
cell carcinoma Mayo Clinic experience J Urol 131 391-393, 1984 
Mangioni С , Bolis G , Molteni Ρ , Belloni С Indication, advantages and limitations of laparoscopy in 
ovarian cancer Gynecol Oncol 7 47-55, 1979 
Piver M S , Lele S В , Barlow J J , Gamarra M Second-look laparoscopy prior to proposed second-look 
laparotomy Obst Gynecol 55 571-573, 1980 
Piver M S Importance of proper staging in ovarian carcinoma Clinics Obstet Gynaecol 10 223-234, 
1983 
Prentice R L, Vollmer W M , Kalbfleisch J D On the use of case series to identify risk factors Biometrics 
40 445-458, 1984 
Richardson G S Scully R E, Nikrui N , Nelson J H Common epithelial cancer of the ovary (second of 
two parts) New Engl J Med 312 474-483, 1985 
Selby Ρ , Buick R N , Tannock I A critical appraisal of the 'human tumor stem-cell assay' New Engl 
J Med 308 129-134, 1983 
Shoemaker R Η , Wolpcrl-DeFilippes M К , Kern D H , Lieber M M , Makuch R W , Mclnick N R , Mill­
er W Τ , Salmon S E , Simon R M , Venduti J M , Von HoffD D Application of a human tumor colony-
forming assay to new drug screening Cancer Res 45 2145-2153, 1985 
Thomson S Ρ , Moon Τ E , Meyskens F L Kinetics of clonogemc melanoma cell proliferation and the 
limits on growth within a bilayer agar system J Cell Physiol 121 114-124,1984 
142 
Warr D , McKinney S , Tannock I Influence of measurement error on assessment ofresponsc to anticancer 
chemotherapy proposal for new criteria of tumor response J Clin Oncol 2 1040-1046,1984 
Yoshimura S , Scully R E , Taft Ρ D , Herrington J В Peritoneal fluid cytology in patients with ovarian 
cancer Gynecol Oncol 17 161-167,1984 
143 
Summary 
The purpose of this study is to distinguish potential and predominantly new con-
cepts or experimental findings that can contribute to the improvement of treatment 
results in ovarian cancer 
Since conventional approaches have untili now not been able to alter the prognosis 
of this disease to a fair extent, the role of the Human Tumour Cloning System (HTCS) 
has been evaluated with respect to its potentials in both therapy selection and evalua-
tion 
CHAPTER 1 gives an overview of etiological factors, leading to ovarian cancer in all 
its forms, which are described with respect to histology, staging and grading Although 
many etiological factors have been recognized, mainly in epidemiological studies, it 
is not possible to define whether or not a certain factor is indeed carcinogenic unless 
experimental work can point out the carcinogenic nature, risk factor identification 
remains uncertain 
A special problem in the diagnosis and classification is posed by the grading of 
tumours, in particular in distinguishing between a borderline malignant or malignant 
tumour Because of its prognostic significance it is suggested that more objective criter-
ia be used, not only for the staging of the tumour (e.g objective asscssment of the 
presence of ascites) but also in grading (e g flow cytometric and morphometnc assess-
ment of malignancy) 
Recent achievements in the diagnosis and classification of tumours in general, and 
of ovarian cancer in particular, also disclose opportunities for better and more accurate 
definition of the extent of the disease Tremendous technical achievements do not, 
however, always warrant better results. The introduction of highly advanced imaging 
techniques such as Computerized Tomography (CT) and Magnetic Resonance Imag-
ing (MRI) has, until now, not resulted in a better assessment of the extent of the disease 
Even when higher resolution can be achieved, the value of these expensive, and for 
the patient often very impressive, systems should be compared with other current tech-
niques, such as ultra sound 
On the other hand, the importance of good and accurate assessment of the extent 
of disease cannot be emphasized enough In view of the high prevalence of lymph 
node metastases and other occult metastases, extensive search for occult disease, 
especially in those cases where the tumour seems to be confined to the anatomical 
limits of the ovary is required The necessary procedures, including extensive biopsy-
ing, arc summarized 
Early detection of ovarian tumours by means of ultrasound and subsequent establ-
ishment of their nature by means of monoclonal antibodies directed towards tumour 
associated antigens belong to the new acquirements for early management 
CHAPTER 2 reviews the treatment of ovarian cancer prior to the introduction of the 
new developments that are discussed in this thesis 
The role of radiotherapy in first line treatment has been assessed in several rctrospec-
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tive and in some prospective studies The literature study is mainly concentrated on 
radiotherapy, this modality was, next to mono-chemotherapy with alkylating agents, 
the most important therapy until the mid-seventies. Although the moving strip tech-
nique has been important in stimulating the radiotherapeutic approach, it must now 
be abandonned No real superiority of radiotherapy above singe agent chemotherapy 
or a combination of both could be observed Moreover, there was no advantage in 
adjuvant irradiating of early stage tumours The role of prc-operative and second-line 
radiotherapy is not yet established 
With respect to surgical treatment a major breakthrough has been the introduction 
of the concept of cytoreductive surgery that deminishes the post-operative tumour 
rests to items smaller than 1 -2 cm in diameter 
In a retrospective study the Radboud hospital experience in 53 patients, treated 
with radiotherapy between 1960 and 1978, is reported This patient group is very heter-
ogeneous, both in patient characteristics as well as in treatment Therefore it is cau-
tiously concluded that in our experience radiotherapy is well tolerated, but that therapy 
results did not improve in the period studied 
Our second retrospective study concerns surgical and chemotherapeutical treatment 
of 67 patients between 1967 and 1979 In an attempt to describe the multiple step 
character of ovarian carcinoma treatment the concept of 'treatment plans' is intro-
duced Each plan consists of several modalities which are executed in subsequent 
'phases' Treatment plans are distinguished according to their sequence and are as-
signed 'primary', 'secundary', etc plan It is typical of the approach in ovarian cancer 
management that often several subsequent treatment plans are often drawn up, irre-
spective of the stage of the disease In the period studied many operations have been 
incomplete according to present-day standards Primary therapy consisted mainly of 
(mono-)chemotherapy, whereas radiotherapy often constituted further treatment 
Especially the still poor results in early stage disease call for new, more accurate and 
effective approaches. 
CHAPTER 3 reviews the experience with cisplatin, a drug which has meant a break-
through in the chemothcrapeutic treatment of ovarian cancer Although it is certain 
that cisplatin yields its best results in combination with other cytostatic agents, the 
optimal scheme for the administration has still not yet been found. 
In 20 patients with advanced ovarian carcinoma we studied a relatively simple 
scheme, based on the already established cisplatm-adriamycin-cyclophosphamide 
combination, but with a lower dosage of the two latter agents In this way we achieved 
low toxicity, paired to an acceptable tumour and patient response. More definite an-
swers should come from larger scale, prospectively randomized studies 
In a theoretical model of the of a clinical study it is shown that surviving fractions 
reported are not only just a relatively small portion of the total patient population, 
but also that until now we do not know and cannot be informed about the real number 
of patients that arc actually cured The various chemothcrapeutic approaches in the 
literature are summarized and proposals for further studies arc made 
In CHAPTLR 4 the Human Tumour Cloning System (HTCS) is presented as a potential 
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means for improving ovarian cancer management The literature is reviewed regarding 
individualized chemosensitivity testing for which purpose this test was originally devel-
oped Partly on basis of our own preliminary experience with the assay, other applica-
tions, notably of tumour cell detection, arc suggested 
However, it is also discussed that the assay as it was initially presented did not 
meet the requirements for a clinical test In an update of the relevant literature as 
well as of our own general experience it is concluded that cloning conditions, and 
especially the criteria for in vitro growth assessment need improvement These consi-
derations led to the three main points that are dealt with in the experimental part 
of this thesis 
a) do the colonies grown in culture really represent a relevant tumour fraction, 
b) does the in vitro growth evaluation method proposed by u s - using temporal growth 
patterns - improve the applicability of the assay, 
c) does in vitro growth correlate with the clinical behaviour of the tumour? 
CHAPTER 5 is devoted to the evaluation of the human tumour cloning method A corre-
lation is made between clonogenecity in the HTCS and the DNA-content of the cul-
tured cells, as measured by flow cytometry This correlation was made for both ovarian 
tumours (24 samples) and renal cell tumours (12 samples) It appears that predomi-
nantly those tumours that contain an abnormal (aneuploid) DN A-stemline show col-
ony growth This associates in vitro tumour cell growth with a prognostically signifi-
cant factor 
For the evaluation of ovarian carcinoma colony growth the use of temporal growth 
patterns is advocated since these reflect the dynamics of in vitro growth, rather than 
the commonly used single time point assessment that can only give a momentary pic-
ture It is demonstrated that by the use of temporal growth patterns more assays be-
come évaluable since the presence of clumps does not hamper interpretation of colony 
increase, the consistency of which can be read from the multiple counts 
In CHAPTLR 6 preliminary results of applications of the assay using the temporal 
growth pattern evaluation are discussed for tumour cell detection and chemosensitivity 
testing Ьот the former application the assay might be complementary to cytological 
examination of abdominal washings in the absence of massive tumour, especially at 
the time of a second-look operation For the latter application temporal growth pat­
terns provide - in the form of the slope of the curve - a potential predictive tool for 
chemosensitivity testing with both the advantage of more quantitatively évaluable tests 
than by using single time point assessment, as well as of a reflection of qualitative 
cytostatic drug effect on the patterns of in vitro growth 
In CHAPTFR 7 - the general discussion - the role of the HTCS in solving problems 
put forward in the first part of this thesis is discussed It is concluded that, although 
HTCS in its present form probably does not offer the solution to the quest for drastic 
improvement in treatment results in ovarian cancer, the potentials of the HTCS for 
therapy selection and tumour cell detection, however, justify further study 
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Samenvatting 
VOORUITZICHTEN IN DE BEHANDELING VAN OVARIUM KANKER, 
met name met betrekking tot tumor cel kweken 
Deze studie heeft tot doel een cntische beoordeling te geven van potentieel waarde-
volle concepten en onderzoeksresultaten, die een bijdrage kunnen leveren aan de verbe-
tering van de behandelingsresultaten van patiënten met ovanumcarcinoom. Aange-
zien conventionele benaderingswijzen tot nu toe niet in staat bleken de prognose van 
deze ziekte in redelijke mate te verbeteren, werd het Human Tumour Cloning System 
(HTCS) waarbij humane tumorcellen gekweekt worden bestudeerd op de mogelijk-
heden welke dit systeem lijkt te bieden voor therapie selectie en therapie evaluatie 
HOOFDSTUK 1 geeft een overzicht van epidemiologie, etiologie, pathologie en kliniek 
van ovanumkanker Hoewel vele risicofactoren beschreven worden, met name in epi-
demiologische studies, is het met mogelijk exact te bepalen of een bepaalde factor 
carcinogeen is of niet tenzij experimenteel de carcinogenc eigenschappen opgespoord 
kunnen worden blijft de bepaling van etiologische factoren onzeker 
Een speciaal probleem betreft de gradering, terwijl daarnaast in het bijzonder het 
onderscheiden van 'borderline' maligniteli en maligniteit moeilijk kan zijn Gezien 
de prognostische betekenis wordt geconcludeerd dat het nuttig /ou /ijn meer objectieve 
entena te gebruiken, met alleen voor stadiermg van tumoren (bijv objectieve bepaling 
van de aanwezigheid van ascites) maar ook voor de gradering (bijv met behulp van 
flow cytometnsche DNA analyse) 
Recente ontwikkelingen ten aanzien van diagnostiek en stadiermg van tumoren in 
het algemeen en in het bijzonder van ovanumtumoren bieden het perspectief van het 
beter vaststellen van tumor uitzaaiing Buitengewone technische aanwinsten zijn echter 
geen garantie voor betere resultaten. De introductie van technologisch hoogstaande 
beeldverwerkings systemen zoals gecomputeriseerde tomografie (CT) en magnetische 
resonantie beeldtechiek (MRI) heeft tot nu toe nog met geleid tot een verbeterde vast-
stelling van het tumorstadium Zelfs als een hoger oplossend vermogen bereikt kan 
worden moet de waarde van deze extreem dure en voor de patient vaak belastende 
technieken afgewogen worden tegen die van bestaande technieken, zoals bijvoorbeeld 
echoscopie 
Anderzijds kan het belang van het vaststellen van het juiste stadium van de tumor 
niet onderschat worden Gezien het frequent voorkomen van lymphklier metastasen 
en andere occulte uitzaaiingen is uitgebreid zoeken naar occulte tumor, o a door uit-
gebreide bioptermg zoals beschreven wordt, aangewezen, vooral in die gevallen waar 
de tumor zich lijkt te beperken tot de anatomische grenzen van het ovarium 
Vroegdiagnostiek van ovanumtumoren door middel van echoscopie en verdere be-
paling van de aard van de tumor middels monoclonale antihchamen, gericht tegen 
tumor geassocieerde antigenen, behoren tot de nieuwe mogelijkheden die tijdige be-
handeling mogelijk maken 
147 
HOOFDSTUK 2 geeft een overzicht van de behandeling van ovanumtumoren vóórdal 
nieuwe behandelingsmogelijkheden, zoals besproken in dit proefschrift, hun intrede 
deden. 
De rol van de radiotherapie in de eerste lijns behandeling wordt bepaald aan de 
hand van retrospectieve en enkele prospectieve studies. De literatuurstudie is met name 
gericht op de radiotherapie deze modaliteit was naast mono-chemotherapie met alky-
lerende middelen, de belangrijkste methode van behandeling tot het midden van de 
zeventiger jaren Hoewel de moving strip techniek leidde tol een opleving van de radio-
therapeutische behandeling van ovarium kanker, moet deze wijze van bestralen thans 
als achterhaald worden beschouwd Een voordeel van radiotherapie boven monoche-
motherapie of van een combinatie van beiden boven monochemotherapie alleen kan 
niet worden aangetoond voor de eerste lijns behandeling. Evenmin blij ken er voordelen 
verbonden aan adjuvante bestraling in vroege stadia. De plaats van pre-operatieve 
en tweede li|ns bestraling is nog onduidelijk 
Het concept van de tumorreducerende operatie, waarbij zo gehandeld wordt dat 
post-operatieve tumorresten beperkt zijn tot kleiner dan 1-2 cm in doorsnede, veroor-
zaakte een belangrijke doorbraak in de chirurgische behandeling 
In een retrospectieve studie melden WIJ de ervaring in het St Radboud ziekenhuis 
met de radiotherapeutische behandeling van 53 patiënten tussen 1960 en 1978 Deze 
groep is zeer heterogeen, zowel ten aanzien van patiënten gegevens als ten aanzien 
van ingestelde behandeling. Daarom kan slechts voorzichtig geconcludeerd worden 
dat in onze ervaring radiotherapie goed wordt verdragen, maar dat de behandehngs 
resultaten in de bestudeerde periode niet verbeterden 
Een tweede retrospectieve studie betreft de chirurgische en cytostatische behande-
ling van 67 patiënten in de periode tussen 1967 en 1979 In een poging het trapsgewijze 
karakter van het beleid rond ovariumcarcioom patiënten aan te geven wordt het begrip 
'behandelingsplan' geïntroduceerd Elk plan kan bestaan uit verschillende behande-
lingsmodaliteiten, die in opeenvolgende fasen worden uitgevoerd Behandelingsplan-
nen worden benoemd naar de volgorde waarin ze worden opgesteld primair, secundair 
etc. Typerend voor de aanpak van ovariumcarcinoom is dat vaak verschillende, elkaar 
opeenvolgende behandelingsplannen moeten worden opgesteld, onafhankelijk van het 
stadium van de ziekte Volgens huidige standaard werden vele operaties in de bestu-
deerde periode onvolledig uitgevoerd Primaire therapie bestond voornamelijk uit 
(mono-)chemothcrapie, terwijl radiotherapie vaak deel uit maakte van een vcrvolg-
behandeling Vooral de nog steeds slechte resultaten bij vroege stadia noodzaakte tot 
een nieuwe en meer effectieve benaderingswijze 
HOOIDSTUK 3 geeft een overzicht van de ervaring met cisplatinum, het cytostaticum 
dat een doorbraak in de chemotherapie heeft betekend Hoewel het zeker is dat cisplati-
num de beste resultaten geeft in combinatie met andere middelen, is het optimale toe-
dicningsschema nog niet gevonden 
Bij 20 patiënten met gevorderd ovariumcarcinoom bestudeerden wij een tamelijk 
eenvoudig schema, gebaseerd op de reeds goed gedocumenteerde combinatie cisplati-
num-adnamycine-cyclophosphamide, maar dan met een lagere dosering van de twee 
laatste cytostatica Hiermee werd een slechts geringe toxiciteit veroorzaakt, terwijl een 
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acceptabele tumor en patient respons werd verkregen. Meer definitieve antwoorden 
moeten komen van grootschalige, prospectief gerandomiseerde studies 
Een theoretisch model van de opbouw van een klinische studie laat zien dat het 
overlevingspercentage dat vermeld wordt niet alleen slechts een klein deel van de pa-
tienten populatie is, maar bovendien dat het werkelijk aantal echt genezen patiënten 
onbekend is Aan de hand van de literatuur worden de vele chemotherapeutische be-
handelingswijzen samengevat en worden voorstellen tot verder onderzoek gedaan 
In HOOFDSTUK 4 wordt het Human Tumour Cloning System (HTCS) besproken, met 
name als een potentieel middel voor de verbetering van de behandelingsresultaten bij 
ovariumcarcinoom Een literatuuroverzicht wordt gegeven met betrekking tot het tes-
ten van individuele gevoeligheid van tumoren voor cytostatica, waarvoor het HTCS 
in eerste instantie was ontwikkeld Deels op basis van onze eigen eerste ervaringen 
met deze test worden andere toepassingen, met name voor tumorcel detectie, voorge-
steld 
Het wordt ter discussie gesteld of de test zoals die in eerste instantie werd aangebo-
den wel voldeed aan de eisen te stellen aan een klinische test Uit een overzicht van 
de meest recente literatuur en onze eigen algemene ervaring wordt geconcludeerd dat 
de kweek condities, maar vooral ook de criteria waarop in vitro groei gebaseerd wordt, 
verbeterd dienen te worden Deze overwegingen leidden tol de drie hoofdpunten, die 
in het experimentele deel van dit proefschrift behandeld worden 
a) vormen de colonies in kweek wel de relevante tumor fractie, 
b) verhoogt de door ons voorgestelde wijze van in vitro groei bepaling - middels groei-
curven - de klinische toepasbaarheid van de test, 
c) correleren in vitro groei kwaliteiten en het klinisch gedrag van de tumor9 
HOOFDSTUK 5 is gewijd aan de evaluatie van de tumorcel kweekmethode Een correlatie 
wordt gevonden tussen cloneerbaarheid in het HTCS en de DNA inhoud van de tu-
morcellen, zoals deze bepaald wordt middels flow cytometric Deze correlatie wordt 
gevonden bij ovanumtumoren (24 monsters) en bij Grawitztumoren (12 monsters) 
Het blijkt dat voornamelijk de tumoren met een abnormale (aneuploidc) DNA 
stamlijn in vitro groei vertonen Dit legt verband tussen het colonie vormend vermogen 
van tumorcellen en een prognostisch belangrijke factor 
Meer dan de gebruikelijke ééndags tellingen, die slechts een moment opname geven, 
weerspiegelen groeicurven de dynamische aspecten van in vitro groei Aangetoond 
wordt dat wanneer groeicurven ('temporal growth patterns') gebruikt worden voor 
de bepaling van groei meer testen evalueerbaar worden, aangezien de aanwezigheid 
van tumor cel klontjes interpretatie van een toename in het aantal colonies niet verhin-
dert, bestudering van colomevorming in de tijd staal namelijk vaststelling van consis-
tente groei toe Voorgesteld wordt groeicurven te gebruiken voor de evaluatie van 
colonie groei van ovariumcarcinoom 
In HOOFDSTUK 6 worden de eerste resultaten van het gebruik van groeicurven bij tumor 
cel detectie en het testen van chemosensiüviteit middels het HTCS besproken Bij toe-
passing voor tumor cel detectie is deze test mogelijk additief aan het cytologisch onder-
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zoek van peritoneale spoel vochten indien geen uitgebreide intra peritoneale tumor aan-
wezig is. Dit geldt met name ten tijde van een second-look operatic. Ten aanzien van 
het testen van chemosensitiviteit biedt hel gebruik van groeicurven - en dan met name 
de helling hiervan - perspectieven voor verdere toepassingen. Groeicurven hebben 
niet alleen het voordeel dat meer testen kwantitatief evalueerbaar worden, maar ook 
dat ze het kwalitatief effect van cytostatica op in vitro groei patronen weergeven. 
In HOOFDSTUK 7 de algemene discussie - wordt de rol besproken die het HTCS 
kan hebben in het oplossen van problemen zoals geschetst in het eerste deel van dit 
proefschrift. Geconcludeerd wordt dat het HTCS in zijn huidige vorm waarschijnlijk 
niet de oplossing biedt in de pogingen te komen tot echt betere behandelingsresultaten 
bij patiënten met ovarium carcinoom. De mogelijkheden die deze test biedt voor thera-
pie selectie en voor tumor cel detectie rechtvaardigen echter verder experimenteel werk 
op dit gebied. 
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STELLINGEN 
behorende bij het proefschrift 
PROSPECTS IN THE MANEGEMENT OF OVARIAN CANCER 
with special reference to Human Tumour Cloning 
R.H.M. Verheijen 
Nijmegen, 19 december 1985 
Stelling I 
Ondanks vooruitgang in de ontwikkeling van diagnostische en therapeutische tech-
nieken is de vroeg-diagnostiek noch de prognose quoad vitam van patiënten met een 
carcinoom uitgaande van het ovarium in de laatste decennia in positieve zin beïnvloed 
Stelling II 
Tumorcel colonies groeien met m de dubbele soft agar laag, maar er tussen 
Stelling III 
Betrouwbare in vitro chemosensitiviteitsbepalmgen voor zowel cytostatica als voor 
antibiotica hebben het groeipatroon in de tijd als basis. 
Stelling IV 
Cytologisch onderzoek van peritoneale spoelvochten verkregen bij operaties voor 
ovanumcarcinoom geeft geen additionele informatie boven het histologisch onderzoek 
van daarbij genomen biopten en kan alléén gebruikt geen uitsluitsel geven omtrent 
de afwezigheid van tumor. 
Stelling V 
Intra-pentoneale en mtra-pleurale tumorceltargclting met isotopen gekoppeld aan 
anti-lichamen gericht tegen antigenen aanwezig op het oppervlak van ovanumcarci-
noomcellen dient nader onderzocht te worden als therapie voor minimal discase, met 
name indien reeds cytostatische behandeling heeft plaatsgevonden 
(Hammersmith Oncology Group, Lancet i. 1441-1443, 1984) 
Stelling VI 
De tweeslachtigheid in de stelling van Bichaf 'l'instant où le foetus commence à exister 
est presque le même que celui où il est conçu' ligt ten grondslag aan zowel de problemen 
rond abortus provocatus alsook aan die van de juridische consequenties van in vitro 
fertilisatie 
(X Bichat, Recherches physiologiques sur la vie et la mort, Paris- Becher & Gabon, 
1822, ρ 187) 
Stelling VII 
'Pelvic Inflammatory Disease' is geen diagnose; invoering van deze term als zodanig 
in het medisch jargon dient dan ook vermeden te worden. 
Stelling VIII 
In de tropen moet bij een pneumonie met onbekende oorzaak een zwangerschapstest 
worden uitgevoerd. 
(P.J.Armon, Tropical Doctor, 10: 184-187, 1980) 
Stelling IX 
DES-kundigheid is slechts een tijdelijke zaak. 
Stelling X 
De voorhoofdspiegel is een bij uitstek gynaecologisch instrument. 
Stelling XI 
Behandeling en bestrijding van tuberculose in ontwikkelingslanden maakt deze ziekte 
daar tot een epidemiologisch probleem van de eerste orde. 
Stelling XII 
De bij de governo methode vrijkomende hoeveelheid tyramine hoeft patiënten die 
MAO remmers gebruiken er niet van te weerhouden Chianti te drinken, zoals werd 
aanbevolen in het schrijven van het Britse Ministerie van Gezondheid en Sociale Zak-
en, nr. HM(N)0729 D08 101127 150M 3/80 М0СЗЗО8. 
(R.Young, Decanter 9: 18, 1984) 
Stelling XIII 
Kerley-B lijntjes kunnen duiden op overmatig gebruik van ondermaatse wijn. 
Stelling XIV 
De laatste stelling bij een proefschrift hoeft niet de leukste te zijn. 



